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Abstract 
 
Preterm premature rupture of membranes (PPROM) is the rupture of fetal membranes prior to 37 
weeks gestation, and before the onset of labour. PPROM complicates 40% of preterm births, 
which can result in lifelong disabilities such as respiratory, cardiac and neurological disorders. 
The causes of PPROM are multifactorial and not well understood. Iatrogenic PPROM is a major 
complication after invasive fetal interventions and occurs in 6-45% of cases. The high prevalence 
of iatrogenic PPROM after fetal surgery, due to the absent healing capacity of fetal membranes, 
reduces the effectiveness of interventions to treat fetal abnormalities demonstrating a need to 
design therapies with clinical potential. 
 
The present study demonstrates that connexin 43 (Cx43) is overexpressed in amniotic membrane 
(AM) after fetoscopic surgery and artificial in vitro trauma. Cx43 was preferentially distributed 
in mesenchymal cells compared to epithelial cells, with significant expression in the fibroblast 
layer compared to the epithelial layer. Polarisation of mesenchymal cell nuclei and collagen fibres 
at the wound edge is also reported. To investigate mechanotransduction AM weakening 
mechanisms we used an ex-vivo bioreactor system to study the effect of cyclic tensile strain. 
Changes in matrix composition (collagen, elastin and GAG), and pro-inflammatory factors 
(MMPs and PGE2) after 24 hours were studied. Cyclic tensile strain significantly increased GAG 
synthesis and release of MMPs and PGE2, with an associated reduction of collagen and elastin 
content, compared to unstrained AM. Furthermore, we demonstrate the reversal of these 
biochemical changes induced by cyclic tensile strain after AM exposure to pharmacological 
agents that target the broad group of PI3-kinases and selectively inhibit AKT-1/2 activity. 
Interestingly, addition of Cx43 and COX-2 inhibiting agents also reversed the biochemical 
response after cyclic tensile strain. It is suggested that alterations in the ECM composition affects 
AM integrity and leads to fetal membrane weakening following cyclic tensile strain. Finally, a 
novel sealing approach based on peptide amphiphile self-assembling gels in the presence of 
amniotic fluid is developed. By using peptide amphiphiles we were able to seal fetal membrane 
defects in vitro. This innovative approach provides a new avenue for a tissue engineering 
approach to prevent PPROM. 
 
The results obtained in this study contributes to our understanding on: (1) AM wound healing and 
repair capacity, the (2) mechanotransduction mechanisms behind AM weakening, and (3) a novel 
tissue engineering approach to seal fetal membrane defects using self-assembly of peptide 
amphiphiles for iatrogenic PPROM prevention.  
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Chapter 1 
 
General Introduction 
	 	
  2 
Chapter 1: General Introduction 
 
Preterm birth incidence is increasing regardless of advances in prenatal care, 
management, and diagnostics. The UK has one of the highest preterm birth rates with 8% 
of births occurring before 37 weeks, amounting to 60,000 preterm deliveries annually; 
and remains the leading cause of death for infants under 5. Globally, there are 15 million 
cases of preterm deliveries, equating to 1 in 10 births, with an estimated 1 million being 
stillborn every year. Preterm premature rupture of membranes (PPROM) complicates 
40% of preterm births, which often result in lifelong disabilities involving respiratory, 
cardiac and neurological disorders. PPROM can result from uterine infection, distension 
of the uterus and fetal membrane, and vaginal bleeding. However, the cause is unclear 
and the pathological mechanisms leading to membrane rupture are not well understood. 
Furthermore, Iatrogenic PPROM is a major complication after invasive fetal interventions 
and occurs in 6-45% of cases. Previous research has shown that the human fetal 
membranes do not heal after spontaneous or iatrogenic rupture. The high prevalence of 
iatrogenic PPROM after fetal surgery reduces the effectiveness of interventions to treat 
fetal abnormalities demonstrating a need to design therapies with clinical potential.  
 
1.1 Fetal membrane embryonic origin and structure 
 
The amniochorion consists of the amniotic and chorionic membranes, which completely 
fuse at approximately 15-17 weeks gestation and loosely attach to the decidua parietalis 
of the uterine cavity. Following delivery, the tissues are collectively termed the fetal 
membranes. To understand the complex structure of the fetal membranes, it is important 
to first understand their embryonic development. 
 
1.1.1 Embryonic development of the fetal membranes 
 
The placenta and fetal membrane tissues are crucial for normal embryonic development. 
The fetal membranes form a membranous sac that contains amniotic fluid and protects 
the fetus from infection during fetal development. The placenta is a feto-maternal organ, 
having a maternal (Decidua basalis) portion formed from the tissue of the uterine wall 
and uterine circulation, and a fetal (Chorion frondosum) portion that develops from the 
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blastocyst during early embryogenesis. The placenta is responsible for transporting 
nutrients and oxygen to the fetus and removing waste products through the maternal blood 
supply, whilst also secreting amongst other proteins human chorionic gonadotropin, 
progesterone and oestrogen hormones to maintain a healthy pregnancy. 
 
The amnion and chorion loosely fuse to form the amniochorion at approximately 15-17 
weeks gestation when sufficient fluid accumulation in the amniotic cavity causes its 
expansion. After fertilisation (day 1), typically in the upper region of the oviduct, 
cleavage occurs (day 2) as the zygote travels to the uterus. This involves continued mitotic 
divisions to form a morula of 16-32 cells (day 3-4). Differentiation of inner cells leads to 
the formation of a blastula, which comprises a surface layer of trophoblast cells 
surrounding a blastocoele (fluid-filled sac) and an inner-cell mass at day 5-7 (Figure 1.1). 
Implantation typically occurs at day 7 when the blastocyst adheres to the endometrium 
that lines the uterus and trophoblast cells begin to invade the maternal tissue. Continued 
differentiation leads to the inner cell mass of the blastocyst assembling to form the 
bilaminar disc, containing the epiblast and hypoblast cell layers (Figure 1.1). The epiblast 
layer, which forms shortly after implantation, helps form the inner surface of the amniotic 
cavity lined with amniotic ectodermal cells. 
 
Typically, towards the end of the third week, gastrulation occurs which is the process by 
which the bilaminar disc is converted into the trilaminar disc, which comprises three germ 
layers: the ectoderm, mesoderm, and endoderm (day 12, Figure 1.1). During the 
gastrulation period, which involves mesoderm spreading (day 18) and enlargement of the 
amniotic sac (day 23), the primitive streak, notochord and prechordal plate all begin 
formation and are responsible for the development of the embryo (Figure 1.1). The 
mesoderm, which is derived from the hypoblast layer of the bilaminar disc, is responsible 
for formation of the amniotic fibroblast layer at approximately day 12 of gestation 
(Figure 1.1). The trophoblast and extraembryonic mesoderm (Figure 1.2a) are 
responsible for the formation of the chorionic sac and chorionic villi, and the chorion that 
later completely adheres to the amnion to form the amniochorion at approximately 15-17 
weeks is derived from the somatic mesoderm and is termed the smooth chorion (chorion 
laeve). Microvilli initially cover the entirety of the chorionic sac, which develops into the 
chorionic frondosum (Figure 1.2b). However, after the early stages of development at 
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approximately 8 weeks the microvilli in close proximity to the decidua capsularis begin 
to regress forming the chorion laeve that later forms the outer layer of the amniochorion 
(smooth chorion, Figure 1.2b). The remaining section of the chorionic sac which contains 
microvilli (villous chorion, Figure 1.2b-c) will form an integral part of the placenta. 
Between approximately 15-24 weeks the amniotic cavity expands due to an increasing 
volume of amniotic fluid which leads to the fusing of the amniochorion and decidua 
Figure 1.1: Early fetal membrane development in the first month of gestation after 
fertilization. The ectoderm layer of the trilaminar disc is responsible for the formation of the 
amniotic epithelial layer, which is in contact with the amniotic fluid throughout gestation. The 
mesoderm derived from the hypoblast layer of the trilaminar disc is responsible for the 
fibroblast layer of the amniotic membrane. Adapted from Sozen et al., (2014)2; Marieb & 
Hoehn (2013)7. 
 
A 
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parietalis (Figure 1.2c). The fetal membranes expelled after delivery of the fetus will be 
comprised of the amniochorion adhered to a layer of decidua parietalis. 
 	 	
Figure 1.2: Later development of the fetal membrane and fusion of key components including 
fusion of the separate amnion and chorion layers to form the amniochorion at 12 weeks gestation 
leading to fusion of the amniochorion with the decidua parietalis lining of the uterine cavity to 
form the fetal membrane at 15-24 weeks gestation. Adapted from Pansky (1982)6. 
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Stages of fetal membrane fusion 
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(B) 
(C) 
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1.1.2 Fetal membrane structure 
 
The fetal membrane is divided into two key membranes: the (1) innermost amniotic 
membrane (amnion) that is in contact with the amniotic fluid, and the (2) outermost 
chorionic membrane (chorion) that adheres to the amnion and the underlying decidua 
(Figure 1.3). The nomenclature of the fetal membranes has remained mostly consistent 
since the first detailed reviews between 1960 and 196619-21. Herein, it was clear that the 
amniotic membrane consisted of five layers: (1) epithelial layer, (2) basement membrane, 
(3) compact layer, (4) fibroblast layer, and (5) spongy layer. More recently, the spongy 
layer has been used interchangeably with intermediate layer3,22-25. The spongy layer 
connects the amniotic membrane to the chorionic membrane, which has four distinct 
layers: (1) the cellular layer, (2) reticular layer, (3) pseudo-basement membrane, and (4) 
trophoblast layer.  
 
It is important to note that the thickness of fetal membranes can change depending on 
species, region and gestational age. Total thickness is reported to vary between 0.5 – 1.5 
mm, and thickness reported to decrease to approximately 0.5 mm in term fetal membrane 
compared to preterm26-28. In term tissue, the amnion is shown to swell whilst the chorion 
and decidua reduce in thickness, most prominently in the region overlying the cervix, 
termed the para-cervical weak zone, or more recently referred to as the zone of altered 
morphology (ZAM, see section 1.2: The zone of altered morphology)29-33. When 
compared to fetal membrane examined closer to the placental disc, the ZAM displays the 
most notable gestational-dependent morphological differences where the connective 
tissue layers reduce in thickness towards term gestation in order to prepare for 
parturition30,34,35. 
 
Importantly, the decrease in fetal membrane thickness over gestation can concomitantly 
reduce stiffness from approximately 8.84 MPa at 15 weeks to 2.29 MPa at 40 weeks36. 
Indeed, researchers are examining whether fetal membrane thickness can be used to 
predict preterm premature rupture of membranes27,37. Therefore, it is necessary to 
consider this variation in fetal membrane morphology when examining the overall 
structure. 
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Figure 1.3: Schematic representation of the human fetal membrane. The key layers of the amnion 
are the epithelial layer, basement membrane, compact layer, fibroblast layer, and spongy 
(intermediate) layer. The key layers of the chorion are the reticular layer, pseudobasement 
membrane, and trophoblast layer. The innermost layer is the amniotic epithelial layer of the amnion 
that is in contact with the amniotic fluid throughout pregnancy and the outermost layer is the 
trophoblast layer of the chorion that adheres to the maternal decidua. The main extracellular matrix 
components and cell populations of each layer are indicated on the right. The red line indicates the 
separation between the amnion and chorion. Adapted from Parry & Strauss (1998)12. 
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The amniotic epithelial layer 
 
The amniotic epithelial layer mainly contains a single layer of cuboidal epithelial cells 
and a small amount of columnar cells that have been identified in the amniotic epithelial 
layer overlying the placenta20. The cuboidal cells are covered in microvilli that protrude 
on the apical and lateral surface into the amniotic fluid forming a brush border membrane 
(Figure 1.4). They are tightly connected via intercellular desmosomes with intercellular 
canals (ICC) found between adjacent cells. The basal part of these cells forms basal 
processes that associate with the underlying basement membrane. 
 
 
The basement membrane 
 
The amniotic basement membrane is a thin layer composed of collagen types III, IV and 
V. The apical surface of the basement membrane shares complex interactions with the 
basal surface of the amniotic epithelial cells via similar interlinking processes. Other 
extracellular matrix proteins in the basement membrane found in high abundance include 
laminin, which interacts with collagen type IV via nidogen and fibronectin proteins, 
known to influence cell differentiation, migration and adhesion. 
  
Figure 1.4: Electron micrograph showing the apical side of cuboidal epithelial cells (EC) 
separated by intercellular canals (ICC) taken from full term amniotic membrane. The 
microvilli that protrude from the epithelial cells into the amniotic fluid can be seen clearly. 
The photo was taken using a scanning electron microscope. Unpublished image taken by 
David Barrett. Scale bar: 10 µm. 
EC 
ICC 
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The compact layer 
 
This is a highly dense and acellular layer connected to the basement membrane by a 
fibrillar network containing mainly collagen type V. This layer provides the majority of 
amniotic membrane strength with stiffness values ranging from 9.14±2.51 N/cm to 
14.47±3.38 N/cm30. The compact layer contains fibronectin and a dense meshwork of 
collagen fibres consisting of collagen types I, III, V, and VI.  
 
The presence of elastin has also been reported in the compact layer38,39. However, there 
is dispute in the literature regarding these findings, with some groups unable to detect 
elastin levels in fetal membranes at all40. More recently, resorcin fuchsin staining 
demonstrated a faint band of elastin in the compact layer of the amniotic membrane3. It 
is suggested that the difficulty in demonstrating elastin presence in fetal membranes could 
be due to the elastin diameter, reported to be 0.016 µm (0.08% dry weight), which is 
roughly 1% of that typically found in the aorta at a diameter of 1-2.5 µm (51.2% dry 
weight)39,41. 
 
The fibroblast layer 
 
The fibroblast layer is much thicker and contains mainly collagen types I, III and VI 
arranged in a disorganised network. Laminin and fibronectin are also found in high 
abundance. This layer contains mesenchymal cells, which are morphologically 
fibroblastic and produce collagen in the stromal layers20,42. Other fetal cell types have 
been reported including macrophages and dendritic cells of the immune system, which 
have been reported to show phagocytic activity20,43,44. Elastin presence has also been 
detected in this layer39,40. 
 
The spongy layer 
 
The spongy layer is used interchangeably with intermediate layer, and its organisation is 
highly variable throughout the fetal membrane regions and between patients. It is this 
layer that connects the amnion to the chorion forming a compressed tissue comprised 
mainly of collagen types I, III and IV. The layer is also highly concentrated in 
proteoglycans, which covalently bind to glycosaminoglycans (GAGs), a highly polar 
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polysaccharide that attracts water molecules and gives this layer its viscous texture20,42. 
The spongy layer partly accounts for increase in amnion thickness found in patients with 
preterm premature rupture of membranes (PPROM)32 and the swelling identified in the 
amnion overlying the cervix in healthy full-term membranes compared to the mid-zone 
amnion region29. 
 
The cellular layer 
 
The cellular layer is the first layer of the chorion adjacent to the spongy layer of the 
amnion. Studies of the cellular layer have been problematic due to it often being absent 
when imaged microscopically in term fetal membrane yet more recognisable in preterm 
tissue20. This layer is reported to be a single layer thick of trophoblast cells23.  
 
The reticular layer 
 
This is the thickest of the chorion layers and contains collagen types I, III, IV, V, and VI. 
It has also been reported to contain fibronectin and proteoglycans45. The cells in the 
reticular layer have been described classically as fibroblasts, although more recently 
mesenchymal cells have been the preferred terminology with several studies showing the 
successful isolation of mesenchymal cells from the chorionic reticular layer46,47. A high 
abundance of macrophages has also been reported20,42. 
 
Pseudo-basement membrane 
 
This is the basement membrane of the trophoblast layer and contains mainly collagen 
type IV, fibronectin, and laminin42,45. 
 
Trophoblast layer 
 
This is the final layer of the chorionic membrane, which adheres to the maternal decidua. 
It is often referred to as the cytotrophoblast layer and reported to be 2-10 trophoblast cells 
deep20. It is also considered the epithelial layer of the chorion. There are two separate cell 
populations, the vacuolated cells adjacent to the pseudo-basement membrane and the 
eosinophilic cytotrophoblast cells, adjacent to the maternal decidua. The cells close to the 
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apical side of this layer, the eosinophilic cytotrophoblast cells, are said to be interwoven 
with collagen types III, IV, V, and VI20,48. After delivery, the trophoblast layer often 
adheres to a thin layer of the decidua parietalis (maternal decidua), which contains blood 
vessels, decidual cells, and macrophages28,44,49. 
 
1.2 The zone of altered morphology 
 
The human fetal membrane is programmed to rupture at term between 37 and 42 weeks. 
In preparation for parturition, the extracellular matrix (ECM) undergoes a remodelling 
process that results in morphological changes at the membrane adjacent to the cervix, 
termed the para-cervical weak zone or more commonly the zone of altered morphology 
(ZAM)29,30,32,34,50-54. 
 
1.2.1 Structural differences in the ZAM 
 
Fetal membrane layer thickness can vary depending on region (Table 1.1). In term fetal 
membrane, at the ZAM region, the amnion is reported to swell whilst the choriodecidua 
reduces in thickness; compared to membrane studied adjacent to the placental disc, away 
from the cervical region29,30. At delivery, the decidual layer overlying the cervix has been 
measured at 56.6 ± 44.4 µm compared to thicker decidual layer measurements closer to 
the placental disc of approximately 121.7 ± 29.8 µm. Interestingly, the total thickness of 
the fetal membranes, including the amniochorion and maternal decidua, was reported to 
be thinner in the ZAM at 191 ± 54 µm compared to 233 ± 54 µm in regions away from 
the ZAM. However, when considering the amniochorion alone, the thickness was greater 
in the ZAM at 136 ± 23 µm, compared to regions away from the ZAM, due to the swelling 
that is observed in the amnion towards term, likely to be a result of the amnion preparing 
to rupture prior to parturition30. 
 
The swelling of the amnion has been reported to occur in the spongy (intermediate) layer 
that connects the amnion with the chorion, whilst there is a reduced thickness in the 
cellular layers, specifically in the trophoblast layer of the chorion29,32,46. More recently, 
second harmonic imaging microscopy of collagen fibres demonstrated that the connective 
tissue layers are thicker in the ZAM (367 ± 100 µm) compared to regions of membrane 
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measured away from the ZAM (249 ± 81 µm), later confirmed following histological 
studies (Figure 1.5)3. 		 	
Figure 1.5: Hematoxylin and eosine (H&E) staining of term human fetal membrane taken away 
from the placental disc (A, away from the zone of altered morphology) and from the zone of 
altered morphology (B). Continuous arrows show the increase in stromal layers of the fetal 
membrane in ZAM due to swelling, and the dotted arrows show the decrease in cellular layer 
thickness in the ZAM, likely associated with increased apoptotic activity. Scale bar: 100 µm. 
Adapted from Mauri et al., (2013)3.  
A B 
Table 1.1: Thickness of fetal membrane layers reported in literature. There are inconsistencies 
between research groups, although it is clear that the fetal membrane (amnion and chorion) 
reduces in total thickness towards the ZAM. Whilst the amnion layer may swell at the ZAM, 
this is negated by the dramatic decrease in the cell-dense chorion layer. 
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1.2.2 Differences in biochemistry of the ZAM 
 
The morphological changes observed in the ZAM have been linked to changes in 
biochemical factors that influence connective tissue integrity and cell viability (Table 
1.2)32. Enzymes involved in extracellular matrix degradation include 
matrixmetalloproteases (MMPs) and elastases, which degrade collagen and elastin. In 
several reports, MMP-9 is shown to increase with labour, whilst MMP inhibitor-3 (TIMP-
3) is found in lower concentrations in the ZAM of term fetal membrane52,53,55. Increased 
Poly (ADP-ribose) polymerase (PARP) cleavage has also been reported in the ZAM, 
indicating an increase in apoptotic activity, compared to regions away from the 
ZAM30,53,56. Furthermore, in animal models it has also been reported that structural 
weakening of the fetal membrane occurs over the cervical region due to breakdown of 
collagen and remodelling of the connective tissue layers, and apoptosis57-59. 
 
Changes in proteoglycan concentration have also been reported60. Specifically, biglycan 
concentration in the amnion of the ZAM region was 40% lower compared to mid-zone 
amnion prior to labour. However, at delivery the ZAM amnion biglycan content increased 
2-fold along with a 50% reduction in decorin concentration60. Biglycan is known to 
disrupt collagen organisation, whereas decorin acts to stabilise collagen. 
 
Previous studies in ZAM show increased translocation of NFκB, which enhances 
production of pro-inflammatory gene expression61-63. Mitogen-activated protein kinases 
(MAPKs) are well known serine/threonine protein kinases that induce catabolic 
signalling in ZAM associated with the pro-inflammatory and apoptotic cascades64. Other 
transcription factor proteins associated with induction of apoptosis have been reported 
and include FOXO1, FOXO3, FOX04, and AP-1, known to trigger apoptosis through 
activation of BIM (Bcl-2-like protein 11) and PUMA (p53 upregulated modulator of 
apoptosis) proteins65-68. Increases in oxidative stress in the ZAM have also been 
reported69. 
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Table 1.2: Key changes reported to increase tissue weakening in the zone of altered 
morphology in preparation for parturition. 
 
Factor Key findings Study 
MMP-9 
TIMP-3 
Increased extracellular matrix 
degradation leading to reduction 
in collagen content. 
McLaren et al., (2000)55 
McLaren et al., (2000)53 
McParland et al., (2003)52 
Biglycan 
Decorin 
Corresponded with a 30% 
decrease in collagen in the 
cervical amnion compared to 
mid-zone amnion after delivery. 
Meinert et al., (2007)60 
NFκB Increased NFκB expression 
corresponded with increase 
transcriptional cofactor proteins 
(CBP) and p300, suggested to 
lead to increased apoptosis and 
MMP synthesis associated with 
the ZAM. 
Reti et al., (2007)61 
Lappas et al., (2002)62 
Lappas et al., (2008)63 
FOXO1 
FOXO3 
FOXO4 
Increase in these transcription 
factors trigger apoptosis via Bcl-
2-like protein 11 and p53 
upregulated modulator of 
apoptosis proteins. 
Lappas et al., (2009)67 
Lappas et al., (2010)68 
PARP Associated with increased 
cellular apoptosis. 
McLaren et al., (1999)56 
MAPK 
AP-1 
Increase associated with 
activation of pro-inflammatory 
cytokines and induction of 
apoptosis 
Lappas et al., (2011)64 
Oxidative stress Oxidative stress augmented IL-
1B induction of MMP-9 
expression. 
Chai et al., (2012)69 
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1.3 Tissue biomechanics of the fetal membrane  
 
Understanding etiology and developing future treatment and preventatives for PPROM 
requires an understanding of how the structure of fetal membrane tissue relates to the 
tissue mechanical properties. Simple clinical observation of the fetal membrane at 
delivery, and during separation of the amnion from the chorion, gives the impression that 
the amnion is the strongest of the layers compared to the chorion. Indeed, uniaxial 
mechanical tests demonstrate the amnion to be the stronger of the two layers70. However, 
more recently, groups have moved towards the use of biaxial loading conditions, which 
better mimics the in vivo conditions when exposed to the pressure exerted from the 
amniotic fluid16,71-75. 
 
1.3.1 Tensile properties of the fetal membrane 
 
The fetal membrane can withstand high pressure; and the amnion, even though much 
thinner than the chorion, has been shown to have the greater tensile strength, likely owing 
to the organisation of collagen and elastin fibres of the compact and fibroblast layers76. 
Average thickness of the amnion is 44 µm compared to the chorion at 188 µm36. In order 
to test the mechanical behaviour, methods were developed in the 1960s to test whole 
membranes, and also more recently to test the amnion alone16,77-80. Interestingly, the 
amnion alone was discovered to have sufficient tensile strength required for a successful 
pregnancy76. Furthermore, the tensile strength can vary and has been shown to decrease 
with gestation28. Following preterm premature rupture of membranes, the amnion has 
greater tensile strength compared to term tissue81. Overall, fetal membrane stiffness was 
reported to be 8.84 MPa at 15 weeks gestation, reducing to 2.29 MPa at 40 weeks of 
gestation36. 
 
The tensile strength of the fetal membrane over gestation (17-41 weeks) has also been 
compared with commercially available products74. The data suggest an increase in tensile 
strength occurring between 17-20 weeks, after which it is maintained until decreasing at 
approximately 38-39 weeks. The reduction in tensile strength was also independent of 
labour, suggesting an important relationship between the biochemical composition and 
tensile properties of the fetal membrane. Tensile strength was measured using a probe 
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that exposed the fetal membrane at a specific point, demonstrating tensile strength as 
grams to burst and deflection at rupture. From 20-38 weeks, peak force to burst averaged 
3.8 N, and reduced to 2.5 N between 39-42 weeks gestation. Deflection at rupture also 
reduced from 5.7 mm to 4.4 mm with the use of a  
3 mm probe applying force at a speed of 50 mm/minute through a 1.3 cm diameter port. 
Indeed, collagen remodelling of the amnion in preparation for parturition has been well 
documented within the zone of altered morphology after vaginal delivery and non-
labouring caesarean section deliveries82. 
 
Many groups have performed biaxial testing using a puncture/probe set-up to assess 
mechanical properties of fetal membranes, whilst others have adopted a burst pressure 
test by introducing air or fluid71,83. However, the latter offers a less controlled system due 
to the possibility of failure randomly throughout the sample. Using biaxial loading 
systems, other leading groups including Oyen et al. have well characterised the 
mechanical failure of human fetal membrane tissue16,84. Importantly, Oyen et al. have 
considered that the integrity of the fetal membrane should be examined, and data 
presented, on an individual layer basis; regarding the amnion and chorion as separate 
layers. They demonstrate comparable data with other groups using biaxial loading 
systems, showing a peak force of 4.3 N in chorioamnion of non-labouring term tissue16. 
They further demonstrate that amnion alone, taken distally from the placenta, has a peak 
of 3.2 N, much lower than amnion obtained overlying the placenta, which has a peak 
force of 5.62 N. The chorion alone is reported to have the lowest peak force of 1.8 N. 
Importantly, there is a consistency in values of failure strength (0.9 MPa) and failure 
tension of the amniochorion throughout the literature and with the use of varying 
mechanical testing devices including biaxial inflation, biaxial puncture and uniaxial 
tension (Figure 1.6)85. 
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Figure 1.6: Comparison of mechanical data obtained from term fetal membranes for failure 
stress (A) and failure tension (B) following different mechanical testing devices including biaxial 
inflation, biaxial puncture and uniaxial tension. Reassuringly, this data shows consistency 
throughout, with little variation between experiment types. Arrows indicate the average values 
(grey diamonds). Adapted from Chua & Oyen (2009)85. 
 
1.3.2 Amniotic membrane mechanics 
 
It has been demonstrated that the amnion dominates the outcome of the overall 
chorioamnion failure properties, indicating a determining layer in premature rupture. 
Research is now being done to characterise the effect of membrane location (relative to 
rupture site and cervix), the effect of pre-loading the tissue, and the effect of ECM 
degradation on mechanical properties. The mechanical strength of the chorion does not 
appear to change over gestation, or whether non-laboured or laboured delivery occurred84. 
Furthermore, the puncture force required for failure of the chorion is approximately half 
that of the amnion. 
 
Our group has recently demonstrated that collagen fibre organisation can influence 
mechanical properties of the human term amniotic membrane86. Using second harmonic 
generation imaging to visualise collagen fibres the orientation could be determined to a 
high resolution (Figure 1.7). Samples were taken either parallel or perpendicular to the 
placental disc and cervical region, identified by placing sterile Babcock forceps onto the 
lower part of the membrane closest to the cervical region following delivery by elective 
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caesarean section. When force was applied in parallel to collagen fibre orientation, 
tangent modulus was higher for both cervical amniotic membrane and placental amniotic 
membrane specimens compared to when force was applied perpendicular, to fibre 
direction. Tangent modulus for placental specimens with force applied in parallel with 
collagen fibres was 7.5 MPa, significantly higher than when compared to cervical 
amniotic membrane (4.9 MPa). We further demonstrated ultimate tensile strength to be 
highest in placental amniotic membrane (4.52 MPa) when force was applied in parallel 
to fibres compared to perpendicular (1.51 MPa). Ultimate tensile strength values were 
also higher in cervical amniotic membrane (2.28 MPa) when force applied parallel to 
fibres compared to perpendicular and more disorganised fibre orientation (0.91 MPa, 
Figure 1.7). Interestingly, values reported in the literature indicate average failure 
strength of 0.9 MPa for the amniochorion.  Similar values have also been reported since 
amniochorion strength in term tissue, reporting being 2.29 MPa, very similar to our failure 
strength reported of 2.28 MPa when cervical amniotic membrane underwent stretch with 
collagen organisation parallel to the direction of strain36,86. This further suggests that the 
amnion alone dominates the overall fetal membrane mechanical properties and is an 
important determinant in fetal membrane rupture. 
 
Although the amnion makes up one third in thickness of the chorioamnion, it is evident 
that this is the load-bearing layer and must be considered a priority for researchers in 
understanding how fetal membranes rupture prematurely at both the biochemical and 
biomechanical level. For this reason, emphasis throughout this thesis is placed on the 
amnion where possible. 
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Figure 1.7: Variations in collagen fibre organisation in amniotic membrane samples of term fetal 
membranes imaged using second harmonic generation imaging. Samples were dissected adjacent 
to the cervical region or placental disc in perpendicular (top panel) or parallel (bottom panel) 
orientations (A). Stress strain curves shown for each condition (B) with tangent modulus values 
greatest in placental region specimens when force was applied in direction of the collagen fibres 
compares to cervical regions. Comparable results were found for ultimate tensile strength (UTS, 
C). Scale bars: 50 mm. CAM: cervical amniotic membrane; PAM: placental amniotic membrane. 
Adapted from Chowdhury et al., (2014)86. 
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Physiological and pathological membrane rupture 
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Chapter 2: Physiological and pathological membrane rupture 
 
Clinical motivations: Worldwide, there are 14.9 million preterm births with direct 
complications accounting for one million deaths87. 1 in 10 babies are born prematurely 
which presents a growing economic burden, costing the British economy $1 billion a year. 
Delaying preterm birth by just one week could save an estimated £260,000.  The socio-
economic cost associated with preterm birth in the United States has been estimated at 
$26.2 billion annually88. There is difficulty in researching PPROM due to its multifaceted 
etiology. This chapter will discuss what is known about physiological and pathological 
membrane rupture, leading on to the aims and objectives of this thesis.  
2.1 Normal physiological events of parturition 
 
There are 3 main mechanisms that can initiate and result in fetal membrane weakening 
and rupture: (1) myometrial contractions, (2) cervical remodelling, and (3) 
decidual/membrane activation. While these mechanisms are physiologically activated at 
term in a normal pregnancy, it is also becoming clear that they can be activated under 
pathological conditions during preterm pregnancy, contributing to PPROM. 
 
Myometrial contractions 
 
There are 3 phases of labour that occur within the myometrium: (1) proliferation phase, 
(2) synthetic phase, and (3) the contraction phase. Animal studies have shown that during 
uterine contraction the expression of cyclooxygenase-2 (COX-2), connexin 43 (Cx43), 
and the oxytocin receptor increases in the myometrium of term and preterm pregnancies89-
91. Stretch of human myometrial cells has also been shown to increase interleukin-8 (IL-
8) expression92. Furthermore, uterine contraction has also been linked with increased 
numbers of myocytes and a higher expression of the anti-apoptotic proteins Bcl-2 and 
Bcl-2l1 during the initial proliferation phase of labour93. Secondly, during the synthetic 
phase it has been shown that myocytes undergo hypertrophy, which correlates with 
increased secretion of the ECM proteins collagen type I and III. The final contraction 
phase within the myometrium has been linked with a decrease in interstitial matrix 
proteins and an increase in the basement membrane proteins, laminin and collagen IV. It 
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is important to note that these observations could be stimulated by infection, blood, 
distension of the uterus, polyhydramnios (excessive amniotic fluid production), and twin 
pregnancies, which have all been linked with myometrium contraction94-97. 
 
Cervical remodelling 
 
The cervical remodelling mechanisms regulate changes in the cervix including softening, 
ripening, dilation, and repair (after delivery). Regarding PPROM, changes in the cervix 
can be crucial and cervical remodelling that leads to shortening of the cervix has been 
shown to occur immediately before vigorous uterine contractions. This remodelling 
process involves the regulation of ECM proteins. Importantly, during cervical ripening 
collagen content decreases and fibrils become more dispersed, which could be explained 
by an increase in glycosaminoglycan (e.g. decorin and hyaluronan) content observed98. 
Dilation of the cervix occurs due to an inflammatory phenomenon that involves an influx 
of macrophages and neutrophils, and matrix degradation. Chemokines then attract 
inflammatory cells such as macrophages that secrete pro-inflammatory cytokines 
interleukin-1β (IL-1β) and tumour necrosis factor-α (TNF-α). These factors then activate 
nuclear factor-κβ (NF-κβ), which blocks progesterone receptor-mediated actions. Animal 
studies have shown the result is enhanced structural remodelling of the cervix, which is 
similar in preterm birth and in the cervix at term99. 
 
Decidual/membrane activation 
 
Normal rupture of the fetal membranes involves a complex anatomical and biochemical 
set of events that have yet to be fully understood. In humans the fetal membranes fuse 
with the decidua during pregnancy and at term they separate at the lower uterine segment, 
where spontaneous rupture of the membranes follows. The zone of altered morphology 
(ZAM) overlies the cervix and is the region of the fetal membrane that is first to undergo 
morphological changes in preparation for delivery3. Changes in the amniotic membrane 
involve basement membrane degradation, swelling of the stromal layers, and a decrease 
in thickness29,33. It has been suggested that immediately before term and preterm 
parturition a heavily glycosylated form of cellular fetal fibronectin (fFN) that is present 
at the chorionic-decidual interface is degraded causing its release into cervical and vaginal 
secretions100. This can initiate matrixmetalloproteases (MMPs) and COX-2, which 
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contributes to membrane softening. More extensive disruption occurs at the ZAM, which 
has been shown to decrease in collagen I, III, and V content. Interestingly, the levels of 
MMP-1, MMP-8, MMP-9, and neutrophil elastase are higher in women with PPROM 
compared to those in preterm labour with intact membranes101. 
2.2 Preterm premature rupture of membranes 
 
Preterm premature rupture of membranes (PPROM) is defined as the rupture of fetal 
membranes at less than 37 weeks gestation and prior to the onset of labour. Preterm birth 
can be divided into previable premature rupture of membranes occurring before 23 weeks 
gestation (generally accepted to be the limit of viability) and preterm premature rupture 
of membranes occurring from 23 to 37 weeks gestation (Figure 2.1). PPROM is further 
subdivided according to proximity to term, with 23 to 32 weeks gestation being remote 
from term PPROM and 32 to 37 weeks being near term PPROM. It is important to note 
that risk of perinatal morbidity and neonatal mortality decreases with increased 
gestational age and latency period (time of rupture to delivery). Chance of survival at 
delivery less than 23 weeks (previable PPROM) is close to 0%, at 23 weeks 15%, at 24 
weeks rises to 55%, and at 25 weeks rises to 80%. 
 
 
 
 
 
 
 
 
 
0 23 32 37 42
Preterm Term
remote from term near term
Gestational age (weeks)
Previable PROM Preterm PROM
Occurs before limit of 
viability (23 weeks).
Immediate delivery leads 
to neonatal death.
Affects 0.6-0.7% of 
pregnancies
High risk of perinatal 
morbidity and neonatal 
mortality.
High survival and 
low morbidity rate
Risk decreases with increased gestational age and latency period
Figure 2.1: Gestational age ranges for preterm and term deliveries. Preterm birth can be 
sub-divided in to previable premature rupture of membranes before 23 weeks gestation and 
preterm premature rupture of membranes occurring between 23 and 37 weeks gestation.  
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Although preterm birth does not always lead to neonatal mortality, over 50% results in 
long-term morbidity with severe life-long complications including respiratory distress 
syndrome, polymicrobial intramniotic infection, intraventricular haemorrhage, fetal 
pulmonary hypoplasia, skeletal deformities, cerebral palsy, and other 
neurodevelopmental impairments. Previable PPROM (<23 weeks) is also complicated if 
there is severe oligohydramnios or anhydramnios as this is a critical time period for fetal 
lung development. The fetus breathes fluid into the lungs, closing off the epiglottis to 
increase airway pressure, which is vital for normal fetal lung development. Pulmonary 
hypoplasia can occur if there is insufficient amniotic fluid in the gestation sac before 23 
weeks. This can lead to neonatal death even if the fetus is born many weeks or months 
after PPROM occurs. 
 
PPROM is a major cause of preterm birth and complicates 40% of preterm deliveries102. 
Overall, 3-5% of pregnancies are complicated by PPROM with 50-75% of patients 
delivering within 1 week, even with the aid of antibiotic therapy. Every year 60,000 
babies are born prematurely (1 in 9 babies in the U.K). Globally, 1 in 10 pregnancies will 
end in preterm birth. Preterm delivery rates are increasing irrespective of maternal and 
fetal medical research advances, with most recent data showing 9.63% of deliveries in 
the U.S. and 5-9% of deliveries in Europe being preterm. PPROM is therefore a major 
clinical problem and represents a growing economic burden worldwide. There is a clear 
shortage of research regarding preterm birth, specifically the pathology behind PPROM 
and the development of therapeutic interventions, which is likely due to its multifaceted 
etiology. 
 
2.2.1 Risk factors of PPROM 
 
Many maternal risk factors have been reported to increase the incidence of PPROM, such 
as a previous PPROM history, preterm labour, cigarette smoking, alcohol and drug 
consumption, anaemia, low socioeconomic status, maternal age, maternal weight (BMI < 
19.8 kg/m2), and antepartum vaginal bleeding (Figure 2.2)103-112. Prior history of PPROM 
is associated with a recurrence rate of 16-32%. Some reports suggest a more pronounced 
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link between PPROM and tobacco use, compared to women who delivered preterm due 
to spontaneous onset of labour103. A maternal age of less than 16 years has been linked 
with a 2-fold increase in preterm delivery when compared to women who were 18 – 29 
years of age108. In addition, a maternal age of 35 and over was also linked with increased 
preterm delivery rates110.  
Uterus, placental and fetal factors linked to increased incidence of PPROM include 
placental abruption reported to account for 15% of PPROM and uterine overdistension 
caused by polyhydramnios and multiple pregnancy. Interestingly, uterine overdistension 
has been linked with initiation of preterm labour by inducing inflammatory pathways111. 
PPROM is also estimated to complicate up to 10% of twin pregnancies. Furthermore, 
infection and inflammation is said to be a key risk factor in PPROM. One study showed 
infection diagnosed as chorioamnionitis occurred in 55% of preterm delivery patients113. 
Chorioamnionitis is likely to stimulate inflammatory processes and increase fetal 
membrane weakening factors (Figure 2.2). Other studies estimate chorioamnionitis is 
four times more prevalent in patients with PPROM than without PPROM113. Furthermore, 
disruption to the fetal membrane due to minimally invasive intrauterine fetal surgery can 
lead to iatrogenic PPROM in 30% of cases. Other procedures including amniocentesis, 
Figure 2.2: List of major maternal, uteroplacental and fetal PPROM risk factors  
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chorionic villus sampling and cervical cerclage can damage the fetal membrane, resulting 
in amniotic fluid leakage and increased incidence of PPROM. 
2.2.2 Pathological mechanisms 
 
The primary signals which initiate the inflammatory process and lead to AM weakening 
are unclear. Chapter 4 discusses in more detail the implication of the gap junction protein 
connexin 43 (Cx43) in absent AM healing. Chapter 6 discusses the implication of Cx43 
in AM weakening mechanotransduction mechanisms. In summary, previous studies in 
animal models have shown that tensile stretch increased myometrial expression of cyclo-
oxygenase-2 (COX-2), the oxytocin receptor and Cx4389-91. In human amniotic cells, 
application of 11 % static stretch activates NF-kB and induced expression of COX-2 and 
prostaglandin E2 (PGE2) production114. Cytokines such as interleukin-1β (IL-1β) activate 
NF-kB and increase production of matrix metalloproteinase-9 (MMP-9) and PGE2 in 
human amniochorion62,115-118. The enhanced PGE2 reduced collagen levels and increased 
tissue softening mediated by increased proteoglycans in human AM55,119,120. The changes 
in the matrix network are characterised by abnormal weakening of AM due to loss in 
tensile strength and mechanical resistance leading to PPROM84,121,122. Taken together, 
these findings highlight the complex nature of factors that control inflammation in fetal 
tissues. In addition, the mechanisms which initiate the repair of clinical PPROM are 
poorly understood making it difficult to identify targets and develop therapies which 
prevent PPROM following fetal therapy or promote AM healing after spontaneous 
PPROM. The proposed work in this thesis will investigate the role of Cx43 in AM tissue 
remodelling and healing. We speculate that a combination of inflammatory and 
mechanical factors disrupt AM biomechanics mediated by abnormal signalling via Cx43. 
Targeted knockdown of Cx43 in skin wounds improves healing and may be a potential 
therapeutic to promote AM healing and treat PPROM. 
 
Furthermore, Cx43 expression is downregulated in normal healing wounds. In human 
diabetic wounds and venous leg ulcers, healing is poor due to upregulation of Cx43 
expression123,124. This gap junction protein is additionally enhanced in several 
inflammatory conditions such as hepatic cirrhosis, acute-on-chronic liver failure and 
astrocytic death after ischaemia-reperfusion injury125,126. Previous studies report that 
topical application of a Cx43-specific antisense containing gel to acute wounds in rodent 
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models significantly accelerates the healing process whilst reducing inflammation and 
scar size123,126,127. Furthermore, in non-healing wound edge biopsies from human venous 
leg ulcers, knockdown of Cx43 with antisense technology resulted in accelerated cell 
migration whilst reducing adhesion, proliferation and led to profound effects on fibroblast 
cytoskeletal dynamics128. 
 
2.3 Iatrogenic preterm premature rupture of the membranes 
 
Intrauterine surgery for perinatal conditions (Table 2.1) has been performed for over two 
decades with precedence given to those conditions that carry the most severe 
complications. Fetal surgery is used when there is evidence that intervention before birth 
can improve the neonatal and adult outcomes in fetuses with structural anomalies, genetic 
or placental complications. The past decade has seen a dramatic increase in diagnostics, 
treatment, and fetal surgery physician expertise, and with that there has been an increase 
in the number of centres willing to offer surgical intervention for fetal abnormalities. 
Iatrogenic PPROM occurs in up to 35% of intra-uterine surgical cases, which undermines 
the success achieved by fetal surgeons129-131. There is also an increased risk of maternal 
infection due to the leakage of amniotic fluid and ascending bacterial infection increasing 
the risk to mother. 
 
2.3.1 Types of fetal surgery 
 
Fetoscopic procedures are the most common form of intra-uterine fetal surgery. 
Ultrasound guidance is used to assist the surgeon on inserting a trocar (Figure 2.3) into 
the uterus, piercing the maternal abdominal wall, the myometrium and ultimately the fetal 
membranes. The diameter of the instrument used varies between 1.3 – 3.3 mm, and can 
often lead to PPROM132-137. Fetoscopic laser ablation for the treatment of twin-to-twin 
transfusion syndrome (TTTS) improves outcome after TTTS but still a third of patients 
lose one or both babies, with most hospitals recording a 60-65% double survival rate138. 
Other common procedures are detailed in Table 2.1. 
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Figure 2.3: Typical 10.0 FR trocar used during fetoscopic surgery. A needle is placed within 
the trocar to assist insertion into the uterus and fetal membranes. The inner shaft of the trocar 
is then removed leaving the blue tube within the uterus and fetal membranes. 	
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Table 2.1: fetal complications and respective fetal surgery procedures. 
Complication Surgical procedure Details and outcome 
Twin-to-twin 
transfusion syndrome 
(TTTS) 
Fetoscopic laser 
photocoagulation. 
Mortality without treatment when diagnosed 
in mid-trimester is >80%139. 
Occurs in 15% of monochorionic twins. 
57% survival rate post-surgery associated 
with high preterm birth rates140. 
PPROM incidence after treatment reported in 
39% of cases at mean gestational age of 
29±4.5 weeks141. 
Congenital 
diaphragmatic hernia 
(CDH) 
Fetoscopic 
endoluminal tracheal 
occlusion. 
1 in 2,000 – 5,000 births. 
~75% survival rate post-surgery142. 
~30% stillborn. 
PPROM incidence after treatment reported in 
16.7% at 28 weeks and 33.3% at 32 weeks 
gestation143. 
Twin reversed arterial 
perfusion sequence 
(TRAPS) 
Selective bipolar 
cord coagulation and 
radiofrequency 
ablation. 
Severe variant of TTTS. 
Occurs in 1% monochorionic twins. 
50% stillbirth of the healthy twin if left 
untreated. 
PPROM incidence after treatment reported in 
22-57% of cases144,145. 
Obstructive uropathy/ 
lower urinary tract 
obstruction (LUTO) 
Performed using a 
percutaneously 
placed 
vesicoamniotic 
shunt. 
Incidence of LUTO is ~2.2 in 10,000 
births146. 
Fetal mortality rate of 43% if left 
untreated147,148. 
One study has shown in selected cases 91% 
survival rate in first year (mean gestation at 
delivery was 34.6 weeks)149. 
PPROM rates not well investigated. One 
study reports 1/7 cases resulted in 
PPROM150. 
Congenital cystic 
adenomatoid 
malformation 
(CCAM) 
Open fetal surgical 
resection of the lung 
mass involving 
maternal 
hysterotomy. 
Fetuses with large lung lesions often become 
hydropic and die in utero. 
One study showed in selected cases 60% 
survival rate following surgery151. 
PPROM incidence after treatment reported in 
16% of cases151-153. 
Sacrococcygeal 
teratoma 
 
 
Open fetal surgery 
involving maternal 
hysterotomy. 
Fetuses with large lesions given precedence 
due to high mortality risk. 
Perinatal mortality of 25-37%154. 
Most common congenital tumour occurring 
in 1-2 per 20,000 pregnancies155. 
PPROM rates not well investigated. 
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Table 2.1 continued. 
 
 
The growing demands to perform prenatal surgery for fetal abnormalities will likely lead 
to the increased incidence of iatrogenic PPROM. Taken into account with a rise in the 
number of pregnancies means it is ever more important for medical research advances to 
be made regarding PPROM prevention with preterm birth rates likely to increase further 
over the next decade. 
 
2.3.2 Fetal surgery effects on the fetal membrane 
 
Following spontaneous PPROM and fetal surgery procedures, the fetal membrane has a 
lack of healing ability. This often leads to devastating complications associated with 
preterm birth and can even mean the difference between life and death for the fetus. This 
absent healing exposes the fetus to ascending bacterial infection and disturbs amniotic 
fluid homeostasis. Numerous attempts have been made to seal fetal membrane defects 
(see section 5.1 fetal membrane sealing strategies) with limited success and no current 
clinically viable option. To date, there are limited studies on the effects of fetal surgery 
on the fetal membrane. Whilst many efforts have been made to prolong the latency period 
and prevent iatrogenic PPROM following fetal surgery, there is a gap in knowledge 
regarding fetal membrane healing. In order to improve the outcome of iPPROM 
preventative strategies it is important to understand why the fetal membrane fails to heal. 
Complication Surgical procedure Details and outcome 
Spina bifida 
(myelomeningocele)  
Open fetal surgery. Occurs in ~1500 infants born each year156. 
15-35% do not survive beyond 5 years157. 
PPROM rate of 46% following prenatal 
surgery158,159. 
Likely to move to a fetoscopic procedure in 
the future to reduce maternal morbidity. 
Congenital heart 
disease 
Balloon aortic 
valvuloplasty. 
Performed for severe mid-gestation aortic 
stenosis leading to hypoplastic left heart 
syndrome. 
A few studies have shown in selected cases 
75% survival rate over 5 years post-surgery. 
160,161. 
PPROM rate not well investigated. 
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The human fetal membrane is not innervated and is largely avascular, although the 
decidual surface of the chorion is occasionally found to contain blood vessels. Therefore, 
it is unreasonable to suggest the occurrence of a typical wound healing response involving 
the sequence of hemostasis, inflammation, proliferation, and remodelling. Gratacos., et 
al reported no spontaneous fetal membrane healing following fetoscopic procedures 
(n=19)162. Further findings suggest sliding of the amnion and chorion layers could be the 
reason for absent amniotic fluid leakage after many fetal surgeries. In addition, membrane 
attachment to the decidua may also prevent amniotic fluid leakage in minimal cases129. 
Frequently there is membrane separation seen after fetoscopic and open fetal surgical 
procedures where fluid is seen in the interface between the myometrium and the fetal 
membranes. Reports have found this condition to be associated with the formation of 
amniotic bands, umbilical cord strangulation, and fetal demise163. The amnion defects 
(14.4 mm2) are generally found to be bigger than the chorion defects (11.1 mm2) likely 
due to the increased distensible properties of the amnion. Absent cell proliferation has 
been detected in the fetal membranes following trauma56. Defect size has not been found 
to change over the elapsed time from surgical intervention to delivery (3-122 days)162. In 
a patient who underwent a repeat fetoscopy procedure, the initial fetal membrane defect 
was examined and exhibited no signs of healing129. There was no sliding of the amnion 
and chorion at the wound site, which was 5-6 mm in diameter. Papanna et al., 
demonstrated an absence of amniotic fluid leakage was most likely due to the membrane-
decidual adherence129. Interestingly, the inner muscular layer of the uterine wall showed 
no evidence of healing; a novel finding that shares similarity with patients that present 
with limited healing following previous caesarean section. 
 
Further studies reveal absent fetal membrane healing at the trocar site following 
fetoscopic laser surgery for twin-to-twin transfusion syndrome (n=31)164. Histological 
analysis showed thickened rounded edges and absent epithelialisation over the wound. 
Myofibroblasts, involved in normal contraction of wounds were also absent in the fetal 
membranes. Limited inflammation was also reported, and apoptosis levels appeared to be 
higher in amniotic epithelial cells compared to mesenchymal cells of the fibroblast layer. 
Currently there is no clinically successful means to plug iatrogenic defects post-surgery. 
This is probably due to poor understanding behind the pathophysiological mechanisms 
that lead to iatrogenic PPROM. Numerous approaches are being developed to prevent 
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PPROM following fetal surgery (see Chapter 5). Therefore, it is imperative to first 
understand why the fetal membranes fail to heal in order to improve the design and 
ultimately the clinical success of these strategies. 
 
2.4 Healing properties of the amniotic membrane 
 
In humans, histological analysis has reported that limited or no healing occurs following 
focal destruction of the membrane after fetoscopic surgery or after larger destruction of 
the membranes following open fetal surgery162,165. In some circumstances sealing has 
been reported when associated with cessation of amniotic fluid leakage after fetal surgery. 
However, it is now known that sliding of the two fetal membrane layers or adherence of 
the fetal membrane to the underlining decidua is likely to have caused the cessation of 
amniotic fluid leakage as opposed to healing mechanisms129,162. The mechanisms behind 
fetal membrane healing, or lack of, are not well understood. Spontaneous healing of the 
fetal membrane has been investigated in several species (Table 2.2). Limited or absent 
spontaneous healing has been reported in humans, non-human primates (rhesus monkey), 
sheep, rat, and rabbit fetal membrane130,162,164-171. Interestingly, this is not always the case, 
as some studies report spontaneous healing of the fetal membrane in swine and mouse 
species172,173. A fetoscopic access port site in a rhesus monkey remained open 6 weeks 
after surgery, showing no evidence of wound healing130. Observation of the fetoscopic 
defect revealed thickened wound edges. Similarly, sheep fetal membrane wounds do not 
heal166. Healing of the rabbit fetal membrane has been difficult to examine due to the 
short gestational period of 31 days. Therefore, time from fetal surgery to harvesting is 
limited to 7 days. When using a 14-gauge (2.1 mm diameter) needle during fetoscopy, 
the resulting histological analysis of wounds 7 days after surgery revealed no evidence of 
healing168. Furthermore, the first animal model to be studied was the rat, which were 
examined histologically171. Following injury the fetal membrane did not fully restore and 
no tissue proliferation was reported, although thickened wound edges were documented. 
 
In contrast, swine and mouse models have shown spontaneous healing properties and 
therefore are not suitable models for the study of fetal membrane sealants that could be 
potentially developed in humans172,173. In swine fetal membrane, defects of up to 4 mm 
in diameter showed spontaneous healing following harvesting of the fetal membrane after 
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approximately 44 days post-laparotomy172. Furthermore, in mouse fetal membrane 
defects of 0.47 mm in diameter, spontaneous healing was reported following 3 days post-
injury173. However, slightly larger wounds (0.91 mm in diameter) showed healing rates 
of only 40%. Furthermore, healing rates of the chorion were poor and incomplete 
compared to the amnion. Interestingly, this study shows macrophage recruitment occurs 
from the amniotic fluid in order to enhance tissue repair. The limited healing response of 
larger defects were attributed to compromised migration of mesenchymal cells and ECM 
deposition. Increased vasculature to the swine and mouse fetal membrane could also 
promote tissue repair. In species that show limited or no healing of the fetal membrane, 
it could be hypothesised that this is an evolutionary trait acting to prevent repair of the 
fetal membranes to avoid sealing of potential infection within the amniotic cavity. 
 
Table 2.2: Key in vivo studies on fetal membrane healing in different species 
 
Species Details Reference 
Human Reported no evidence of spontaneous healing when 
fetal membranes (N=19) were focally destroyed 
during intra-uterine fetoscopy. 
Delivery occurred between 3-112 days after 
fetoscopy. Proliferation indices were very low in 
chorion (range: 0-7%) and absent in amnion (0%). 
Gratacos et al., (2006)162  
 
 
 
Reported no evidence of spontaneous healing when 
fetal membranes (N=31) were focally destroyed 
during intra-uterine fetoscopy. 
Only evidence of tissue remodelling included 
thickened edges at the wound margin. 
No evidence of myofibroblasts presence in the 
fibroblast layer of the amnion, indicating the 
contraction phase of wound healing mechanisms is 
absent. 
Papanna et al., (2015)164 
 
 
 
Reported no evidence of fetal membrane restoration. 
Histological analysis revealed increased collagen 
staining in fetal membranes at suture sites 
(13.22±2.84%) compared to non-sutured sites 
(6.16±1.09%) in patients that underwent open fetal 
surgery for myelomeningocele (N=10).  
Suture sites show loss of amniotic epithelium 
compared to non-sutured sites. 
Carvalho et al., (2017)165 
Rhesus 
monkey 
Reported no evidence of spontaneous healing after 
fetoscopy (N=1). Following 6 weeks from fetal 
membrane damage to harvesting, the defect 
remained open. 
Devlieger et al., 
(2006)130 
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Sheep Limited ability to heal reported.  
Sheep underwent fetoscopic balloon occlusion of the 
trachea for experimental treatment of congenital 
diaphragmatic hernia between 88-99 days of 
gestation. At 145 days, histology of membrane 
defects did not show restoration (N=8). 
Devlieger et al., 
(2002)166 
Rabbit Limited ability to heal reported. 
Rabbits underwent fetoscopy at 23 days and samples 
were harvested at 32 days. It is reported that 40% of 
rabbits showed membrane restoration after 1 week. 
Interestingly MMP-2 and MMP-9, and MMP 
inhibitors all increased in amniotic fluid after 
surgery. 
Devlieger et al., 
(2000)167 
Limited ability to heal reported.  
Rabbits underwent fetoscopy at 23 days and samples 
were harvested at 30 days. Membrane integrity was 
maintained in 25% following injury with 14-gauge 
needle (2.1 mm defect diameter) when histologically 
assessed 7 days post-injury. However, complete 
restoration was not reported. 
Mallik et al., (2007)168 
 
Swine Yucatan miniature pigs were used to undergo 
laparotomy with a 12 Fr trocar (4 mm defect 
diameter) at 70 days gestation (term: 114 days). 
After histological examination, spontaneous healing 
of swine fetal membranes was reported following 
iatrogenic injury (N=14). 
Papanna et al., (2015)172 
Rat First known publication to study the response of 
animal fetal membrane to injury. Rats were 
subjected to laparotomy using 21-gauge needle (0.8 
mm defect diameter). Following 1, 2, and 5 days, the 
fetal membranes were harvested. At day 1, no 
sealing was evident and thickening of the wound 
edge was most profound in the amnion. By day 5, 
wound size had reduced but complete closure did not 
occur. Reduction is wound size was speculated to 
occur due to prolonged contraction of the uterine 
muscle. 
Sopher (1972)171 
Mouse 0.47 mm diameter wounds showed spontaneous 
healing 3 days post-injury in a mouse model. 
However, larger wounds (0.91 mm in diameter) 
showed healing rates of only 40%. Healing rates of 
the chorion were poor and incomplete compared to 
the amnion. Macrophage recruitment from the 
amniotic fluid reported to occur to enhance tissue 
repair. 
Mogami et al., (2017)173 
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2.5 Aims and Objectives 
 
Aim 1: We examined whether surgically induced membrane defects elevate Cx43 
expression in the wound edge of the AM and drives structural changes in collagen that 
affects healing after fetoscopic surgery. 
 
HYPOTHESIS: Connexin 43 is overexpressed in human fetal membrane defects after 
fetoscopic surgery. 
 
OBJECTIVES: We examined cell morphology and collagen microstructure by scanning 
electron microscopy and second harmonic imaging microscopy in fetal membranes taken 
from women who underwent fetal surgery. Immunofluoresence and real-time qPCR was 
used to examine Cx43 expression in control and wound edge AM. 
 
PROJECT OUTCOMES: Overexpression of Cx43 in the AM after fetal surgery induces 
morphological and structural changes in the collagenous matrix that may interfere with 
normal healing mechanisms. 
 
Aim 2: We investigated whether trauma induces Cx43 overexpression in human fetal 
membrane defects after artificial surgery. 
 
HYPOTHESIS: Cx43 is overexpressed in human amniotic membrane after in vitro 
trauma within our artificial fetoscopic trauma model. 
 
OBJECTIVES:  Term human FM were traumatised in vitro using an artificial trauma 
model that mimics fetoscopic surgery. Cell morphology and Cx43 were examined in the 
wound edge AM by immunofluorescence confocal microscopy and compared to control 
AM. Collagen microstructure was examined by second harmonic generation imaging. 
Cell viability was assessed with calcein and ethidium staining. 
 
PROJECT OUTCOMES: We showed that Cx43 is overexpressed in wounded fetal 
membranes after trauma and drives structural changes in collagen that slows down cell 
migration across the FM defect.   
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Aim 3: We will develop effective therapeutic repair of the FM defect created after 
fetoscopic surgery by (1) engineering bioactive membranes with peptide amphiphile 
sealants that promote tissue regeneration in the FM defect triggered by human amniotic 
fluid. 
 
HYPOTHESIS: PAs have the potential to co-assemble with the host macromolecules 
from the AF environment and form composite bioactive membranes with spatial and 
temporal control that effectively seal the FM defect.  
 
OBJECTIVES: Using the artificial trauma model, we will explore self-assembly of the 
PAs and examine structural properties and physical characteristics by SEM, histology and 
IMF. Mechanical properties, permeability and sealing response will be examined after 
sealing. 
 
PROJECT OUTCOMES: We were able to show potential sealing capacity of PAs in the 
FM defect using the artificial fetoscopic trauma model. 
 
Aim 4: To examine the effect of repetitive cyclic tensile strain on human fetal membrane 
weakening mechanisms and identify potential upstream therapeutic targets for prevention 
of ECM degradation. 
 
HYPOTHESIS: We hypothesise that CTS (1) increases Cx43 expression and 
overstimulates the PGE2 pathway, resulting in accelerated matrix breakdown and AM 
mechanical failure in a tissue-dependent manner and that (2) knockdown of Cx43 will 
restore normal tissue remodelling and promote healing mechanisms and repair in AM 
tissue after trauma. 
 
OBJECTIVES: We will perform cyclic tensile strain of human amniotic membrane 
samples using an ex-vivo bioreactor system. Analysis of strained and unstrained tissue 
samples will be performed to examine the production of fetal membrane sulfated 
glycosaminoglycan (sGAG), collagen, elastin; and release of prostaglandin E2 (PGE2) 
and total matrixmetalloprotease activity (MMP). We will examine the inhibition of Cx43, 
AKT, PI3-kinase and COX-2 on fetal membrane weakening mechanisms following cyclic 
tensile strain. 
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PROJECT OUTCOMES: We believe that downregulation of Cx43 with Cx43asODNs 
promotes AM healing and could be used to prevent AM weakening observed in PPROM 
patients. 
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Chapter 3 
 
Materials and Methods
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Chapter 3: Materials and methods 
 
3.1 Patient recruitment and tissue procurement  
3.1.1 Ethical approval 
 
Ethical approval was granted by the Joint UCL/UCLH Committees on the Ethics of 
Human Research (REC: 14/LO/0863). For the transfer of human fetal membranes (FM), 
placenta and amniotic fluid (AF) between University College London and Queen Mary 
University of London, a material transfer agreement (MTA) was arranged in accordance 
with the Human Tissue Act 2004. Human FM (n=69) were collected with informed 
consent from women undergoing elective caesarean section at University College London 
Hospital NHS Foundation Trust. Women with placenta praevia, multiple pregnancy, 
antepartum haemorrhage, PPROM, fetal growth restriction, clinical chorioamnionitis, 
meconium stained liquor, and maternal diabetes were excluded from the study. 
 
3.1.2 Collection of term fetal membranes after Caesarean section 
 
Term FM were collected following Caesarean section at 37-42 weeks gestation. 
Following delivery of the baby but before delivery of the placenta, a sterile Babcock 
tissue clip was placed on the lower edge of the FM overlying the internal os of the cervix 
within the uterine incision to provide a landmark. The placenta was separated from the 
uterus by gentle cord traction and after checking for clinical purposes in a clean hood, it 
was sampled. FM were dissected into 30 x 30 mm specimens, washed with Earle’s 
Balanced Salt Solution (EBSS) for 2 minutes to remove excess maternal blood and 
incubated in DMEM + 20% FCS (Sigma-Aldrich, UK). For experiments involving 
mechanotransduction studies and the use of the ex-vivo bioreactor, two regions were 
dissected from each amniotic membrane (AM): 
 
• Cervical amniotic membrane (CAM) 
The tissue was dissected within 5 cm of the region identified by the Babcock tissue 
clip overlying the internal os of the cervix. 
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• Placental amniotic membrane (PAM) 
The tissue was dissected at least 15 cm from the site identified as cervical AM and 
within 3 cm of the placental disc. 
 
3.1.3 Collection of fetal membranes after fetal surgery 
 
FM were also collected from patients that underwent fetoscopic laser ablation for twin-
to-twin transfusion syndrome (TTTS) and twin reversed arterial perfusion sequence 
(TRAPS); fetoscopic tracheal occlusion for fetal congenital diaphragmatic hernia (CDH), 
and open fetal surgery for spina bifida closure. These surgeries occurred at UCLH and 
University Hospitals Leuven, Belgium. Ethical approval was granted by the Ethics 
Committee at the KU Leuven (Ref: P008-2011) for samples obtained from Belgium. 
However, the procurement of these samples following patient consent was sometimes 
difficult, as patients would return to their booking hospital after treatment in the Fetal 
Medicine Units at KU Leuven or UCLH. In these cases, an effort was made to obtain a 
letter of access, which would allow collection of the tissue from other hospitals once 
delivery had occurred. This included Royal Berkshire Hospital (Reading), North 
Middlesex University Hospitals NHS Trust, and West Hertfordshire Hospitals NHS Trust 
(Watford General Hospital). 
 
Fetal surgical procedures were performed between 15+0 and 28+1 weeks of gestation and 
between 1 and 145 days before birth. During the surgery, the fetoscopic entry site was 
created by using a 10-Fr Teflon cannula (Cook Medical, Strombeek Bever, Belgium) and 
pyramidal trocar device (Karl Storz, Tuttlingen, Germany). At delivery, the fetoscopic 
defect site was identified by careful macroscopic survey of the fetal membrane, and the 
tissue around the wound was carefully excised. For the open fetal surgery, the 
hysterotomy wound was excised as part of the routine entry into the uterus at caesarean 
section, and then the membranes were stripped from the overlying myometrium. A 
control region in the fetal membrane that was aligned in the same axis as the fetal defect 
and was at least 5 cm away from the wound edge was excised. FM was washed with 
Earle’s Balanced Salt Solution (EBSS) for 2 minutes to remove excess maternal blood. 
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3.1.4 Amniotic fluid collection  
 
AF was collected from women undergoing fetoscopic laser ablation of placental vascular 
anastomoses for twin-to-twin transfusion syndrome in mid-trimester pregnancies. 
Immediately after ultrasound-guided placement of the laparoscope into the amniotic 
cavity, AF was withdrawn using sterile syringes (50-2000 ml). AF was also collected after 
amniodrainage and amniocentesis for polyhydramnios and diagnostic testing, 
respectively. 
 
3.2 Biochemical analysis of fetal membranes 	
3.2.1 Fetal membrane digestion 
 
To obtain dry weight of tissue, samples were freeze dried (-106oC, 0.03mbar) for 24 hours 
and then weighed. Freeze dried tissue was then digested by placing in 1 mL of activated 
papain enzyme digestion solution (100 mM Sodium Phosphate Buffer/5 mM 
Na2EDTA/10 mM L-cysteine 4U/mL papain) in a sterile tube. Samples were incubated 
overnight at 60oC for 18 hours and then vortexed to ensure full digestion. Tubes were 
then stored at -80oC until biochemical assay was performed. 
 
3.2.2 Determining DNA levels 
 
To measure DNA content within fetal membrane digest and media samples, the DNA-
specific fluorometric dye, Hoechst 33258 was used to generate a standard curve (Figure 
3.1). Hoechst 33258 binds to adjacent adenine-thymine base pairs of DNA and emits 
fluorescence at a wavelength of 460 nm. 
 
Deoxyribonucleic acid sodium salt from calf thymus (Sigma-Aldrich, D1501) was used 
as the standard and first diluted to 20 µg/ml using digest buffer and 2X saline sodium 
citrate (SCC) buffer mixed in a 1:1 ratio. Digest buffer was made by dissolving cysteine 
hydrochloride (0.788 g) and EDTA (0.403 g) in 0.5 L PBS, ensuring a pH of 6.0 by 
adjusting with 1 M NaOH if necessary. A 20X SSC buffer stock was prepared by 
dissolving sodium chloride (87.65 g) and trisodium citrate (44.1 g) in 0.5 L deionised 
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H2O and ensuring a pH of 7.0. Samples and standards are plated (100 µL/well) using a 
white polystyrene 96-well Nunc™ microplate. A working concentration of Hoechst 
33258 reagent is prepared by diluting 1:1000 with SSC/digest buffer (1:1). Hoechst 
reagent (100 µL/well) was then added to each well before measuring the fluorescence 
(460 nm) using the BMG FLUOstar OPTIMA microplate reader. 
 
 
3.2.3 Determining sulphated glycosaminoglycan content 
 
Dimethylmethylene blue (DMMB) reagent was prepared in a fume hood. DMMB (0.016 
g) was first added to ethanol (5 mL). Sodium formate (2.0 g) was then added to deionised 
H2O (850 mL). These two solutions were mixed until completely dissolved. The resulting 
mixture was made up to 1 L using deionised H2O. The pH was checked using a pH meter 
and adjusted to pH 3.0 if necessary. The final solution is light sensitive and therefore 
stored in the dark. 
 
Figure 3.1: Typical DNA assay standard curve showing the relationship of fluorescence 
intensity (460 nm) and the fluorimetric dye, Hoechst 33258. 
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Chondroitin sulphate was used to prepare a standard curve (Figure 3.2). The standard (1 
mg/mL) was diluted 1:10 with digest buffer before preparing a dilution series of 0-50 
µg/mL. Standard curves were checked to ensure R2 values of above 0.98. Prior to plating 
all standards and samples were vortexed. Samples and standards are run in triplicate (40 
µL/well) using a clear 96-well plate. A multichannel pipette was used to add DMMB 
reagent (250 µL/well). Plates were added to the SpectroNano Star and shaken at 360 rpm 
(10 seconds) prior to measuring absorbance at 595 nm. 
 
3.2.4 Quantification of collagen levels 
 
Amniotic membrane samples were digested using pepsin and acetic acid instead of papain 
in order to preserve the triple helix structure of collagen. Pepsin (1 mg/mL, Sigma, Poole, 
UK) was dissolved in 0.5 M acetic acid and added to freeze dried tissue samples for 48 
hours at 4oC on a rocker. Samples were then centrifuged at 15,000 x g for 1 hour. The 
supernatant was discarded and 1 mL of 6 M HCl was added to each sample and vortexed. 
The resuspended pellet was heated to 115oC for 24 hours and then samples were stored 
at -80oC until the hydrolysation and neutralization procedure using concentrated HCl. 
 
Concentrated HCl (38%) was added to each sample in a 1:1 ratio (approximately 100 µL 
each) and vortexed. The micro-centrifuge tubes were then placed in a heating block at 
Figure 3.2: Typical DMMB assay standard curve showing the linear relationship of 
absorbance at 595 nm and the chondroitin sulfate standards. 
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110oC for 18 hours. Samples were cooled to room temperature and centrifuged at 5000 x 
g for 5 minutes. Samples were dried in a fume hood for approximately 48 hours in a 
heating block at 50oC with the micro-centrifuge tube lids removed. 200 µL ultra-pure 
H2O was then added to each sample to dissolve pellet and vortexed until complete 
resuspension was achieved. Samples were stored at 4oC until the hydroxyproline assay 
was performed. 
 
The following solutions were prepared prior to running the hydroxyproline assay: 
 
• Hydroxyproline stock solution – 1 mg/mL trans-4-Hydroxy-L-proline (56250 
Fluka). This was stored at 4oC (maximum of 3 months). 
 
The following solutions were prepared fresh prior to each assay: 
 
• Citrate stock buffer – 5.04 g citric acid monohydrate (Sigma, C1909), 11.98 g 
sodium acetate trihydrate (Sigma S7670), 7.22 g anhydrous sodium acetate 
(Sigma, S2889), and 3.4 g sodium hydroxide (Sigma, 655104) was dissolved in 
80 mL ultra-pure H2O. 1.26 mL glacial acetic acid was added and pH adjust to 
6.1. Ultra-pure water was added to a total volume of 100 mL and solution filtered 
using Whatman paper. 
• Assay buffer – 1.5 mL n-propanol (Sigma, 402893) was added to 1 mL ultra-pure 
H2O and made up to 7.5 mL using citrate stock buffer. 
• Chloramine T Reagent – 141 mg Chloramine T (Sigma, 857319) was added to 0.5 
mL ultra-pure H2O and heated to 60oC for 10 minutes to dissolve. 0.5 mL n-
propanol and 4 mL citrate stock buffer was added and the solution wrapped in tin-
foil until use. 
• DMBA reagent – 4.5 g 4-(Dimethylamino)benzaldehyde (Sigma, 39070) was 
dissolved in 6 mL n-propanol and 3 mL 70% perchloric acid (Sigma, 244252) and 
the solution wrapped in tin-foil until use. 
• Hydroxyproline standard – 50 µg/mL hydroxyproline solution was prepared from 
1 mg/mL stock in PBE and vortexed. 
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A standard curve was prepared in triplicate using a clear 96-well plate (Figure 3.3). 60 
µL of samples and standards were used. To each well, 20 µL assay buffer and 40 µL 
Chloramine-T reagent was added and the plate was incubated for 20 minutes at room 
temperature in the dark to allow hydroxyproline oxidation. 80 µL DMBA reagent was 
added to each well ensuring solution is well mixed and clear. The plate was sealed and 
incubated for 20 minutes at 60oC for 20 minutes and then cooled to room temperature. 
The seal was removed, and absorbance read at 570 nm using the SpectroNano Star plate 
reader. 
 
3.2.5 Determining elastin content 
 
For determination of elastin content in fetal membranes, the fastin elastin quantitative 
dye-binding method (Biocolor) was used, which employs the dye 5, 10, 15, 20-
tetraphenyl-21H,23H-porphine tetra-sulfonate (TPPS). The binding of TPPS to elastin 
was first discovered in 1962 and termed “The Winkelman Reaction” after James 
Winkelman who discovered that most tissues took up the dye but only elastin would retain 
TPPS overtime. The assay has the ability to measure soluble tropoelastins, lathyrogenic 
elastins, and insoluble elastins when solubilized to elastin polypeptide fragments (α-
elastin, κ-elastin). The TPPS dye binds to non-polar and basic amino acid sequences 
found within mammalian elastin. It contains four sulfate groups and a synthetic 
Figure 3.3: Typical hydroxyproline assay standard curve showing the linear relationship 
between absorbance (570 nm) and trans-4-Hydroxy-L-proline dye. 
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porphyrin, 5,10,15,20-tetraphenyl-21H, 23H-porphyrin, which is water soluble in the 
sulfonate form.  
 
Extraction of insoluble elastin from fetal membrane 
 
Samples were lyophilized to obtain dry weight. Hydrophobic elastin within the fetal 
membrane tissue was first converted to a water-soluble derivative (α-elastin) by heating 
to 100oC in 0.25 M oxalic acid for one hour using a metal heating block. Samples were 
cooled to room temperature and centrifuged at 10,000 rpm for 10 minutes. The 
supernatant was collected and used for analysis. The residual tissue was then treated again 
with 0.25 M oxalic acid for one hour at 100oC. Initially, three heat extractions were used 
to determine if complete solubilisation of the tissue elastin had occurred.  
More than 98% tissue elastin was obtained from extraction 1. 50 µL of test sample and 
α-elastin standard were prepared in duplicate aliquots. Reagent blanks were prepared 
using 100 µL of test solution solvent (buffer/PBS/water/0.25 M oxalic acid). 
 
Elastin isolation 
 
Elastin was precipitated using elastin precipitating reagent pre-cooled to 4oC in a ratio of 
1:1. Equal volumes were added to both standards and test samples. The microcentrifuge 
tubes were vortexed and left for 15 minutes at room temperature to complete precipitation 
of α-elastin. Tubes were centrifuged at 10,000 x g for 10 minutes to pack the precipitated 
α-elastin. The tube was then inverted and supernatant discarded. Elastin-dye complex 
formation was performed by adding 1 mL dye reagent to each tube. The contents were 
then mixed by inverting and elastin precipitate dispersed by vortexing. Tubes were then 
placed on a shaker at room temperature for 1.5 hours to allow sufficient reaction between 
α-elastin and the dye reagent. Tubes were then centrifuged at 10,000 x g for 10 minutes. 
Supernatant was removed by inverting and tapping the tube to ensure excess unbound 
dye was removed. The elastin-dye complex can be observed as a reddish-brown deposit. 
Dye dissociation reagent (250 µL) was then added to each tube and vortexed. Tubes were 
then left at room temperature for 10 minutes before vortexing again to ensure all dye 
passed into solution. The contents of each tube were then transferred to a 96-well 
microplate (250 µL/well) and absorbance read at 513 nm. The absorbance of elastin 
reference standards were plotted to determine elastin content within test samples. 
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3.2.6 Determining prostaglandin E2 release 
 
Prostaglandin E2 concentration was determined using the Parameter PGE2 immunoassay 
(R&D Systems), which is based on a forward sequential competitive binding technique. 
PGE2 competes with horseradish peroxidase (HRP)-labeled PGE2 for a limited amount of 
binding sites on a mouse monoclonal antibody. During the first incubation PGE2 within 
the sample was allowed to bind to sites on the monoclonal antibody. During the second 
incubation HRP-PGE2 binds to the remaining monoclonal antibody binding sites. After 
washing to remove unbound materials, enzyme activity was determined by addition of a 
substrate solution. The colour development was then stopped using a stop solution and 
the absorbance was read at 450 nm (Figure 3.5). Colour intensity was inversely 
proportional to PGE2 sample concentration. 
80µg elastin 
Figure 3.4: Typical elastin assay standard curve showing the linear relationship between 
absorbance (513 nm) and elastin standard. 
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3.2.7 Determining total MMP activity 
 
Protease activity was measured using the fluorogenic peptide substrate (BIOMOL Cat. 
P-128) with sequence: DNP-Pro-β-cyclohexyl-Ala-Gly-Cys(Me)-His-Ala-Lys(NMA)-
NH2 (DNP=2,4-dinitrophenyl; NMA=N-Me-2-aminobenzoyl). Proteases (MMP-1, 
MMP-3, MMP-7, MMP-8, MMP-9, MMP-11, MMP-12, MMP-13, ADAM9/MDC9) 
cleave the Gly-Cys(Me) peptide bond resulting in a strong fluorescence by NMA 
(quencher) at 440 nm, once cleavage separates it from the aromatic DNP moiety. The 
active protease activity can be measured by correlating with fluorescence. 
 
The peptide substrate (MW: 1077.2) was dissolved with DMSO to 20 mM stock 
concentration and stored at -20oC in the dark. 10X substrate assay buffer [500 mM 
HEPES + 100 mM CaCl2 + 0.5% Brij-35 (30% conc.)] was prepared and pH maintained 
at 7 using 1 M formic acid or 1 M NaOH. This was used to prepare 1X substrate assay 
Figure 3.5: Typical prostaglandin E2 assay standard curve showing the relationship 
between absorbance (450 nm) and PGE2 standard based on a forward sequential 
competitive binding technique. 
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buffer A (without EDTA) and 1X substrate assay buffer B (with 500mM EDTA). 20 mM 
MMP substrate was added to each buffer to a concentration of 10 µM (1:2000 dilution). 
EDTA stops reaction and therefore 1X substrate assay buffer B was used as a negative 
control. Substrate assay buffer A and B alone were also used as negative controls. 20 µL 
of sample was added to a 96-well black flat-bottomed Nunc™ F96 MicroWell™ plate 
and 50 µL substrate assay buffer A or B was added in triplicate. A linear regression 
analysis of fluorescence at 340 nm excitation from 0-120 minutes was measured using 
the BMG FLUOstar OPTIMA microplate reader with shaking before each cycle (cycle 
number = 75 seconds; flashes = 10; delays = 0.5). 
 
3.2.8 Western blotting 
 
Western blotting was performed to investigate protein expression of Cx43, AKT, and the 
housekeeping control, GAPDH in amniotic membrane samples.  
 
Protein isolation 
 
RIPA lysis buffer (Sigma R0278) was prepared by adding 1 Roche complete mini 
protease inhibitor cocktail tablet per 10 mL buffer and supplementing with 50 µL 200 
mM activated sodium orthovanadate (Na3VO4) phosphatase inhibitor. Briefly, 200 mM 
Na3VO4 (Sigma S6508) was prepared by dissolving 367.8 mg in 10 mL ultra pure water 
(UPW) and pH adjusted to 10 using 1 M NaOH or 1 M HCl. At pH 10 Na3VO4 appears 
as a yellow solution, which was then boiled until the solution turned colourless and pH 
readjusted to 10. Tissue samples were snap frozen in liquid nitrogen prior to 
homogenisation using the Mikro Dismembrator U (Sartorious) for 2 minutes at 2000 rpm. 
The resulting tissue powder was resuspended in 100 µL RIPA lysis buffer. To ensure 
efficient homogenization, the lysate was then triturated through a 21G needle with a 1 
mL syringe up to 5 times. The lysate was then centrifuged for 15 minutes at 14,000 rpm 
and the supernatant containing the soluble protein fraction was collected. 
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3.2.8.1 BCA assay 
 
A Bicinchonic Acid (BCA) assay kit (Pierce 23227) was used to determine protein 
concentration. Bovine serum albumin (BSA; Sigma A2153) was used as the standard to 
generate a standard curve ranging from 0 – 2 mg/mL. A working reagent was prepared 
by adding BCA Reagent A to BCA Reagent B in a 50:1 ratio. 10 µL of each sample and 
standard was added to a 96-well microplate in duplicate and 200 µL of working reagent 
added to each well. The plate was mixed on a plate shaker for 30 seconds and then 
incubated at 37oC for 30 minutes. The SPECTROstar Nano (BMG Labtech) microplate 
reader was used to measure absorbance at 562 nm. A 4-parameter logistic regression 
curve (Figure 3.6) was generated using blank corrected absorbance values for each BSA 
standard against concentration (µg/mL) to determine protein concentration of unknown 
samples. 
 
 
Figure 3.6: Typical BSA standard curve showing the relationship between absorbance (562 
nm) and BSA standard. 
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3.2.8.2 SDS PAGE and protein transfer 
 
An equal volume of the supernatant soluble protein fraction (20 µg) was mixed with 
Laemmli 2x (Sigma 83402) loading buffer and boiled for 5 minutes at 100oC to denature 
proteins. Precast gels (Bio-Rad 456-9033) were removed from packaging and rinsed with 
1x running buffer prepared from 10x tris/glycine/SDS (Bio-Rad 161-0732). The kD™ 
Mini-PROTEAN© TGX™ precast gel was then placed in the loading bath and 1x running 
buffer loaded up to corresponding line depending on amount of gels being run. 30 µL of 
protein samples were then loaded into each well along with 5 µL of a Precision Plus 
Protein™ WesternC™ standard (Bio-Rad 161-0376) and the gel run at 200 mV for 30 
minutes. 
 
The gel was removed from the cassette after SDS-PAGE and placed into a Tran-Blot 
Turbo™ mini nitrocellulose transfer pack (Bio-Rad 170-4158). A roller was used to 
remove air bubbles and the protein transfer was run at 25V for 7 minutes. The 
nitrocellulose membrane was removed and stained in 0.1% Ponceau S (Sigma 141194) 
for 2 minutes to locate protein bands. The membrane was washed in PBS + 0.1% Tween 
for 5 minutes and placed into a 50 mL tube. 5% BSA was used to block for 1 hour on a 
roller at room temperature. The blocking solution was removed and primary antibody at 
desired concentration (Table 3.1) with endogenous control primary antibody added with 
PBS + 0.1% Tween and 5% BSA overnight at 4oC on a roller. The membrane was then 
washed with PBS + 0.1% Tween three times for 10 minutes at room temperature on a 
roller. The secondary antibody at the desired concentration (Table 3.1) was added with 
PBS + 0.1% Tween and 5% BSA for 1 hour in the dark at room temperature on a roller. 
The membrane was washed twice in PBS + 0.1% Tween for 10 minutes and once in PBS 
for 10 minutes in the dark at room temperature on a roller. 
 
3.2.8.3 Protein blot imaging 
 
Protein blots were scanned using the LI-COR Odyssey infrared imaging system for 
protein detection via infrared fluorescence. The Odyssey software was used for 
quantitative analysis of protein bands. Integrated intensity values were exported, and data 
normalized to endogenous control values. 
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Membrane stripping 
 
Protein blots were stripped by incubating in restore western blot stripping buffer (Thermo 
Scientific) for 30 minutes at room temperature with gentle agitation. Blots were washed 
twice in PBS-T for 10 minutes and could then be blocked as previously described. 
3.2.9 List of antibodies used in this thesis 
 
Table 3.1: Details of primary and secondary antibodies used in the present study. 
 
Antibody Species Predicted 
band size 
(kDa) 
Company 
(Catalogue no.) 
Dilution 
Cx43 Rabbit 43 Sigma C6219 1:4000 (IFM) 
1:8000 (WB) 
AKT-1/2/3 
 
Rabbit 56 Abcam 126811 1:1000 (WB) 
GAPDH 
 
Mouse 36 Abcam 8245 1:10,000 
(WB) 
Alexa 
Fluor® 488 
Goat (anti-
rabbit IgG) 
- Molecular probes® 
(Life 
Technologies™) 
1:400 
IRDye 
800CW 
Donkey 
(anti-rabbit 
IgG) 
- LI-COR 926-32213 1:10,000 (WB 
detection) 
IRDye 
680RD 
Goat (anti-
mouse IgG) 
- LI-COR 926-68070 1:10,000 (WB 
detection) 
IFM: Immunofluorescence microscopy; WB: Western blot 
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3.3 Measuring gene expression 
Gene expression analysis was performed for Cx43, COX-2, COL1A1, and GAPDH genes 
using the following steps outlined in this section. 	
3.3.1 RNA extraction 
 
Total RNA was extracted from tissue samples that had been stored in liquid nitrogen or 
preserved in RNALater. The workbench and homogenizing apparatus were cleaned of 
RNase contamination using RNase Away (Sigma-Aldrich). The Mikro Dismembrator U 
(Sartorious) tissue homogeniser was used to grind frozen tissue samples by placing the 
snap frozen tissue sample in the grinding chamber at 2000 rpm for 2 minutes. The 
grinding chamber also contained a metal ball bearing to assist homogenization. Following 
the homogenization, the chamber was removed and placed in a fume hood. TRI reagent 
(Sigma-Aldrich) added to the chamber covering the ground tissue and allowed to thaw 
for 5 minutes. TRI reagent is a monophasic solution of phenol and guanidinium 
isothiocyanate that denatures proteins and solubilizes biological material. A micropipette 
was then used to mix the thawed solution and transfer to a clean RNase-free tube.  
 
3.3.2 RNA isolation and purification 
 
To each tube containing the solubilised tissue solution, 200 µL of chloroform (Sigma-
Aldrich) was added and tubes were vortexed. The tubes were then centrifuged for 5 
minutes at 12,000 x g. Chloroform causes the solution to separate into 3 phases: (1) The 
aqueous phase containing RNA; (2) the middle interphase containing DNA; and (3) the 
organic phase containing proteins and lipids. The aqueous phase containing RNA was 
carefully transferred to a fresh RNase-free tube ensuring no contamination with the 
interphase containing DNA. Molecular biology grade isopropanol was then added to 
precipitate the RNA. The tube was vortexed and left for 10 minutes at room temperature 
to ensure full precipitation. The precipitated RNA was centrifuged for 10 minutes at 
12,000 x g. The supernatant was discarded, and the RNA pellet was washed using ice 
cold 75% ethanol and mixed by gentle inversion. The tube was centrifuged for 5 minutes 
at 7,500 x g and the supernatant (ethanol) discarded. The tube was inverted and left to air 
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dry for 10 minutes to remove excess ethanol. The RNA pellet was resuspended using 100 
µl RNase-free water and vortexed if necessary to assist RNA rehydration. 
 
The RNAeasy mini kit (Qiagen) was used for RNA purification and all work was 
performed on ice. Lysis Buffer RLT and 100% ethanol was added to the sample and 
mixed by pipetting. The solution was transferred to an RNAeasy spin column and 
centrifuged at 8,000 x g for 1 minute. The flow through was discarded. Wash Buffer RW1 
was added to the RNAeasy spin column and centrifuged at 8,000 x g for 1 minute. The 
flow through was discarded. This was repeated with half the volume of wash Buffer RW1 
and the flow through discarded following centrifugation at 8,000 x g for 1 minute. Elution 
Buffer RPE was added to the RNAeasy spin column and incubated for 5 minutes at room 
temperature. Following incubation, the RNAeasy spin column was centrifuged at 8,000 
x g for 1 minute, and the flow through discarded. Ice cold 75% ethanol was added to the 
RNAeasy spin column and centrifuged at 8,000 x g for 2 minutes. The flow through was 
discarded and the column allowed to dry for 5 minutes to remove ethanol. The RNAeasy 
spin column was then centrifuged again at 8,000 x g for 5 minutes to remove traces of 
ethanol. The inner RNAeasy spin column was then transferred to a fresh collection tube 
and 50 µL RNase-free water was added. To elute the RNA the RNAeasy spin column 
was centrifuged at 10,000 x g for 1 minute. The RNA is found in the flow through and 
this was transferred to a fresh RNase-free tube before removing DNA contamination. 
 
The Ambion® DNA-free™ DNase Treatment Kit was used to remove DNA 
contamination from the RNA preparations and then remove DNase and divalent cations 
(magnesium and calcium which catalyse RNA degradation when heated) from the 
sample. The procedure is designed to remove trace to moderate amounts of DNA (up to 
50 µg DNA/mL RNA) from RNA preparations to a level that is non-detectable during 
real-time RT PCR. 
 
Treatment was performed in 0.5 mL tubes to facilitate removal of the supernatant after 
treatment with the DNase inactivation reagent. 10X DNase I buffer (0.1 volume) and  
1 µL rDNase I was added to the RNA and gently mixed. The solution was incubated for 
30 minutes at 37oC. The DNase inactivation reagent was resuspended by vortexing and 
added (0.1 volume). The solution was incubated for 2 minutes at room temperature and 
mixed intermittently to re-
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centrifuged at 10,000 x g for 1.5 minutes and the supernatant (purified RNA) was 
transferred to a fresh tube. The Nanodrop ND-1000 spectrophotometer was used to 
measure yield and purity of purified RNA preparations. 
 
3.3.3 First strand cDNA synthesis by Reverse Transcription 
 
Reverse transcription was performed using the Enhanced Avian RT First Strand Synthesis 
Kit (Sigma-Aldrich) to produce high quality full-length cDNA from total RNA. Between 
200 – 500 ng total RNA were transferred to a 500 µL thin-walled PCR microcentrifuge 
tube and placed on ice. Nuclease-free water and 1µL Oligo (dT)23 primer, which 
specifically binds the polyA tail of mRNA, was added to a total volume of 10 µL. The 
tube was placed in a thermal cycler for 5 minutes at 70oC to denature RNA and then 
immediately placed onto ice to prevent RNA aggregation. A mastermix was prepared for 
each reaction using 10X buffer for eAMV-RT (1X final concentration), Enhanced avian 
RT enzyme (1 unit/µL), RNase inhibitor (1 unit/µL), deoxynucleotide mix (500 µM each 
dNTP), and water. 10 µL of the prepared mastermix was added to the denatured RNA to 
allow a total volume of 20 µL per reaction. A minicentrifuge was briefly used to ensure 
all liquid had collected at the bottom of the microcentrifuge tube. Tubes were placed into 
the thermal cycler and heated for 1 hour at 42oC. The first strand cDNA has now been 
prepared and this was stored at -20oC or used immediately for the PCR amplification step. 
 
3.3.4 Quantitative real-time PCR 
 
Forward and reverse primer concentrations were optimized for the following genes: (1) 
connexin-43 (Figure 3.8), (2) cyclooxygenase-2 (Figure 3.9), (3) Collagen type I α1 
(Figure 3.10), and (4) GAPDH (Figure 3.11). Following the primer optimisation steps 
described below, a clear 96-well PCR plate was used to prepare each PCR reaction 
containing cDNA, primers and SYBR green master mix (2X) which binds to DNA. After 
setting up each reaction the PCR plate was briefly centrifuged to ensure all liquid was 
collected at the bottom of each well. The plate was placed in the Mx3000P Stratagene 
PCR machine. A quantitative SYBR green dye and normal 3-step PCR procedure was 
selected. A dissociation/melt curve was also selected to analyse the PCR specificity and 
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check for the formation of primer-dimers in the sample during the final analysis. The 
cycle parameters detailed in Table 3.2 were used during PCR procedure. 
 
Table 3.2: Thermocycling conditions for quantitative polymerase chain reaction. 
 
1. Denaturation/RT 
Inactivation 
95oC 3 minutes 1 cycle 
2. Denaturation 
3. Annealing 
4. Extension 
95oC 
55oC 
72oC 
30 seconds 
1 minute 
1 minute 
40 cycles 
5. Final Extension 
6. Hold 
72oC 
4oC 
5 minutes 1 cycle 
 
3.3.5 Quantitative PCR assay optimisation and data analysis 
 
Threshold cycle (CT) values obtained from the Mx3000P Stratagene PCR machine were 
analysed using the MxPro QPCR software. Amplification plots were generated for each 
reaction with fluorescence (dRn) against cycle number (Figure 3.7). The threshold was 
set within the lower third of the linear phase of the amplification plot and remained 
constant for all experiments. Mean CT values were normalized to GAPDH endogenous 
control data and the Pfaffl method used to calculate gene expression fold change as 
described below. Furthermore, ROX reference dye (Invitrogen) was used to normalize 
the fluorescent reporter signal as an internal reference to normalize for non-PCR related 
fluctuations in fluorescence caused by pipetting error and machine “background noise”, 
as well as to compensate for instrument excitation and detection variations. 
 
Optimising the qPCR assay 
 
Primers were optimized for use with fetal membrane cDNA samples and to ensure 
amplification reaction efficiencies between 95-105%. PCR primer concentrations were 
optimised using a dilution series of known template concentrations to establish a standard 
curve (Figure 3.8-3.11) and identify the reaction efficiencies shown in  
Table 3.3. The log starting quantity (relative, x-axis) of each known concentration in the 
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dilution series was plotted against the CT value for the corresponding concentration (y-
axis). A variety of information could now be deduced from this standard curve including 
the efficiency of the reaction and other reaction parameters that include the correlation 
coefficient (R2), slope, and y-intercept. Importantly, the R2 value is a measure of the 
linearity of the standard curve with <0.98 generally considered acceptable. 
 
Table 3.3: Forward and reverse gene sequences with optimal concentrations and 
correlating reaction efficiency values. 
Cx43: connexin 43; COX-2: cyclooxygenase-2; COL1A1: Collagen type I α1; GAPDH: Glyceraldehyde 3-
phosphate dehydrogenase (housekeeping gene). 
 
Ideally, to obtain most reproducible data, the efficiency of a reaction should be close to 
100% as possible, meaning the template will double after every PCR cycle during the 
exponential phase of the amplification. To identify the reaction efficiency, the slope of 
the log-linear phase from the amplification plot was used in the following equation where 
E = reaction efficiency: ! =	10&( ()*+,-) 
 
A number of factors can influence the efficiency of a reaction and lead to reaction 
efficiencies below 90% including the purity of the RNA used for cDNA synthesis, not 
using optimal reagent concentrations; and length, structure, and GC content of the 
amplicon. Furthermore, the reaction efficiency can often reach above 110% due to the 
presence of PCR inhibitors within the reagents. Importantly, reaction efficiency between 
90% and 110% is considered acceptable which correlates to a slope of -3.58 to -3.10 and 
Gene Sequence nM Efficiency 
Cx43 Forward: 5’CTCGCCTATGTCTCCTCCTG-3’, 
Reverse: 5’-TTGCTCACTTGCTTGCTTGT-3’ 
100 98% 
COX-2 Forward: 5′-GGACAGGATTCTATGGAG-3′, 
Reverse: 5′-GGATGTCAACACATAACTC-3′ 
200 98% 
COL1A1 Forward: 5′-CCCCGAGGCTCTGAAGGT-3′,  
Reverse: 5′-CACCAGCAATACCAGGAGCA-3′ 
300 101% 
GAPDH Forward: 5’-TCTCTGCTCCTCCTGTTC-3’, 
Reverse: 5’-CGCCCAATACGACCAAAT-3’ 
300 97.5% 
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assists towards PCR assay reproducibility. Furthermore, the specificity of primers were 
improved following optimisation procedures (Figure 3.12). 
 
Figure 3.7: Amplification plots showing typical before and after amplifications for Cx43 
and GAPDH qPCR assays following several optimisation steps that improved RNA 
purification, DNA contamination removal prior to first strand cDNA synthesis, and 
optimisation of primers during the final qPCR assay. The bottom panel shows 
amplification plots with negligible noise indicating removal of DNA contamination. 
Repeats reactions also appear reproducible compared to top panel following 
optimisation steps. The amplification plots show typical 10-fold dilution series for Cx43 
primers (left) and GAPDH primers (right) where red arrows indicate poor repeats prior 
to optimisation steps and yellow arrows show improved coupling of repeats at each 
dilution of cDNA. 
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The optimal reaction efficiency obtained from standardized PCR assays were then used 
to help calculate gene expression fold change using the Pfaffl’s method174, which uses 
the equation below during analysis of CT values, taking into account reaction efficiency 
values (E). 
 
/0123	 = 	 41 + !6789-:;6789-:∆=> (?!@AB0C2DE013E − G0HICJ)41 + !K-L-8-MN-;K-L-8-MN-∆=> (?!@AB0C2DE013E − G0HICJ) 
 
 
Typical standard curve analysis for Cx43, COL1A1, GAPDH, and COX-2 primers 
 
 
 
 
Figure 3.8: Standard curve showing initial copy number of template vs. threshold cycle (Ct). 
Real-time PCR of 10-fold serial dilutions of human amniotic membrane cDNA was performed 
using 100 nM of a Cx43 forward and reverse primer. Reactions (3 replicates per dilution) 
were incubated 2 minutes at 95°C, followed by 40 cycles of 95°C, 15 sec; 60°C, 1 minute; 
72°C, 1 minute using an Mx3000P quantitative PCR instrument. 
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Figure 3.9: Standard curve showing initial copy number of template vs. threshold cycle (Ct). 
Real-time PCR of 10-fold serial dilutions of human amniotic membrane cDNA was performed 
using 300 nM of a COL1A1 forward and reverse primer. Reactions (3 replicates per dilution) 
were incubated 2 minutes at 95°C, followed by 40 cycles of 95°C, 15 sec; 60°C, 1 minute; 
72°C, 1 minute using an Mx3000P quantitative PCR instrument. 
Figure 3.10: Standard curve showing initial copy number of template vs. threshold cycle (Ct). 
Real-time PCR of 10-fold serial dilutions of human amniotic membrane cDNA was performed 
using 300 nM of a GAPDH forward and reverse primer. Reactions (3 replicates per dilution) 
were incubated 2 minutes at 95°C, followed by 40 cycles of 95°C, 15 sec; 60°C, 1 minute; 
72°C, 1 minute using an Mx3000P quantitative PCR instrument. 
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Figure 3.11: Standard curve showing initial copy number of template vs. threshold cycle (Ct). 
Real-time PCR of 10-fold serial dilutions of human amniotic membrane cDNA was performed 
using 200 nM of a COX-2 forward and reverse primer. Reactions (3 replicates per dilution) 
were incubated 2 minutes at 95°C, followed by 40 cycles of 95°C, 15 sec; 60°C, 1 minute; 
72°C, 1 minute using an Mx3000P quantitative PCR instrument. 
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Figure 3.12: Melting curve analysis before and after key optimisation steps taken in the design of the 
PCR protocol. Cx43 and GAPDH primers are given here as an example. Key steps included 
improvement of RNA purification, DNA contamination removal prior to first strand cDNA synthesis, 
and primer optimisation. A rise in absorbance intensity indicates the dissociation of double-stranded 
DNA during heating; therefore, ideally a single peak (yellow arrow) is desirable and indicates a high 
standard of primer specificity without primer-dimer formation. 
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3.4 Determining cell viability 
 
Live-dead staining 
 
Cell viability was determined using a two-colour assay to stain and identify viable or non-
viable cells within the tissue using Calcein-AM (Molecular Probes, Cambridge, UK) and 
Ethidium homodimer-1 (Calbiochem, Nottingham, UK), respectively. To assess cell 
viability of fetal membrane specimens, 2 mL DMEM+20%FBS containing 5 µM Calcein-
AM and 5 µM Ethidium homodimer-1 was prepared. The tissue specimen was submerged 
fully in the solution for 30 minutes with gentle agitation at room temperature. The 
specimen was then mounted on a glass slide and a coverslip was placed on top to flatten 
the tissue. Calcein-AM can permeate cells and is non-fluorescent, however, upon contact 
with intracellular ubiquitous esterases, calcein-AM is converted to highly fluorescent 
polyanionic calcein which is well retained within live cells. In live cells, calcein produces 
an intense uniform green fluorescence (~515 nm) when excited at ~495 nm. Ethidium 
homodimer-1 enters non-viable cells where the cell membrane has been perforated and 
non-covalently binds to nucleic acids producing a 40-fold increase in fluorescence. In 
non-viable cells, Ethidium homodimer-1 will bind DNA and emit a red fluorescence (635 
nm) when excited with green light at 495 nm. 
 
Data procurement and statistical analysis 
 
To determine cell viability, fluorescence microscopy (Leica, Milton Keynes, UK) was 
used with a x20 objective. A typical fetal membrane sampling area was imaged with a 
field view of approximately 0.5 mm x 0.5 mm and the number of viable (green) and non-
viable (red) cells were recorded. The percentage viability was then calculated [(viable 
cells/total cells)*100%] through full thickness fetal membrane containing both epithelial 
and fibroblast layer cell populations. The mean percentage viability was calculated from 
3 replicate cell counts from different field views of approximately 0.5 mm x 0.5 mm and 
data presented with standard error of the mean. To determine cell viability in fetal 
membrane that had been treated with various peptide amphiphile solutions, the same 
procedure was performed however, the tissues were previously incubated with specific 
peptide amphiphiles in 24-well plates for 2 hours at 2% (w/v). The peptide amphiphile 
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solution was then replaced with DMEM+20%FBS for up to 24 hours before assessing 
cell viability. 	
3.5 Immunofluorescence confocal microscopy 
 
Tissue preparation 
 
Amniotic membrane samples were fixed in 4% PFA for 2 hours at room temperature and 
then transferred to PBS. Samples were washed twice in PBS for 5 minutes on a shaker. 
After the second wash, samples were transferred to PBS +Triton X-100 (0.1%) + lysine 
(0.1%) to permeabilise intact cell membranes in order for primary and secondary 
antibodies to enter the subcellular structure and bind target antigens. Tissue samples were 
then blocked to reduce non-specific binding using 1% serum from the secondary antibody 
host (rabbit) with PBS + Triton X-100 (0.1%) and placed on a shaker at room temperature 
for 1 hour.  
 
The primary antibody for Cx43 (anti-rabbit; Sigma-Aldrich C6219) was then used to stain 
blocked tissue samples at 1:4000 dilution in PBS + Triton X-100 (0.1%). Primary 
antibody stain was placed in cold room (4oC) overnight on a shaker (16 hour incubation).  
The tissue was washed in PBS 3 times on a shaker for 5 minutes each.  Alexa Fluor 488 
anti-rabbit (Life Technologies) was used as a secondary antibody at a dilution of 1:400 in 
PBS + Triton X-100 (0.1%). Tissue samples were incubated for 1.5 hours on a shaker at 
room temperature and then washed in PBS 3 times on a shaker at room temperature for 
10 minutes each. DAPI was then used to stain DNA by diluting to 1:1000 and incubating 
in PBS +Triton X-100 (0.1%) for 15 minutes at room temperature on a shaker. Samples 
were then washed 3 times in PBS for 5 minutes on a shaker at room temperature.  
 
Tissue samples were carefully placed onto Superfrost/Plus microscope slides (Fisher 12-
550-15) and folds removed carefully using tweezers with minimal manipulation of the 
tissue. Three drops of viscous CitiFluor (anti-fade mountant) were added to the tissue and 
coverslips (22x30-1.5, Fisher 12-544-D) carefully lowered onto the solution to reduce the 
chance of air bubbles. Clear varnish was used to seal the coverslip and slides were stored 
at 4oC in the dark until imaging.  
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Antibody control staining was performed to identify the specificity of the Cx43 antibody. 
Primary and secondary antibody incubations alone reveal no punctate staining (Figure 
3.13 a, b). However, positive control staining of mesenchymal cells within the fibroblast 
layer of the amniotic membrane reveal punctate staining expected from Cx43 plaques 
(Figure 3.13 c, green channel) of around 0.1 – 1 µm. Increasing the intensity of the green 
channel reveals autofluorescence of mesenchymal cells in all conditions (Figure 3.13 a-
c, dark green). 
 
Amniotic membrane samples were imaged using a Leica TCS SP8 acousto-optic 
beamsplitter (AOBS) multi-photon laser scanning confocal microscope (Leica, Milton 
Keynes, UK) with a Coherent Chamerleon Ultra, Ti Sapphire mode-locked IR laser 
(Coherent UK Ltd, Cambridge, UK). Samples were imaged using a 25x/0.95 NA water-
immersion objective. The Cx43 signal (920 nm excitation) was collected with the non-
descanned external HyD detector through a FITC emission filter (500 – 550 nm barrier 
filter). The DAPI signal was collected sequentially with 405 nm excitation to avoid bleed 
through of the nuclear signal into the Cx43 signal and emission signal via the confocal 
pin-hole to the de-scanned HyD detector between 400 and 490 nm. 
 
Microscope slides were placed into the slide holder on the mechanical stage and could be 
manipulated using the IPC2U microscope controls in X, Y and Z directions. Before 
imaging the Leica STP6000 monitor was switched on and the optical parameter oscillator 
(OPO) and remote was connected. Prior to imaging, the condenser was always reset to 
ensure the light was focused at the correct distance from the sample. 
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Figure 3.13: Cx43 antibody specificity was determined by staining cervical term amniotic 
membrane tissue in incubations of primary antibody only (A) secondary antibody only (B) and 
positive control primary and secondary antibody (C).  When threshold was increased during 
image analysis, autofluorescence of mesenchymal cells is present in negative controls (A,B), 
however with the same threshold, connexin-43 plaques (0.1 -1 µm) can be seen using 1:4000 
dilution Cx43 primary antibody and 1:400 dilution Alexa Fluor® 488 secondary antibody (C). 
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3.6 Second-harmonic generation imaging microscopy 
 
Second-harmonic imaging microscopy utilises the non-linear optical effect known as 
second-harmonic generation (SHG). As above, the Leica TCS SP8 AOBS multi-photon 
confocal laser scanning microscope was used for image acquisition and the SHG signal 
was collected via the transmission detector and 430 – 450 nm barrier filter with a pump 
wavelength of 880 nm at 80 fs pulse width. To obtain SHG signals the 460/20 nm SHG 
filter (half 920 nm wavelength) was inserted. The pinhole was set to maximum throughout 
imaging. The SHG signal was collected sequentially with Cx43 and DAPI signals, 
therefore the laser was retuned automatically following collection of these signals. 
 
3.7 Image analysis 
3.7.1 Immunofluorescence data analysis 
 
Full thickness volumes (approximately 150 µm) of amniotic membrane samples were 
acquired at 1.5 µm z-section intervals using the data acquisition system and Leica LAS 
X software; which can control the motorized stage containing the sample. Figure 3.14 
shows representative full thickness AM term explants imaged using optimal parameters 
for confocal laser scanning microscopy and second harmonic imaging microscopy. The 
parameters for laser power, detector gain, and offset remained constant for each sample 
so that direct comparisons could be made per patient and permit quantification. Data was 
collected a resolution of 1024 x 1024 and a speed of 600 Hz with bidirectional mode 
enabled to allow scanning in both directions. A line average of 3 was used in order to 
reduce background noise.  
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Figure 3.14: Optimal AM imaging parameters for confocal laser scanning 
immunofluorescence (blue – nuclei) and second harmonic generation microscopy (red – 
collagen). Example shows full thickness AM with separate layers including (1) amniotic 
epithelial layer, (2) compact layer, (3) fibroblast layer, and (4) intermediate spongy layer. 
The AM cross-section reveals nuclei staining for the epithelial cells of the epithelial layer (1) 
and mesenchymal cells of the fibroblast layer (3). 
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ImageJ (Fiji) was used to perform image analysis and quantification. Cx43 
immunostaining levels were quantitatively evaluated per tissue area and per cell nuclei 
using a well-established pixel-counting method in control and wounded AM. Maximum 
projections were performed in the AM to examine the cell populations in the fibroblast 
and epithelial layer. The images were converted to binary images using identical 
threshold values and objects exceeding 2 pixels were counted to identify Cx43 positive 
pixels per tissue area (pixels per 500 µm2 area of tissue) or per cell nuclei. Key steps taken 
to quantify both nuclei amount and Cx43 expression are shown in flow charts below 
(Figure 3.15 and 3.16). To quantify, initially the image was converted to binary and 
threshold adjusted with a dark background applied. Images were then converted to black 
and white and a particle analysis was performed given in pixel units. In order to remove 
background, 2-Infinity was applied, which removes noise of 2 pixel units or less. Results 
were enabled for total pixels per area in µm2 and also total area coverage. Nuclei count 
was also carried out by thresholding and performing a particle analysis, however, smaller 
particles were excluded by applying 200-infinity and the “fill hole” parameter applied to 
avoid double counts. The “watershed” feature was also applied in order to separate nuclei 
that appeared to overlap and would have been miscounted. 
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Analysis of nuclei count 
 
Figure 3.15: Key steps in image processing for nuclei count within epithelial and fibroblast layer 
of the amniotic membrane using ImageJ software. 
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Analysis of protein Cx43 plaque count 
 
 
 
Figure 3.16: Key steps in image processing for Cx43 plaque count within epithelial and fibroblast 
layer of the amniotic membrane using ImageJ software. 
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3.8 Scanning electron microscopy 
 
SEM was used to provide a view of the surface topography of tissue or self-assembled 
membranes. The technique allowed imaging of large areas (up to 50 µm2) of sample to 
study microstructure and nanofibrous 3-D architecture up to a resolution of 3 nm and a 
magnification range between 20x and 30,000x. The SEM involved acceleration and 
focusing of electrons into a sample chamber from an optical column, which contains the 
electron gun and lenses. The sample is then scanned in a sequence of horizontal lines and 
the image is constructed after detection of secondary electrons that are ejected from 
specific points of the sample. A low acceleration voltage of 5 kV was used as the SEM 
beams were not required to penetrate the sample.  
 
Human tissue samples were fixed in 4% paraformaldehyde for 2 hours at room 
temperature. Peptide amphiphile and amniotic fluid self-assembled membranes were 
fixed in 2.5% glutaraldehyde (0.1% NaCl) for 2 hours at room temperature and then 
washed three times in MilliQ water. Samples were then dehydrated in increasing 
percentages of ethanol for 10 minutes each in 20%, 50%, 70%, 90%, 96%, and 100%. 
Samples were then dried using the critical point drier (K850, Quorum Technologies, UK). 
The samples were mounted onto copper tape and placed on stub. The sample was then 
sputter coated with palladium/gold (30 nm). Samples were then placed onto the sample 
stage within the SEM chamber and then the vacuum environment was induced. The 
imaging was performed using an Inspect F50 (FEI Comp, Netherlands). 
 
3.9 Histological analysis 
 
3.9.1 Chemical fixation 
 
Fetal membrane tissue was fixed in 4% paraformaldehyde for 2 hours at room 
temperature and then transferred to PBS and stored at 4oC. Fixation in 4% 
paraformaldehyde is ideal for a number of routine histological applications such as 
haematoxylin and eosin (H&E) staining. Due to the difficulty in maintaining a flat 
orientation of fetal membrane tissue, the tissue was fixed within a cassette sandwiched 
between 2 pieces of gauze before being submerged in 4% paraformaldehyde. If necessary 
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amniotic membrane was later separated from the chorionic membrane by gentle traction 
and dissected into approximately 2 cm x 2 cm specimens. PA membranes were fixed in 
2.5% glutaraldehyde by applying directly to the in vitro fetal membrane wound model or 
within the PDMS channel with MilliQ water for 2 hours at room temperature and then 
transferred to PBS and stored at 4oC. The PA membranes were then washed four times 
with MilliQ water. 
 
3.9.2 Tissue processing 
 
Due to fetal membrane tissue being approximately 300 µM in thickness, the tissue was 
placed onto a small corkboard and pinned at each corner to maintain the orientation and 
prevent tissue curling. In the circumstance when fetal membrane wounds and tissue 
sealants were being examined it was at this point that a pin would be used to mark the 
wound edge/tissue sealant region with india ink to identify during tissue sectioning. Fixed 
tissue was then embedded in paraffin wax following dehydration by graded ethanol 
washes from 0% - 100% in order to prevent tissue distortion. This was then followed by 
xylene washes, which promotes efficient impregnation of the hydrophobic paraffin wax. 
During this process the water in fixed tissue is replaced with paraffin wax, which enables 
thin sections (5 µM) to be cut from the block using a sledge microtome and mounted onto 
glass slides. 
 
3.9.3 Tissue staining 
 
Haematoxylin and eosin (H&E) stain involves a routine procedure to identify cell types 
and cell components. Specifically, haematoxylin is a basic dye that stains the cell nucleus 
blue, and eosin is an acidic dye used to stain the cytoplasm and connective tissue different 
shades of red. The tissue is initially rehydrated by placing the glass slide into a bath of 
xylene for 8 minutes. The xylene bath was repeated twice and then the glass slide was 
placed into a series of ethanol baths including 100%, 90%, 80%, 70%, and 50% ethanol, 
with each bath being repeated twice to ensure rehydration.  
 
After rehydration the slides were washed in water and then placed in a bath of 
haematoxylin for 8 minutes to stain cell nuclei. Excess stain was then removed by placing 
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the slides under a slow running tap for 8 minutes. The slides were then run through a brief 
series of graded ethanol washes (50%, 70%, 80%, 96%) for 30 seconds each. The slides 
were then placed in a bath of eosin for 2 minutes to stain cytoplasm and connective tissue. 
Following this, the slides were placed again in a bath of 96% ethanol for 30 seconds and 
then underwent 4 washes in 100% ethanol for 30 seconds each. The remainder of the 
work was then performed in a fume hood. To dehydrate fully, the slides were placed in 2 
baths of xylene for 4 minutes each. The coverslip was then cleaned using xylene with a 
Pasteur pipette and the slide placed on a tissue face up. A drop of mounting solution 
(DPX) was placed on the slide and a cover slip (24 mm x 60 mm) placed on top. The 
cover slip was compressed until no bubbles were visible and left to dry overnight in the 
fume hood. 
 
The Verhoeff’s Van Gieson (EVG) stain was used to identify elastic fibres in fetal 
membrane tissue. The elastic fibres are stained blue-black and background stained 
yellow. As before, the tissue was de-paraffinised and hydrated to distilled water. The 
slides were then stained in Verhoeff’s solution for 1 hour until tissue is completely black. 
The slides were then rinsed under the tap twice and differentiated in 2% ferric chloride 
for 2 minutes. Running the slides under the tap twice and then treating them with 5% 
sodium thiosulfate for 1 minute stopped differentiation. The slides were then washed 
under the tap for 5 minutes and counterstained in Van Gieson’s solution for 5 minutes. 
The tissue was then dehydrated through to 100% ethanol and placed in 2 baths of xylene 
for 4 minutes each. As before, the cover slips were placed on top and compressed until 
no bubbles were visible. 
 
3.10 Statistics 
 
All results in this study were shown as the mean from replicates and individual 
experiments with error bars representing the mean +/- standard error of the mean. One-
way or two-way analysis of variance (ANOVA) with Bonferroni-corrected post-hoc 
analysis was used to determine statistical significance of normally distributed data 
(confirmed by the Shapiro-Wilk normality test) between means (determined in SPSS 
software, version 24.0 IBM; Chicago, IL, USA) to reduce Type I errors where α = 0.05. 
The number of patients and replicates are indicated in figure legends. In all comparisons 
 
 
 75 
P < 0.05 was considered statistically significant for tests involving comparisons of wound 
edge vs. control amniotic membrane; strained vs. non-strained amniotic membrane; and 
treated vs. non-treated amniotic membrane groups. Densitometry analysis using ImageJ 
(Fiji) was performed for quantification of western blot bands and the mean grey value of 
3 separate experiments determined for comparisons. 
 
For gene expression statistical analysis, relative quantification of the target gene against 
a reference gene was performed in order to obtain relative expression ratio, which 
incorporated the PCR efficiency values (described previously in “PCR data analysis and 
optimisation” section). Briefly, PCR efficiencies for optimal primer pair concentrations 
were derived from standard curves (n=3) by preparing a ten-fold serial dilution of cDNA 
from a sample that represented the control. The real-time PCR efficiencies (E) of 
amplification for target genes were defined according to the relation, E = 10[-1/slope]. 
The R2 value of the standard curves exceeded 0.99 and revealed efficiency percentage 
values ranging from 97.5–101%. Primer specificity was verified by examining the 
melting curves. Relative quantification of the target gene was estimated by normalising 
the target to the reference gene (GAPDH) and to the calibrator sample (patient matched 
control AM) by a comparative Ct approach. For each sample, the ratio of target Ct and 
reference Ct was calculated, as previously described175,176. Ratios were expressed on a 
logarithmic scale (arbitrary units). 
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Cx43 is overexpressed in human amniotic membrane 
after fetal surgery and artificial in vitro trauma
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Chapter 4: Cx43 is overexpressed in human amniotic membrane after fetal 
surgery and artificial in vitro trauma 
 
4.1 Introduction 
 
This chapter investigates the expression of Cx43 in human amniotic membrane samples 
following fetal surgery and after in vitro trauma using an artificial fetal membrane wound 
model. Fetal membranes fail to heal after fetal surgery, resulting in increased incidence 
of iatrogenic PPROM, which occurs in approximately 35% of intra-uterine surgical cases. 
This can lead to severe lifelong complications including cerebral palsy and respiratory 
disorders. In order to develop successful iatrogenic PPROM preventatives and 
therapeutics it is important that research expands the current understanding behind human 
fetal membrane healing. This chapter furthers our understanding of human amniotic 
membrane wounds, by investigating the expression of Cx43, changes in cell morphology, 
and collagen orientation at the amniotic membrane wound edge. Previous research has 
shown Cx43 has an important role in normal wound healing, where it is initially 
downregulated. This is associated with the adoption of a cellular migratory phenotype, 
promoting cell migration across the wound edge. However, overexpression of Cx43 has 
been reported in chronic wounds that show limited or no healing, such as diabetic skin 
wounds and venous leg ulcers. To our knowledge, this chapter reports novel findings that 
show high Cx43 expression in amniotic membrane wounds following fetal surgery and 
in vitro trauma. Importantly, this could provide the premise for the development of a 
Cx43 targeted therapy that promotes amniotic membrane wound repair. 
 
4.1.1 Gap junction structure and function 
 
Gap junctions are specialised membrane channels composed of connexin proteins. Each 
connexin protein acts as a sub-unit, of which six make up a single hemichannel (also 
known as a connexon, Figure 4.1). They allow intercellular communication between 
adjacent cells through a hydrophobic channel (1 – 1.5 nm diameter), enabling passive 
diffusion of ions and metabolites of up to 1 kDa, including signalling molecules such as 
Ca2+, IP3, cyclic AMP, cyclic GMP, and siRNA molecules177-179. Connexins have a highly 
 
 
 78 
conserved structure amongst 21 known human genes, differing only slightly in regards to 
cytoplasmic domains that vary depending on interactions with connexin-associated 
proteins, such as cytoskeletal proteins, signalling molecules, adhesion molecules, 
phosphatases, and kinases including protein kinase B (PKB) also known as Akt180-182. 
Human connexins are a large gap junction protein family that are most commonly named 
after their molecular weight and include: Cx23, Cx25, Cx26, Cx30.2, Cx30, Cx31.9, 
Cx30.3, Cx31, Cx31.1, Cx32, Cx36, Cx37, Cx40.1, Cx40, Cx43, Cx45, Cx46, Cx47, 
Cx50, Cx59, and Cx62180. 
 
4.1.2 Cx43 activation and plaque formation 
 
Cx43 protein, encoded for by the GJA1 gene, is the most ubiquitously expressed 
connexin, and the most commonly found within mammalian tissue. This signifies an 
important role in cell-cell communication, and with a short protein half-life of 1-3 hours, 
indicates the importance of correct Cx43 gene and protein expression in the dynamic 
regulation of multiple physiological events such as cell growth, cell differentiation, cell 
migration, and cell death183,184. In a homomeric gap junction, six Cx43 proteins will form 
one connexon; therefore upon docking to an adjacent hemichannel, one gap junction will 
comprise 12 Cx43 proteins. Once Cx43 oligomerises into a connexon within the trans-
golgi network it is trans-located to the plasma membrane where it can associate with other 
connexons to form a gap junction185. It is important to note that these gap junctions do 
not exist in isolation, but are found in clusters that form gap junctional plaques within the 
cell membrane (Figure 4.1a)186. When tissue is stained using specific Cx43 antibodies, 
and imaged using immunofluorescence confocal microscopy, these Cx43 plaques can 
form 0.1-1 µm puncta. 
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Figure 4.1: Schematic of gap junctional plaque and connexin structure. Gap junctions occur 
between adjacent cells after the docking of two hemichannels (A). Individual connexin proteins 
comprise four transmembrane domains, two extracellular loops, one intracellular cytoplasmic 
loop, and an N- and C- terminus (B).  Hemichannels (connexons) can also exist in a homomeric 
or heteromeric forms, meaning all six connexin sub-units are the same isoform or a combination 
of different isoforms (C). Gap junctions can form between homomeric connexons of the same 
isoform (homomeric membrane channel), homomeric connexons of different isoforms 
(heterotypic membrane channel), and heteromeric connexons termed heteromeric membrane 
channels (D). Adapted from Verheule & Kaese (2013)10. 
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4.1.3 Cx43 activation regulates healing in wounded skin 
 
Connexins play an important role in regulating the wound healing process187-189. Four key 
overlapping phases occur during wound healing, including (1) hemostasis, (2) 
inflammation, (3) proliferation and migration, and (4) remodelling. Cx43 downregulation 
is observed following cutaneous wounding123. Cx43 expression in wound edge 
keratinocytes has been shown to decrease in the epidermis at 5 hours post-injury, 
continuing to decrease until negligible detection is found at 24 hours123. This is 
concomitant with an increase in keratinocyte migration across the injury. Interestingly, 
compared to migrating keratinocytes at the leading wound edge, which show negligible 
Cx43 expression, the keratinocytes that are proliferating further back from the leading 
edge demonstrate comparably high Cx43 expression123. A reduction in Cx43 has been 
linked to an absence of cell-cell communication, which pertains to keratinocyte 
migration, and once re-epithelialisation is complete, Cx43 levels return to original 
levels187. Furthermore, Cx43 expression in wound edge dermal fibroblasts is also shown 
to decrease as early as 2 hours post-injury190. This reflects the adoption of a migratory 
phenotype as the fibroblasts move into the wound to secrete granulation tissue. 
 
Normal cutaneous wound healing involves a vasculature, and as such Cx43 levels have 
been studied in the endothelial cells of blood vessels191. It has been found that Cx43 is 
rapidly upregulated in blood vessel endothelial cells within the first 3 hours post-injury, 
which remains high during the inflammatory period192. The inflammation leads to 
swelling of the dermis and leakage of fluids, leukocytes, and proteins due to 
proinflammatory signals being released at the wound edge, which in turn correlates with 
Cx43 upregulation. This inflammatory response has been extensively studied in normal 
wound healing, with proinflammatory factors reported to favour the transformation of 
keratinocytes and fibroblasts into a migratory phenotype, promoting re-epithelialisation 
and granulation tissue secretion at the wound site193. Degranulating platelets and mast 
cells initially secrete pro-inflammatory signals such as platelet-derived growth factor 
(PDGF) leading to recruitment of neutrophils and monocytes. Macrophages are then 
derived from monocytes, which engulf bacteria and other wound debris, as well as 
secreting fibroblast growth factor 2 (FGF-2) and transforming growth factor 2 (TGF-β1). 
Interestingly, in embryonic wound healing the embryo cannot mount an inflammatory 
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response to injury, and it has been shown that wounds heal following contraction in a 
“purse-string” fashion, without scar formation, and without cell migration across the 
wound edge194,195. In light of this, some research has emerged demonstrating that 
inflammation could in fact be more damaging to the wound healing process, and 
contribute to scar formation and destruction of healthy cells in adjacent tissue196. 
 
Similar to skin tissues, fibroblasts of the oral gingival mucosa express Cx43 as the 
predominant connexin197. However, oral wound healing appears more rapidly than in 
cutaneous wounds, often with reduced scarring. Like in skin, Cx43 is rapidly 
downregulated in the leading wound edge epithelial and fibroblast cells, returning to basal 
levels at 60 days post-wounding197. Interestingly, this group also found that suppressing 
Cx43 function in fibroblasts using the Cx43 mimetic peptide, Gap27, led to enhanced 
migration. 
 
4.1.4 Cx43 and chronic wound healing 	
In contrast to normal cutaneous wound healing, there are several chronic wounds 
described in the literature that demonstrate changes in connexin expression, particularly 
Cx43198. Diabetic wounds present with prolonged healing times due to the multiple 
damaging effects that hypoglycaemia and oxidative stress has on the tissue, which often 
results in the formation of ulcers. These ulcers show limited healing abilities, and 
interestingly, significantly upregulation of Cx43 protein and gene expression has been 
reported at the wound edge in venous leg ulcers, diabetic foot ulcers and pressure ulcers. 
 
Venous leg ulcers 
 
Venous leg ulcers present with sustained inflammation and atypical fibroblast and 
keratinocyte behaviour199-201. Cx43 expression in biopsies taken from human venous leg 
ulcers has been compared with healthy human skin punch biopsies128. It was found that 
in healthy biopsies, Cx43 levels decreased at the wound edge, whereas in venous leg ulcer 
biopsies, higher Cx43 expression was observed throughout the entire dermis of the 4 mm 
biopsies. Furthermore, there was no evidence of Cx43 downregulation at the leading 
wound edge, where downregulation would typically lead to cell migration and healing.  
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Diabetic foot ulcers 
 
In diabetic rat models, wounds show dramatic Cx43 upregulation in the keratinocytes of 
the leading wound edge, which leads to the formation of wound edge bulbs that contain 
non-migrating cells in the first 24 hours126. Keratinocytes are only reported to migrate 72 
hours post-injury, which correlates with Cx43 levels returning to normal. In human 
diabetic foot ulcer biopsies, fibroblasts in the dermal region show 10-fold increase in 
Cx43 expression compared to intact diabetic skin and non-diabetic skin wounds124. 
Similarly this has also been reported in diabetic skin wound models of the rat where Cx43 
upregulation in wound edge keratinocytes led to reduced cell migration126. 
 
Pressure ulcers 
 
Pressure ulcers arise over a prolonged period of pressure to an area of skin that leads to 
ischemia, and tissue necrosis, typically over a bony prominence. They can also arise 
following repetitive pressure to the skin resulting in ischemia-reperfusion damage. 
Increased hemichannel activity and Cx43 upregulation has been noted in a pressure ulcer 
model202. In pressure ulcer biopsies Cx43 was upregulated in the epidermis, with uneven 
expression reported at the wound edge198. Overall, Cx43 was overexpressed by 10-fold 
when compared to patient matched intact skin. Cx43 expression in the dermis of pressure 
ulcers was substantially higher with a 57-fold increase at the leading wound edge 
compared to controls. Further away from the wound edge, Cx43 remained high, showing 
a 37-fold increase 1 mm away from the leading wound edge. 
 
Taken together, chronic wounds show similarity in the striking upregulation of Cx43 
linked with preventing fibroblast migration, and its downregulation appears to be pivotal 
in the ability of wounds to heal efficiently as seen in normal cutaneous wound healing. 
Furthermore, in wounds with privileged healing abilities such as the gingival mucosa and 
buccal membranes, there is rapid Cx43 downregulation at the wound edge, to almost 
negligible detection; resulting in rapid healing and reduced scarring. To date, the levels 
of Cx43 expression in wounded FM has not been investigated. 
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4.2 Methods 
 
4.2.1 Fetal membrane used for fetal surgery study 
 
Fetal membranes (n=18, Table 4.1) were collected from preterm and term deliveries 
following elective caesarean section after informed consent at University College 
Hospital London and University Hospital Leuven, Belgium. Women underwent 
fetoscopic surgery for treatment of twin-to-twin transfusion syndrome (TTTS, n = 16), 
fetal congenital diaphragmatic hernia (CDH, n = 1) and twin reversed arterial perfusion 
sequence (TRAPS, n = 1). The most common indication for fetoscopic intervention was 
TTTS (Figure 4.2). TTTS involves the uneven supply of blood from the placenta, which 
results in the two fetuses developing at different rates. There are 5 stages, with the severity 
increasing at each stage. Stage 1 involves imbalance of amniotic fluid, with a large 
amount around the recipient twin and smaller amount around the donor twin. Stage 2 
involves the inability of the donor twin to produce urine, which is difficult to observe in 
the bladder via ultrasound examination. Stage 3 involves the imbalance of blood affecting 
the heart function in one or both fetuses. Stage 4 presents with signs of heart failure in 
one twin. Stage 5 involves death of one or both fetuses. Typically Stage III TTTS patients 
are considered for fetoscopic intervention. 
 
Mean gestational age at surgical intervention was 23+3 weeks with a range of 15+0 – 29+3 
weeks. Mean gestational age at delivery was 30+4 with a range of 23+0 – 37+4 and median 
GA of 30+6 weeks. Mean time from surgical intervention to delivery was 55 days with a 
range of 1 – 145 days (median: 42 days). Mean maternal age at delivery was 31 with a 
range of 20 – 39 years of age. From the sample group, four patients delivered within one 
week of surgical intervention (22.2%), six delivered between 8-50 days (33.3%), and 
eight delivered between 51-100 days (44.4%). From the sample group, 94% delivered 
preterm (less the 37 weeks) following fetoscopic surgery. 
 
During the surgery, the fetoscopic entry site was created using a 10-Fr Teﬂon cannula 
(Cook Medical, Strombeek Bever, Belgium) and pyramidal trocar device (Karl Storz, 
Tuttlingen, Germany). At delivery, the fetoscopic defect site was identiﬁed by careful 
macroscopic survey of the fetal membrane, and the tissue around the wound was carefully 
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excised a long with control samples. One open fetal surgery case was collected, however 
the hysterotomy scar appeared infected and there was meconium presence in the amniotic 
fluid, likely leading to increased chance of infection. For this reason, the hysterotomy 
wound was removed from this study and data analysis focused completely on fetoscopic 
wound defects. A control region in the fetal membrane that was aligned in the same axis 
as the fetal defect and was at least 5 cm away from the wound edge was excised for 
comparison. 
 
 
 
Figure 4.2: Reasons for fetoscopic surgery shown as a percentage. TTTS: twin-to-
twin transfusion syndrome; CDH: congenital diaphragmatic hernia; TRAPS: twin 
reversed arterial perfusion sequence. 
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Table 4.1: Clinical information for patients undergoing laser ablation therapy.  
  
Patient No. Maternal 
age at 
delivery 
Indication for 
surgery 
GA at 
intervention 
GA at 
delivery 
Patient 1 
 
39 TTTS stage I 24+0 35+5 
Patient 2 
 
28 TTTS stage I 19+3 29+4 
Patient 3 28 CDH 28+1 32+6 
Patient 4 
 
32 TTTS stage III 26+5 26+6 
Patient 5 35 TTTS stage II 24+3 25+3 
Patient 6 
 
20 TTTS stage II 18+5 30+1 
Patient 7 
 
34 TRAPS 15+0 35+0 
Patient 8 
 
33 TTTS stage III 22+2 23+0 
Patient 9 
 
29 TTTS stage III 21+6 35+5 
Patient 10 
 
36 TTTS stage V 19+3 37+4 
Patient 11 
 
33 TTTS stage III 25+3 31+5 
Patient 12 
 
29 TTTS stage IV 19+5 29+5 
Patient 13 
 
34 TTTS stage III 17+6 23+3 
Patient 14  36 TTTS stage III 19+1 27+5 
Patient 15 33 TTTS stage IV 26+6 27+5 
Patient 16 27 TTTS stage IV 29+3 33+3 
Patient 17 33 TTTS stage III 27+3 32+4 
Patient 18 23 TTTS stage IV 29+0 31+4 
TTTS: twin-to-twin transfusion syndrome; CDH: congenital diaphragmatic hernia; 
TRAPS: twin reversed arterial perfusion sequence; GA: gestational age. 
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4.2.2 Fetal membranes used for the in vitro artificial fetoscopic trauma model 
 
Fetal membranes (n=12) were collected from term deliveries following caesarean section 
after informed consent at University College Hospital London. Mean gestational age at 
delivery was 39+2 weeks with a range of 38+0 – 41+5 weeks (median: 39+1 weeks). Mean 
maternal age at delivery was 32 with a range of 23 – 38 years of age (median: 33 years). 
Indication for caesarean section (Figure 4.3) includes placenta praevia (low placenta), at 
least one previous caesarean section, previous stillbirth, breech position (fetal in bottom-
down position) and medical reasons, in this case including two patients with heart 
conditions. One patient had both placenta praevia and previous caesarean section. 
 
 
Figure 4.3: Indication for caesarean section shown as a percentage. These samples 
were used for developing the in vitro wound model and investigating amniotic 
membrane wound healing. 
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4.2.3 Development of artificial in vitro fetal membrane trauma model 	
In order to investigate fetal membrane wounds, an in vitro artificial fetoscopic trauma 
model was developed. The flow chart below shows the four key stages in preparing fetal 
membrane wounds and the steps taken to ensure consistency between experiments could 
be maintained. 	 	
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4.3 Results: Investigation of AM trauma after fetoscopic surgery 	
4.3.1 Scanning electron microscopy of wounded fetal membranes after fetoscopic 
surgery 
 
Initial observation of the fetal membrane at the macroscopic and microscopic level was 
important to understand the features of the wound in both amniotic and chorionic 
membrane fetoscopic defects (Figure 4.4). This specific case shows the macroscopic and 
microscopic appearance of a fetoscopic wound after 71 days since fetoscopic surgery, 
with delivery occurring preterm at 29+4 weeks gestation by caesarean section. Electron 
micrographs of the fetal membrane defect following fetoscopic surgery show the 
insufficiency of fetal membranes to heal. The defect size was approximately 3 mm in 
diameter for both AM and CM layers, however this varied due to the irregular defect 
shape. Thickened wound edges were seen specifically in the AM. The increase in folding 
at the wound edge in the AM could be a result of increased tensile properties causing the 
wound edges to retract more than is seen in the CM at the time of laparoscope entry. In 
comparison, the CM did not appear to have the same thickened edges and the wound 
margin was more irregular. Extracellular matrix fibres were exposed at the wound edge 
in both AM and CM, visible at 10,000 x magnification (Figure 4.4c). Nanofibres 
appeared more compact in the AM than the CM.  		 	
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Figure 4.4: Electron micrograph of the fetal membrane wound following fetoscopic surgery. The 
amniotic membrane wound (A) appears to have a thickened bulb at the wound edge (B) compared to 
the chorionic membrane wound (D,E). Extracellular matrix nanofibres can be seen in the amniotic 
membrane (C) and chorionic membrane (F) at 10,000 x magnification. This electron micrograph shows 
that the wound persists with absent healing even 71 days since fetoscopic surgery in both membrane 
layers. Fetoscopic surgery was performed at 19+3 weeks gestation and delivery was at 29+4 days. 
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4.3.2 Cell morphological changes in wounded AM after fetoscopic surgery 
 
No morphological changes were observed in cuboidal amniotic epithelial cells when 
comparing wound edge (comprising up to 500 µm from wound margin) to control regions 
(> 5 cm from wound margin). In contrast, mesenchymal cells of the fibroblast layer 
exhibited increased polarisation at the wound edge compared to control (Figure 4.5a-f). 
Polarisation occurred in parallel to the wound margin. Mesenchymal cells in the control 
region did not show the same morphology, although they were not completely rounded 
but slightly oval. The epithelial layer could be seen to curl over at the wound margin 
around the perimeter of the entire defect (Figure 4.5g), which could occur following 
removal of the laparoscope. Mesenchymal cells of the fibroblast layer appeared to form 
more clustered regions at the wound edge, with highly dense areas seen within 
approximately 200 µm of the wound margin. Amniotic epithelial “bulbs” were observed 
at the wound edge consistently around the perimeter of the wound margin (Figure 4.5h, 
i). These were a continuation of the epithelial surface and appeared to be aggregates of 
epithelial cells, having possibly attempted to crawl over the wound bed as seen during the 
typical re-epithelialisation stage of wound healing 
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Figure 4.5: Immunofluorescence confocal laser scanning microscopy of wounded amniotic membrane 
fetoscopic surgery and representative control region with nuclear staining using DAPI. The wound 
edge amniotic membrane shows polarised mesenchymal cells that orientate tangential to the wound 
margin (A, B, C, red arrows). In comparison, control amniotic membrane taken from at least 5 cm 
away from the wound site in the same axis shows more rounded mesenchymal cell nuclei (D, E, F, red 
arrows). Cross-sectional image analysis reveals amniotic epithelial cell curling at the wound edge 
(yellow arrows) and a dense region of mesenchymal cells close to the wound edge (approximately 200 
µm from the leading wound edge). The wound distance depicted in “G” is not to scale and wound 
margins have been moved together. Another feature at the amniotic membrane wound edge are 
epithelial cell bulbs, which appear to be aggregates of amniotic epithelial cells (H). Polarised 
mesenchymal cell nuclei (red arrows) can also be seen behind the epithelial cell bulb (I, dotted yellow 
outline). Dotted white lines indicate wound margins. 
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4.3.3 Quantification of mesenchymal cell polarisation in the wounded AM after 
fetoscopic surgery 
 
Quantification of mesenchymal cell nuclei (Figure 4.6) shows increased polarisation at 
the wound edge compared to patient matched controls (Figure 4.6, insert, p<0.001). 
Three patients were used in the analysis, with wound edge nuclei (n=107) compared with 
patient matched control (n=100). Overall, there was a 124.9% increase in polarity at the 
wound edge (within 200 µm of the wound margin). In wound edge nuclei, y-axis 
dimensions ranged from 7.215 µm – 38.991 µm, and x-axis dimensions ranged from 
2.581 µm – 9.467 µm. In control regions (>5 cm from wound edge) mesenchymal nuclei 
y-axis dimensions ranged from 7.42 µm – 18.625 µm, and x-axis dimensions ranged from 
4.132 µm – 14.502 µm. Mean wound edge mesenchymal nuclei dimensions were 15.8 
µm by 5.3 µm. Mean control mesenchymal nuclei dimensions were 12 µm by 8.35 µm. 
 
Figure 4.6: Quantification of mesenchymal cell nuclei morphology at the wound edge (<100 
µm from wound margin) and control (>5 cm from wound edge) in amniotic membrane following 
fetoscopic surgery. Wound edge nuclei (n=107, red) were measured from 3 different patients 
along with control nuclei (n=100, blue) from patient matched control regions. Red dots indicate 
individual wound edge sample point and blue dots indicate individual control sample points. Y-
axis indicates the longest distance measured per cell (µm) and x axis-indicates the 
corresponding x-axis dimension (µm), measured perpendicular to the nuclear y-axis. Insert 
shows overall y/x ratio with a value of 1 indicating a complete sphere (dotted blue line). Values 
further away from 1 indicate increased nuclear polarisation. The wound edge nuclei show 
increased polarity compared to control nuclei (***p<0.001). 
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4.3.4 Changes in Cx43 and COX-2 gene expression in AM wounds after fetoscopy 
 
Cx43 (GJA1) gene expression increased approximately four-fold in wounded AM 
compared to control AM (P<0.001, Figure 4.7). Similarly, pro-inflammatory cytokine 
cyclooxygenase-2 (COX-2) gene expression increased approximately three-fold in 
wound edge samples compared to control (p<0.001). Collagen type I (COL1A1) gene 
expression showed no significant changes when comparing wound edge and control 
samples. Analysis included four patients (n=12-18 replicates) where error bars represent 
the standard error of the mean. Gene expression was normalised to patient matched 
control samples and presented as a ratio value with gene amplification efficiency values 
taken into account during fold change calculation. 
  
Figure 4.7: Gene expression fold change for Cx43 (GJA1), COX-2, and COL1A1 with y-axis 
presented as logarithmic scale. Cx43 and COX-2 gene expression increased approximately 4-
fold and 3-fold in wound edge samples, compared to patient matched controls, respectively 
(both p<0.001). No difference was reported in COL1A1 gene expression. Analysis included 
four patients, with 12-18 replicates performed during analysis per patient. 
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4.3.5 Changes in Cx43 protein expression in wounded AM after fetoscopic surgery 
 
Typical Cx43 staining showed puncta of approximately 0.1–1 µm sized plaques (Figure 
4.8). Representative images from a human fetoscopy patient show Cx43 plaques are 
predominantly expressed in wound edge mesenchymal cells of the fibroblast layer 
compared to basal Cx43 expression levels of control tissue (imaged at least 5 cm from 
the wound margin) control. Furthermore, Cx43 plaques are negligible in the epithelial 
layer of both wound edge and control regions. 
 
Cx43 positive pixels were quantified per tissue area (pixels per 500 µm2 area of tissue) 
and per cell nuclei (Figure 4.9). Overall, 8 patients were included in analysis, with 8-10 
replicates per patient for both wound edge and patient matched control regions. Analysis 
of Cx43 protein quantification as pixels per 0.5 mm2 and per cell nuclei showed no 
difference in epithelial cells in control AM compared to wound edge AM. Epithelial cells 
showed negligible Cx43 protein expression, virtually non-detectable, in both control and 
wound edge samples. Quantification of Cx43 per area showed mesenchymal cells 
expressed higher Cx43 protein levels compared to epithelial cells in both control (P<0.05) 
and wound edge AM (P<0.001). Cx43 protein expression was higher in mesenchymal 
cells at the wound edge compared to patient matched control regions (P<0.001). 
Similarly, quantification of Cx43 pixels per cell nuclei showed higher expression in 
mesenchymal cells compared to epithelial cells in both control (P<0.05) and wound edge 
(P<0.05) samples. Cx43 expression per cell increased in wound edge mesenchymal cells 
compared to control mesenchymal cells (P<0.05).  
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Figure 4.8: Human amniotic membrane fetoscopy patient Cx43 staining at wound edge (WE) and 
control regions. Typical Cx43 puncta of approximately 0.1 – 1 µm sized plaques (3 different wound 
edge regions shown A-C) that are predominantly expressed in the mesenchymal cells of the 
fibroblast layer. Cx43 puncta is still evident at basal expression levels in the control regions (>5 
cm) from the wound margin (D). However negligible Cx43 staining is observed in the epithelial 
layers for both wound edge and control regions. Wound margin indicated by the dotted white line. 
Scale bars = 100 µm. 
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Figure 4.9: Cx43 protein quantification per area (A) and per cell nuclei (B). Quantification 
was performed using ImageJ particle analysis to quantify pixels per area and cell nuclei. No 
difference is reported in Cx43 expression in the epithelial layer of wound edge and control 
AM. Cx43 expression is higher in mesenchymal cells compared to epithelial cells in both 
control and wound edge AM. Cx43 expression is higher in the fibroblast layer of the wound 
edge compared to control fibroblast layers. Eight patients were involved in analysis with 8-
10 replicates per patient. Statistical significance is indicated as *p<0.05, **p<0.01, 
***p<0.001. 
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4.3.6 Collagen alignment and intensity in wound edge vs. control regions 	
Comparison of SHG intensity (presented in arbitrary units across an area of 
approximately 425 x 425 µm sample region) shows an increase in intensity at the wound 
edge regions compared to control (Figure 4.10a, representative patient with 10 replicates 
around perimeter of wound edge). Overall, there was a five-fold SHG signal intensity 
increase in wound edge regions compared to patient matched controls (Figure 4.10b, n=8 
patients, p<0.001) 
 
To infer the preferred collagen alignment direction, we performed an orientation 
distribution analysis using ImageJ. SHG images were converted to binary and 2D 
orientation analysis performed using the directionality plugin. Collagen fibres showed 
increased organisation at the wound edge (Figure 4.11a), where fibres aligned tangential 
to the wound edge, similarly to the tangential alignment of the mesenchymal cell nuclei. 
Control regions showed more typical disorganised and “basket-shaped” fibre orientation 
that is interwoven throughout the imaged region in random fashion (Figure 4.11b). 
Surface intensity plots of wound edge (Figure 4.11c, e) and control regions (Figure 
4.11d, f) show the formation of a thicker, highly aligned collagen ring at the wound 
margin that could be seen around the perimeter of the wound edge. Representative 
histogram analyses of wound edge (Figure 4.11g) and control regions (Figure 4.11h) 
show a higher amount of collagen fibre alignment at the wound edge compared to control 
regions. 
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Figure 4.10: Second harmonic generation signal intensity in wound edge and control specimens 
across full thickness amniotic membrane samples approximately 425 µm2. Figure shows 
representative SHG profile with 10 replicates around perimeter of wound edge (within 500 µm 
of wound margin, A). There was an approximately five-fold mean SHG signal intensity increase 
in wound edge regions compared to patient matched controls (N=8 patients, B). Error bars 
represent mean ± SEM, where statistical significance is indicated by ***p<0.001. 
  100 
Figure 4.11: Second harmonic generation imaging analysis of collagen density SHG signal 
intensity in wounded amniotic membrane compared to control. AM collagen fibres were aligned 
parallel to the wound margin (A,C) compared to disorganized fibres in AM control regions 
(B,D). Surface intensity plots show formation of a ring of collagen at the wound edge, which 
had higher intensity (E) compared to patient matched control AM (F). Histogram analysis 
shows increased collagen alignment at the wound edge (G) compared to control regions (H).  
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4.4 Results summary 
 
• 94% of patients (17/18) who underwent fetoscopy delivered preterm (less than 37 
weeks gestation). Mean gestational age at delivery was 30+4 weeks (range: 23+0 – 
37+4; median: 30+6 weeks).  Mean duration from surgical intervention to delivery 
was 55 days. From the sample group, 22.2% delivered within 1 week following 
surgical intervention. 
 
• Electron micrographs reveal the absent healing of fetal membrane wounds (~3 
mm in diameter) following fetoscopy for intrauterine fetal surgery, even up to 71 
days post-surgery. High magnification electron micrographs at the wound edge 
reveals a dense ECM network in both amnion and chorion that appears to be 
denser in the amnion. 
 
• Following fetoscopy, the defect diameter is similar in amnion and chorion layers, 
however, the defect shape is irregular in the chorion compared to the amnion, 
which may be due to increased elasticity of the amnion. 
 
• Wound edge mesenchymal cells are polarised and arranged in a tangential 
orientation around the perimeter of the wound margin. In comparison, control 
region (more than 5 cm from the wound edge) mesenchymal cells are oval shaped 
and arranged in random orientations. 
 
• The wound edge appears to have a higher density of mesenchymal cells within 
approximately 200 µm of the wound margin, indicating a higher rate of 
proliferation, compared to control regions. 
 
• Cx43 and COX-2 gene expression is upregulated in amniotic membrane wound 
edge specimens compared to patient-matched control regions (more than 5 cm 
from the wound edge). COL1A1 did not show a statistically significant difference 
in wound edge samples compared to patient-matched control regions. 
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• Cx43 protein expression (per area and per nuclei) increased in amniotic membrane 
mesenchymal cells at the wound edge compared to control regions. No 
statistically significant difference in Cx43 protein expression was reported in 
amniotic epithelial cells at the wound edge compared to control regions. 
 
• SHG intensity increased in wounded amniotic membrane compared to control 
regions. This could indicate a change in density of collagen at the wound edge 
compared to control regions. The density of collagen appears to increase without 
a change in mRNA collagen, therefore increased collagen intensity could result 
from increased content per area unit and not through increased synthesis of 
collagen.  
 
• Collagen fibres, indicated by SHG signals, showed increased alignment at the 
wound edge, and were organised tangential to the wound margin in a similar 
fashion to mesenchymal cell polarisation. In contrast, control SHG signals were 
arranged in random orientations, and fibres were shorter compared to bundles of 
fibres at the wound edge. 
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4.5 Results: Investigation of AM wounds after in vitro artifical trauma 
4.5.1 Cell morphological and Cx43 changes in AM after trauma 
 
In control AM region, mesenchymal cell nuclei showed no change in morphology. In 
wound edge samples, mesenchymal cell nuclei were polarised in a similar fashion to AM 
after fetoscopic surgery samples (Figure 4.12a, c). They lined up tangential to the wound 
edge within approximately 200 µm from the wound margin and around the full perimeter 
of the wound (Figure 4.12e, f). In control AM, mesenchymal cell nuclei were oval shaped 
(Figure 4.12b, d). The epithelial surface curled over at the leading wound edge from 2 
hours, which was more profound at 168 hours (Figure 4.12g, h). However, no epithelial 
“bulbs” were discovered after in vitro trauma, which were a common feature in fetoscopic 
surgery samples. Furthermore, unlike the epithelial layer in fetoscopy surgery samples, 
which expressed negligible Cx43 protein, there appears to be a higher level of Cx43 
protein expression after in vitro trauma in amniotic epithelial cells (Figure 4.12i, inserts). 
This could be due to term fetal membrane being used and therefore highlights Cx43 
expression could vary with gestational age. 
Temporal changes in Cx43 protein expression were quantified per area (0.5 mm2) and per 
cell nuclei (Figure 4.12i and Figure 4.13a, b). Cx43 temporal expression was 
investigated at 2, 12, 24, 168 hours (7 days), after in vitro trauma in the AM. Cx43 protein 
expression in the wound edge increased in mesenchymal cells from 2 hours to 12 hours, 
and the levels were sustained for up to 168 hours. Cx43 protein expression was higher in 
mesenchymal cells at the wound edge compared to control mesenchymal cells from 12 
hours, sustained for up to 168 hours. Interestingly, at 2 hours there is a decrease in Cx43 
at the wound edge in mesenchymal cells compared to control mesenchymal cells when 
quantifying Cx43 per area. This was not the case in Cx43 per cell nuclei, which indicates 
that Cx43 plaque size may decrease overall at 2 hours post-trauma. However, the number 
of plaques may remain constant until 12 hours where an increase in Cx43 protein is seen 
at the wound edge. Furthermore, when quantifying Cx43 protein expression per area, 
there was an increase (P<0.001) from 24 hours to 168 hours; however, this was not 
replicated per cell nuclei. This could indicate Cx43 plaque size is increasing but not 
necessarily the number of Cx43 plaques. 
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Figure 4.12: Immunofluorescence confocal laser scanning microscopy of nuclei morphology 
and Cx43 protein expression. Mesenchymal nuclei was polarised at the wound edge (A, C) 
compared to oval shaped mesenchymal nuclei in control AM regions (B, D). Scanning electron 
microscopy shows polarised mesenchymal cells of the fibroblast layer at the wound edge 
(E,F). Epithelial curling can be seen at the wound edge from 2 hours to 168 hours (G, H). 
Cx43 protein expression can be seen at the wound edge and patient matched control AM 
region at 2, 12, 24, and 168 hours post-trauma. Cx43 protein expression increases from 2 – 
12 hours, which is sustained to 168 hours in the mesenchymal cells of the fibroblast layer. 
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Figure 4.13: Cx43 protein quantification per area (0.5 mm2, A and B) and per nuclei (C and 
D) following in artificial vitro trauma of human amniotic membrane. Cx43 protein levels 
increase from 2 hours to 12 hours in the wound edge of the amniotic membrane, which is 
maintained at high levels for 168 hours post-trauma.  Analyses included N=12 patients with 
8-10 replicates per fetal membrane. Mean gestational age at delivery was 39+2 weeks. Error 
bars represent mean ± SEM, with statistical significance is indicated as *p<0.05, **p<0.01, 
***p<0.001. 
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4.5.2 Collagen alignment in wound edge and control AM after in vitro artificial trauma  	
Collagen alignment increased from 24 hours to 168 hours at the wound edge (Figure 
4.14a, b). Similar to fetoscopic surgery wounds, fibres aligned tangential to the wound 
edge around the perimeter of the wound (Figure 4.14a). Histogram analysis shows 
collagen fibres were more aligned at the wound edge compared to control regions (>5 cm 
from wound edge, Figure 4.14a). Control regions reflected that seen in fetoscopic surgery 
patients where fibres were shorter and more disorganised in an interwoven fashion.  
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Figure 4.14: Second harmonic generation imaging analysis of collagen alignment in wound 
edge AM compared to control AM following artificial in vitro trauma. At 24 hours, collagen 
fibres in the wound edge showed basket-shaped bundles. However, at 168 hours, fibres were 
aligned tangential to the wound edge in AM (A). In control AM, collagen fibres showed typical 
disorganized interwoven fibres. However, at 168 hours, the fibres appeared shorter and less 
dense in the AM (A). Histogram analysis shows alignment increased in wound edge at 168 
hours compared to both control and wound edge AM at 24 hours, which showed some 
alignment compared to control AM (B). 
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4.6 Results summary 
 
• Human fetal membranes can be cultured within the artificial fetal membrane 
trauma model to investigate reproducible defects of approximately 0.8 mm in 
diameter for 7 days. 
 
• The amniotic epithelial layer curls over at the wound margin, which appears more 
profound at day 7 compared to 2 hours, indicating epithelial cell migration around 
the perimeter of the wound margin. 
 
• Amniotic membrane epithelial cells do not change morphology at the wound 
edge; and control region mesenchymal cells (more than 5 cm from wound edge) 
have an oval shaped morphology occurring in random orientations. 
 
• Amniotic membrane mesenchymal cells polarise towards the wound edge and 
express greater levels of Cx43 protein expression compared to control AM. 
 
• Cx43 puncta of 0.1-1 µm is reported in both amniotic epithelial cell and 
mesenchymal cell populations, indicating variability in Cx43 plaque size. 
 
• Cx43 protein expression (per area and per nuclei) at the wound edge increases 
between 2-12 hours in the fibroblast layer, which is maintained and increases 
further at 168 hours after artificial trauma. 
  
• Cx43 protein expression is higher in amniotic epithelial cells at the wound edge 
compared to control regions at 12 hours, however, whilst Cx43 increases in both 
wound edge and control amniotic epithelial cells, there is no difference reported 
at 24 and 168 hours. Interestingly, there is an initial decrease in Cx43 protein 
expression at the wound edge in amniotic epithelial cells compared to control (per 
area) at 2 hours but not when quantified per epithelial nuclei. This could indicate 
that Cx43 plaque size may decreases whilst the number of Cx43 plaques remains 
unchanged. 
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• SHG reveals that collagen fibres in control amniotic membrane are arranged in a 
disorganised orientation at both 24 and 168 hour incubation periods. However, in 
control tissue at 24 hours, collagen fibres appear longer and more defined, 
compared to 168 hours where fibres are finer and shorter, indicating partial 
degradation over the 7 day incubation period. 
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4.7 Discussion 
 
This study set out to investigate the AM wound following fetoscopic intra-uterine fetal 
surgery and in vitro trauma. Specifically, changes at the wound edge in cell morphology, 
Cx43 expression, and collagen orientation were examined and compared to patient 
matched control regions of the AM without trauma. Furthermore, the study developed an 
in vitro model for creating reproducible fetal membrane defects that could be incubated 
for up to 7 days to assess wound healing and provide data which could be compared with 
that obtained in AM wounds after fetoscopic procedures. 
 
The inability of AM to heal following injury, both in utero following fetoscopic surgery, 
and in vitro following trauma is demonstrated in this study. Within the cohort of fetoscopy 
patients, no spontaneous healing of the fetal membrane was observed. The study 
documents key changes in cell morphology observed at the wound edge. Polarisation of 
mesenchymal cells of the fibroblast layer was evident within approximately 200 µm from 
the wound margin. The mesenchymal cells orientate in a tangential fashion to the wound 
margin, indicative of that reported during embryonic wound healing and wound 
contraction mechanisms of healing. Aggregates of epithelial cells extending from the 
amniotic membrane epithelial surface is also evident in fetoscopy wounds, although these 
were not evident following in vitro trauma up to 7 days. We show Cx43 expression in 
AM, and how overexpression is reported at the wound edge compared to patient matched 
control regions.  
 
During investigation of in vitro amniotic membrane trauma, Cx43 protein expression per 
area decreased at 2 hours post-injury, however then dramatically increased at 12 hours, 
which was sustained for up to 168 hours, when compared to amniotic membrane regions 
away from the wound edge. Cx43 protein expression per cell remained unchanged at 2 
hours post-injury, however, it then increased at 12 hours and was sustained for 168 hours. 
This indicates that whilst the amount of Cx43 plaques per cell remains unchanged at 2 
hours post-injury, the size of Cx43 plaques is initially decreased, before a striking 
upregulation is observed at 12 hours post-injury. In addition to high Cx43 protein 
expression at the wound edge, Cx43 and COX-2 gene expression is also found to be 
upregulated at the wound edge. COX-2 mRNA levels increase in response to 
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inflammatory cytokines and therefore indicates a level of inflammation occurring at the 
wound edge compared to control regions. The study further demonstrates changes in 
collagen alignment by the use of second harmonic generation imaging. It was found that 
high-resolution collagen imaging could be performed in the AM, obtained using 
transmission geometry for SHG signal collection. This is an improvement on previous 
attempts to image collagen fibres, which have relied on backscattered geometry, and does 
not provide the resolution obtained in the present study3. Indeed, the use of SHG imaging 
has provided novel findings and shown high alignment of collagen fibres at the wound 
edge. Collagen fibres align tangential to the wound margin in the same fashion as 
mesenchymal cell polarisation around the perimeter of the wound. In contrast, control 
regions show disorganised and shorter collagen fibres arranged in an interwoven fashion. 
 
Previous studies have documented human fetal membrane healing through studying 
histological changes after fetoscopic surgery162,164. However, limited detail is provided, 
with the studies stating observation of thickened rounded edges and little macroscopic 
evidence of tissue remodelling. In contrast to Papanna et al., who reports disordered 
orientation of collagen fibres at the trocar site, the present study reports conflicting 
evidence with highly aligned collagen fibres that orientate tangential to the wound margin 
around the full perimeter of the wound164. However, this study provides supporting 
evidence regarding the thinning of collagen fibres distal from the wound site. This could 
be explained by increased deposition of granulation tissue at the wound edge leading to 
observation of mature thick collagen. The ability of second harmonic generation imaging 
using transmission geometry to visualise collagen fibres also provides a higher resolution 
and level of detail not attainable through histological examination, which could explain 
why this was not previously reported. Increased collagen deposition noted at the AM 
wound edge following fetoscopic surgery for TTTS and after in vitro trauma is in 
agreement with a recent study showing increased collagen staining intensity at the wound 
edge following open fetal surgery for myelomeningocele165. The picrosirius red stain is 
associated with type I collagen, which increased in surgical regions (13.22±2.84%, N=10) 
compared to control non-surgical regions (6.16±1.09%, N=10) from the same patient.  
Other previous studies have used cell monolayer models to study repair kinetics of human 
fetal membranes203-205.  
The effect of mechanical injury on repair mechanisms of amniotic epithelial and 
mesenchymal cell monolayers found increased ability of epithelial cells to repair, usually 
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within around 40 hours, compared to mesenchymal cell monolayers204.	 Furthermore, 
Devlieger et al., discovered gestational age dependent repair kinetics of fetal membrane 
defects using a monolayer model developed using amniocytes obtained from human fetal 
membranes205. Although the study only investigated healing up to 48 hours, it was 
reported that proliferation at the monolayer wound edge increased as well as in 
monolayers derived from preterm tissue205.  
 
Interestingly, traits from both normal cutaneous wound healing and embryonic wound 
healing are reported in this study. These include overexpression of COX-2, which is 
reported in the pro-inflammatory phase of normal cutaneous wound healing. 
Furthermore, tangential alignment of both mesenchymal cells and collagen fibres of the 
fibroblast layer is indicative of that seen in “purse-string” wound contraction mechanisms 
reported in embryonic wound healing196. Interestingly, “purse-string” wound contraction 
occurs before the embryo is able to mount an inflammatory-mediated wound healing 
response, and contraction allows healing without the need for cell migration over the 
wound bed, and without the secretion of scar tissue196. However, we report both the 
alignment of mesenchymal cells at the wound edge and an increase in collagen intensity, 
which indicates the secretion of granulation tissue. The overexpression of Cx43 at the 
wound edge, could inhibit mesenchymal cell migration, leading to the highly aligned ring 
of collagen and tangentially orientated mesenchymal cells at the wound edge, indicative 
of that seen in “purse-string” wound healing. However, further studies are needed to 
determine the mechanisms of wound healing in the AM. 
 
To my knowledge this is the first study to investigate Cx43 expression in the AM and 
after trauma. Comparison with the literature is therefore limited, although similar findings 
have been reported in other chronic wounds that show a lack of healing, specifically 
diabetic foot ulcers, venous leg ulcers, and pressure ulcers198. Interestingly, striking 
upregulation of Cx43 expression is reported in wound edge biopsies of chronic wounds 
compared to intact skin. Furthermore, Cx43 overexpression at the wound edge is also 
contradictory to that seen during normal cutaneous wound healing, where a reduction in 
Cx43 is reported. In addition, wounds that show a privileged healing response such as the 
gingival mucosa membrane of the mouth, show a rapid reduction of Cx43 at the wound 
edge197. 
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Cx43 has been linked with the regulation of cell migration, and with a short half-life of 
1-3 hours indicates a key regulatory role in wound healing dynamics. Overexpression of 
Cx43 is linked to poor wound healing outcomes in chronic wounds. However, 
knockdown of Cx43 using Cx43asODNs leads to the adoption of a migratory phenotype 
and has been shown to accelerate wound healing128. Interestingly, knockdown of Cx43 
leads to a decrease in cell adhesion and proliferation, whilst promoting cell migration, a 
necessary step in efficient wound healing. Furthermore, increased lamelipodial 
protrusions that assist migration occur following Cx43 knockdown, associated with 
increased Rac-1 and RhoA GTPase activity. 
 
The negligible Cx43 protein expression observed in the AM epithelial layer of fetoscopy 
patients could indicate other cell-cell proteins dominate preterm (less than 37 weeks 
gestation) such as tight junctions and anchoring junctions including adherens and 
desmosomes. However increased Cx43 expression in epithelial cells was noted after 
artificial in vitro trauma. This could be due to gestational differences as term tissue (37-
42 weeks gestation) was used in vitro in contrast to fetoscopy patient studies that had a 
mean gestational delivery age of 30+4 weeks. Unexpectedly, collagen type I expression 
did not change. This could be explained by the presence of different collagen types and 
other collagen types dominating in the amniotic membrane which may explain the 
increased SHG intensity seen at the wound edge which is known to detect collagen types 
I and III, which are known to exist in the amniotic membrane206. However, it should be 
noted that gene expression levels do not always correlate with protein levels and can be 
influenced by post-translational modifications. 
 
The main cohort of patients had undergone fetoscopic surgery for TTTS. Treatment of 
congenital diaphragmatic hernia and twin-reversed arterial perfusion sequence involves 
a fetoscopic procedure similar to TTTS treatment, and therefore these fetal membrane 
defects were also included in analyses. Consultation with the fetal surgeon and careful 
macroscopic survey of the membranes after delivery enabled the quick location of 
laparoscope entry within 20 minutes of delivery for each patient. Due to the nature of the 
surgery, consented fetoscopy patients were often discharged from UCLH to return home 
to distant locations in England. Initially, this provided a noticeable constraint to the study, 
however this was partially alleviated by contacting other hospitals and obtaining letters 
of access for sample collection. Furthermore, a collaborative effort with University 
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Hospital Leuven, Belgium, provided another avenue for collection. Indeed, the mean time 
from fetoscopy surgery to delivery was 55 days, therefore a concerted effort to track 
patient’s progress was necessary but often sample collection could not occur due to 
unpredictable and emergency delivery often occurring overnight after women presented 
with PPROM. 
 
During development of the artificial in vitro trauma model, an area of FM away from the 
zone of altered morphology between the mid-zone and placental disc was dissected for 
consistency. The zone of altered morphology is known to undergo biochemical changes 
in preparation for parturition and in turn affects the mechanical integrity. Furthermore, 
FM were taken from term patients who had undergone elective caesarean section and had 
not gone into labour. Therefore, any changes in biochemistry and mechanical integrity 
that could arise following contractions was avoided. It should be noted that patient 
variability is likely to result in some differences, however this could not be avoided and 
therefore ample fetal membranes were collected and replicates performed during analyses 
to minimise this concern. 
 
Intra-uterine fetal surgery rates are increasing for fetal conditions. Therefore, the 
importance of research into FM healing is important in order to more effectively design 
preventatives and reduce future iatrogenic PPROM rates. This study provides an in-depth 
examination of the AM defect following fetal surgery and in vitro trauma. 
Characterisation of the wound edge and identification of Cx43 overexpression provides 
an important foundation for the development of future therapies and iatrogenic PPROM 
preventative strategies. Furthermore, the inability of FM to heal has often been described 
as the “Achilles’ heel” of fetal surgery with no explanation yet provided. For the first time 
we implicate Cx43 overexpression in thwarting the ability of AM to heal once injured, 
and therefore the effects of Cx43 modulation in AM healing could provide therapeutic 
options for preventing iatrogenic PPROM. 
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Chapter 5: Molecular self-assembly of peptide amphiphile membrane 
macrostructures triggered by amniotic fluid for sealing human fetal membrane 
defects 
 
5.1 Introduction 	
This chapter outlines previous clinical and experimental attempts that have been made to 
seal fetal membrane defects. Currently there is no clinically available method to seal fetal 
membrane defects following fetal surgery that reduces the rate of PPROM or improves 
perinatal outcome. The results of this chapter highlight a novel approach towards sealing 
fetal membrane defects and could provide the basis for the development of a new 
therapeutic for PPROM prevention and treatment. 	
5.1.1 Previous approaches for sealing fetal membrane defects 
 
There has been a resurgence in attempts to seal and repair fetal membranes over the past 
decade with the histological identification of absent fetal membrane healing by Gratacos 
et al., and the recent reports of the amniotic membrane being a potential source of stem 
cells162,207-209. To date, fibrin-based sealants (the amniopatch), gelatin sponges, and 
collagen amniografts have been used clinically in an attempt to seal the hole in the FM of 
patients following spontaneous and iatrogenic PPROM210-213. Experimental attempts to 
seal fetal membrane defects following fetoscopy also include the use of gelatin sponges, 
collagen plugs, and fibrin-based glues214-219. Other innovative approaches have also been 
tested including decelullarised human amniotic membrane, bioactive small intestinal 
submucosa membranes, and more recently innovative synthetic hydrogels that seek 
biological inspiration from the mussel and sandcastle worm highly adhesive 
secretions168,220-224. However, attempts for both treatment of PPROM and experimental 
methods for iatrogenic PPROM prevention have had limited success with inconsistent 
outcomes.  
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5.1.1.1 Sealants used clinically for spontaneous PPROM 
 
Fibrin-based sealants used to treat PPROM 
 
Table 5.1 shows a summary of the publications describing sealants used clinically. Initial 
descriptions of the use of fibrin-based sealants to prevent leakage of amniotic fluid after 
spontaneous PPROM involved the intracervical injection of maternal platelets that 
activate thrombin and the coagulation process. This was combined with a cervical 
cerclage to prevent the resulting fibrin clot from leaking out225. The resulting fibrin clot 
produced through the conversion of fibrinogen to fibrin in the presence of thrombin was 
thought to act as a glue to prevent amniotic fluid leakage and reduce the risk of ascending 
bacterial infection. This strategy was later refined and referred to as the amniopatch 
procedure, developed by Quintero et al., in an attempt to improve outcome214. The intra-
amniotic injection of platelets was immediately followed with cryoprecipitate, which 
contains fibrinogen, fibronectin, and clotting factors (factor VIIIc, factor XIII, von 
Willebrand factor) to help stabilise the fibrin plug after it adheres to the damaged 
AM226,227. However successful prevention of amniotic fluid leakage was not achieved in 
all cases following treatment between 16-24 weeks of gestation, resulting in poor clinical 
outcome for one third of cases214,228. Other research groups tested the ability of fibrin-
based sealants to prevent fluid leakage and seal artificially punctured fetal membranes in 
a modified syringe model229. Combinations of Aminocaproic acid and aprotinin that 
inhibit fibrinolysis for prolonging clot life, a commercially available preparation (Tisseel, 
Baxter Corp; Glendale, California) of fibrinogen, thrombin, and aprotinin, and platelets 
alone were tested. The commercially available Tisseel and cryoprecipitate/thrombin 
combinations performed best to prevent fluid leakage. 
 
Major limitations of fibrin-based strategies have since emerged and include the 
inconsistency of outcomes between groups, which report approximately a 51-61% fetal 
survival rate212-214,216,230,231. The technique of intra-amniotic injection was also performed 
blind, and therefore targeting of the fibrin clot to the FM rupture is not always possible. 
These strategies were also associated with chorioamnionitis, pulmonary hypoplasia, 
intrauterine fetal death, acute fetal bradycardia, development of amniotic bands, severe 
respiratory distress syndrome, and maternal pulmonary edema216,218,230. Furthermore, the 
procedure to prepare fresh blood products is expensive and lengthy, and further 
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complicated by safety procedures that can take up to 48 hours to resolve. Although some 
achievements were made with an average of 10 weeks from procedure to delivery, the 
patient sample size is often small with research regularly referring to single patient 
outcomes. The overall survival rate reported is poor (51-61%) and the association with 
intrauterine fetal deaths highlighted the potentially harmful effects of introducing blood-
clotting factors into the intra-amniotic region. Recent cohort studies confirmed that the 
success reported by the amniopatch procedure in some studies should be approached 
cautiously228,232. Contradictory results show a success rate of 63.5% in iatrogenic PPROM 
patients compared to 21.4% reported by Sung et al., who reported an even lower success 
rate of 11.8% after amniopatch treatment for spontaneous PPROM patients228,232. 
 
Regarding treatment of spontaneous PPROM using the amniopatch procedure, difficulty 
lies in locating site of rupture, the variation in defect size, and the increased chance of 
infection, meaning the standardisation of protocols often varies in clinical practice. In 
addition, success of the amniopatch procedure is often defined as cessation of amniotic 
fluid leakage and restoration of normal amniotic fluid volume, therefore it is important to 
note these studies do not address whether the structural integrity of the fetal membranes 
have been functionally restored. Follow up studies involving histological analysis would 
prove beneficial in evaluating the true sealing potential of the amniopatch procedure. 
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Table 5.1: Fibrin-based strategies for sealing fetal membrane defects. 
Species Sealant Model Key findings Study 
Human 
PPROM 
(n=19) 
Fibrin glue Tested 
clinically  
Intracervical application. 60% survival rate reported between 1979 and 
1982225. 
 
Genz et al., 
(1979)213 
Human 
PPROM 
(n=26) 
Fibrin 
adhesion 
TISSUCOL® 
Tested 
clinically 
Repeated intracervical application up to six times until ceasing of AF leakage. 
65% survival rate reported. However, most surviving neonates occurred in 
patients who were >26 weeks gestation.  
 
Baumgarten & 
Moser 
(1986)225 
Human 
iPPROM (n=1) 
Amniopatch  Tested 
clinically  
Patient was readmitted with PPROM 4 days after umbilical-cord ligation of 
monoamniotic acardiac twin via fetoscopic guidance. Transabdominal Intra-
amniotic injection of a platelet-cryoprecipitate plug. AF volume was restored. 
Final outcomes not provided. 
 
Quintero et al., 
(1996)226 
Human Fibrin glue FM explants The effect of fibrin glue on FM tensile strength examined. Fibrin glue 
increased tensile rupture in wounded FM explants. However, this remained 
lower than non-wounded control FM. 
 
Harmanli et 
al., (1998)233 
Human 
iPPROM (n=7) 
Amniopatch Tested 
clinically 
Restoration of AF volume n=3. Sudden fetal death n=2. Oligohydramnios 
persisted in 1 patient with AF leakage. Miscarriage occurred in 1 patient with 
no further leakage. 
Transabdominal intra-amniotic injection of platelets and cryoprecipitate. 
 
Quintero et al., 
(1999)212 
Human  
PPROM 
(n=12) 
Fibrin glue Tested 
clinically 
Intracervical application. Survival rate=53.8% Patients with poor prognosis 
(<24 weeks) selected. 
 
Sciscione et 
al., (2001)230 
Human  Platelets, 
Tisseel & 
thrombin  
FM explant 
syringe 
model 
Wounds created with a 20 gauge needle. Fibrin/thrombin-based combination 
best candidate for preventing AF leakage.  
Reddy et al., 
(2001)229 
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Human,  
sPPROM 
(n=4) iPPROM 
(n=4) 
Platelet, fibrin 
glue, and 
collagen slurry 
injection. 
Tested 
clinically 
More success in treating iPPROM than spontaneous PPROM. Spontaneous 
PPROM patients: n=2 delivered preterm within 2 days, n=1 fetal demise, n=1 
delivered 31 weeks with respiratory distress syndrome. iPPROM patients: 
n=3 delivered viable infants at 26, 32, and 34 weeks, n=1 further membrane 
rupture with fetal termination. 
 
Young et al., 
(2004)216 
Human,  
PPROM (n=5) 
Amniopatch  Tested 
clinically 
AF volume restoration in 4 of 5 patients who underwent CVS between 12-18 
weeks gestation. Fetal demise occurred (n=3) at 1, 2, and 26 days post-
procedure. Only one viable infant delivered. 
 
Cobo et al., 
(2007)234 
Human 
PPROM (n=1) 
Amniopatch  Tested 
clinically 
Amniocentesis at 3 weeks after PPROM at 18 weeks gestation. Viable infant 
delivered at 38 weeks. 
 
Mandelbrot  et 
al., (2009)235 
Human 
iPPROM (n=3) 
Amniopatch  Tested 
clinically 
Restored AF volume in 2 patients within 7 days. One patient required 2nd 
procedure to restore membranes. All 3 patients delivered viable infants. One 
infant born at 30 weeks gestation. 
 
Pathak et al., 
(2010)236 
Human 
sPPROM 
(n=1-7) 
iPPROM 
(n=19-24) 
Amniopatch Tested 
clinically 
Very low survival reported (14.3%). 
One patient delivered viable infant at 39 weeks gestation. 
 
TWO CENTRE STUDY: Procedure restored membranes in 58%. Overall 
neonatal survival was 55%. 
Restoration of AF volume achieved in 12 patients (63.2%) who delivered at 
a mean of 35 weeks gestation. 
 
SUCCESS RATE between 15-23 weeks gestation: sPPROM (11.8%) vs 
iPPROM (36.4%). 
Ferianec et al., 
(2011)237 
Kwak et al., 
(2013)238 
Richter et al., 
(2013)239 
Chmait et al., 
(2017)228 
Sung et al., 
(2017)232 
 
 
  121 
Gelatin and collagen based sealing strategies used for treating PPROM 
 
Strategies other than fibrin-based sealants have been attempted to improve PPROM 
clinical outcome and include the use of gelatin sponge (Table 5.2). In much the same 
way, the gelatin sponge, known as Gelfoam, is used to prevent amniotic fluid leakage 
from the amniotic cavity218. However, the technique has been described as a complex and 
aggressive form of PPROM prevention, which did not yield promising clinical 
outcomes240. Sudden fetal death was also associated with this technique that involved 
constant replenishment of amniotic fluid by amnioinfusion, cervical cerclage, 
administration of Gelfoam, and a combination of antibiotics with perioperative tocolysis. 
Further amnioinfusion were often required to maintain amniotic fluid volume and 
therefore with low neonatal survival rates reported, it remains an unpopular clinical 
option. 
Collagen amniograft have also been tested clinically in spontaneous PPROM. The 
collagen amniograft is placed over the defect endoscopically and sealed in place using 
fibrin glue. This technique is more involved compared to instillation of fibrin glue or 
gelatin plugs and requires a lengthy surgery time (approximately 2.5 hours). Furthermore, 
the continued inflation of the amniotic cavity using carbon dioxide was required, putting 
the fetus at more risk. 
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Table 5.2 Gelatin and collagen based PPROM sealing strategies 
 
 
 
To date, there has been limited success in improving clinical outcomes to treat women 
after spontaneous PPROM213. Whilst improvements have been made regarding fibrin-
based sealants and development of the amniopatch, the safety and efficacy are not well 
established due to small patient groups, lack of comparative control groups, and 
contradictory results between different research centres. Furthermore, clinical attempts to 
use gelatin sponge plugs and collagen amniografts have been associated with low 
neonatal survival and low patient groups, making it difficult to foresee the true efficacy 
and safety for use in the clinic. Before translation to the clinic, the development of sealing 
strategies for treating PPROM should be thoroughly investigated by improvement of in 
vitro cell and tissue explant mode followed by studies in animal models prior to 
implementation within organised pre-clinical trials that have appropriate control groups. 
It is important to note that the use of fibrin-based glues, gelatin sponges, and collagen 
amniografts discussed so far have been used clinically as a treatment following rupture 
of membranes after spontaneous PPROM making it difficult to design approaches that 
can seal the fetal membrane defect with an irregular shape and size. 
5.1.1.2 Tissue engineering strategies for iatrogenic PPROM prevention 
 
Species Sealant Model Key findings Study 
Human Gelatin 
sponge plug 
 
Syringe 
model 
 
Gelatin sponge was able to prevent 
AF leakage when the wound diameter 
was >7 mm. 
O’Brien et 
al., 
(2001)241 
 
Human 
sPPROM 
(n=14) 
iPPROM 
(n=1). 
Gelfoam and 
amnioinfusion 
 
Tested 
clinically  
 
Administration of gelatin sponge into 
amniotic cavity. Intervention 
occurred between 13-21 weeks 
gestation. Overall neonate survival 
was 30%. 2 intrauterine fetal deaths. 
 
O’Brien et 
al., 
(2002)240 
 
Human 
sPPROM 
(n=1). 
Collagen 
amniograft 
 
Tested 
clinically  
 
Collagen graft was endoscopically 
placed over a 2 cm defect and sealed 
in place with fibrin glue. 
AF leakage persisted 14 days post-
procedure. Viable infant delivered at 
30 weeks gestation. 
Quintero 
et al., 
(2002)242 
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Iatrogenic PPROM occurs in 30% of patients following fetoscopic surgery243. It has been 
reported that PPROM does not always occur following fetoscopy possibly due to sliding 
of the amniotic and chorionic membranes over one another and adherence of the fetal 
membrane wound edges to the underlying myometrium129,162. Nevertheless, iatrogenic 
PPROM presents an on-going challenge for the field of intrauterine fetal surgery, where 
it is often termed the “Achilles’ heel” of intrauterine surgical intervention. 
 
Many technical and biological challenges have hindered the development of fetoscopic 
wound sealants for healing the wounds in the fetal membranes. For example, sealants 
must take into consideration the size of the fetal membrane defect (approximately 250 
µm in thickness; 5 mm diameter) when acting as a plug to prevent amniotic fluid leakage. 
Localisation and accessibility of the fetoscopic wound may be challenging, since the 
wounds created after fetoscopic surgery can lead to tears that are irregular in shape and 
size. Therefore, the plugging material must favourably be injectable and remain stable in 
a wet environment that will contain amniotic fluid and often the presence of maternal and 
fetal blood. Furthermore, as previously reported in Chapter 4, there is an absence of fetal 
membrane healing, which further complicates the potential of previously used sealants to 
integrate efficiently with the native tissue and induce healing mechanisms in the 
wound244,245. 
 
To date, very few studies exist regarding prophylactic sealing of fetoscopic puncture sites 
in the clinic. As described in the previous section for treatment of PPROM (5.1.1.1 
Sealants used clinically for spontaneous PPROM) fibrin-based sealants have also been 
tested for prevention of iatrogenic PPROM. Injection of platelets, followed by fibrin glue 
and powdered collagen slurry was administered endoscopically following cord ligation 
for twin-to-twin transfusion syndrome or amniocentesis (Table 5.3). From the 8 patients, 
6 progressed with no evidence of amniotic fluid leakage for 8 weeks or more216. Since, 
the use of gelatin sponge plug has been tested clinically for sealing fetoscopic defects 
following fetoscopy for twin-to-twin transfusion syndrome131. However, there was no 
improvement in patient outcome when compared to patients that did not receive the 
gelatin sponge plug. Furthermore, a larger retrospective cohort study (n=134) has 
confirmed no significant difference in iatrogenic PPROM rates in patients who received 
gelatin sponge plug (39% progressed to iPPROM) compared to those that did not (34% 
progressed to iPPROM)211. More recently, the collagen plug has been tested clinically in 
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patients following fetoscopic endoluminal tracheal occlusion for congenital 
diaphragmatic hernia210. From 54 patients who received the collagen plug, 48% 
developed PPROM; and of the 87 who did not receive the collagen plug, 39% went on to 
develop iPPROM. 
 
Table 5.3: Collagen and gelatin plug strategies for prevention of iPPROM 
 
Species Sealant Model Key findings Study 
Sheep (n=5) 
Rhesus 
monkey 
(n=5) 
Gelatin sponge 
plug (Gelfoam) 
Sheep and 
rhesus monkey 
fetoscopy 
model. 
Gelatin sponge plug placed in fetal 
membrane wound endoscopically. 
Rapid swelling of the plug reported. 
All sheep fetuses survived 
intervention. 
2 primate fetuses were aborted. 
Histological analysis of membranes 
was not performed. 
Luks et al., 
(1999)246 
Rabbit (n=32 
does, with 
288 sacs). 
Fibrin sealant, 
autologous 
maternal blood 
plug and  
collagen plug 
Mid-
gestational 
fetoscopy 
rabbit model. 
Fetoscopy wound closure technique 
occurred at day 22 and harvested at 
day 32. Amnion resealed in 20-44% 
of controls when surgically closed. 
However, none of tested techniques 
significantly improved outcome. 
Deprest et 
al., (1999)247 
Fetal rabbit 
(n=36) 
1. human 
amnion 
membrane 
(n=23) 
2. collagen foil 
(n=16) 
3. collagen plug 
(n=19) 
4. collagen plug 
with cultured 
amnion cells 
(n=19). 
Mid-
gestational 
fetoscopy 
rabbit model. 
Fibrin sealant was additionally 
administered following insertion of 
plugging technique. 
Resealing occurred in 58-64% of 
cases in all but the human amnion 
alone technique as defined by 
restoration of amniotic fluid at day 
30 gestation. No sealing technique 
was significantly better than the 
other. 
Papodopulos 
et al., 
(2006)248 
Rabbit Platelet-
enriched 
collagen plug 
with amniotic 
fluid cells 
(n=44) and 
without 
amniotic fluid 
cells (n=32). 
Mid-
gestational 
fetoscopy 
rabbit model. 
Fetoscopic needle puncture 
occurred at day 23 gestation before 
plugging with collagen plug with or 
without amniotic fluid cells.  
Cell proliferation was increased in 
collagen plugs enriched with 
amniotic fluid cells. 
N=14/44 of collagen plugs with 
amniotic fluid cells remained. 
N=18/32 of collagen plugs without 
amniotic fluid cells remained. 
Liekens et 
al., (2008)249 
Human Gelatin sponge 
plug (Gelfoam). 
Tested 
clinically. 
No difference in outcome after 
gelatin sponge plugging of 
fetoscopic port site compared to 
patients who did not receive gelatin 
sponge. 
Papanna et 
al., (2010)131 
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Human 
(n=134). 
Absorbable 
gelatin sponge 
plug 
Tested 
clinically. 
Retrospective 
cohort study 
for patients 
undergoing 
fetoscopy. 
Gelatin sponge placed in 74 patients. 
60 patients did not receive the 
gelatin plug. 
There was no difference in iPPROM 
rates. 
39% of patients who received 
gelatin plug developed iPPROM. 
34% of control patients who did not 
receive gelatin plug developed 
iPPROM. 
Papanna et 
al., (2013)211 
Human Collagen plug 
imbued with 
fibrinogen and 
plasma 
FM explant 
model. 
Amniotic fluid leakage decreased by 
1/3rd with plasma and fibrinogen 
addition. Some fibrin formation 
occurred in fibrinogen and plasma 
soaked collagen plugs. 
Engels et al., 
(2013)250 
Human 
(n=141) 
Lyostypt 
collagen plug 
(B. Braun) 
Single centre 
cohort study 
for  patients 
undergoing 
fetoscopic 
endoluminal 
tracheal 
occlusion for 
congenital 
diaphragmatic 
hernia. 
Collagen plug is rolled into cylinder 
and placed into membrane defect. 
N=54 received collagen plug 
N=87 did not receive collagen plug.  
48% of patients who received 
collagen plug experienced PPROM. 
39% of patients who did not receive 
a plug experienced PPROM. 
Engels et al., 
(2014)210 
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Other than these limited clinical studies, preclinical assessment of sealing strategies has 
mainly focused on the mid-gestational rabbit model. Fibrin-based sealants and collagen 
plugs also showed limited clinical success in the mid-gestational rabbit model247-250. 
Other strategies have included the use of bioactive membranes from porcine small 
intestine and decelullarised human amnion (Table 5.4)168,170,224. More recently, efforts 
have been made to adopt the favourable approach of injectable sealants as opposed to the 
placement of 3D biomaterial plugs such as collagen and acellular amnion scaffolds. 
 
Table 5.4: Other strategies for sealing fetal membrane defects for prevention of 
iPPROM 
  
Species Sealant Model Key findings Study 
Human Laser 
welding  
FM explant 
model. In 
vitro laser 
welding. 
Cryoprecipitate, 50% albumin, and 
polyetrafluoroethilene (e-PFTE) used as 
solder medium. 
Amniotic membrane laser welding 
successful in 82.6% of membranes when 
using e-PFTE compared to 10.7% when 
using cryoprecipitate. 100% unsuccessful 
using albumin as solder medium. 
Mendoza et 
al., (1999)251 
Rabbit 
(n=20 
does, 
n=100 
gestation
al sacs). 
Bioactive 
membrane 
(porcine 
small 
intestine) 
Mid-
gestational 
fetoscopy 
rabbit model. 
N=50 fetoscopic wounds were sealed with 
biocompatible matrix derived from porcine 
small intestine containing TGFB and FGFB. 
Membrane integrity restored in 70% after 
plug insertion compared to 41% in control 
sacs that did not receive plug. Amniotic band 
observed in one treated sac. 
Devlieger et 
al., (2003)224 
Rabbit 
(n=8 
does). 
Acellular 
human 
amnion 
Mid-
gestational 
fetoscopy 
rabbit model. 
75% of sacs treated with decelularised term 
human amnion showed amniotic integrity 
compared to 25% in control sacs that did not 
receive plug. 
Mallik et al., 
(2007)168 
Rabbit Engineered 
native 
amniotic 
scaffold 
and 
polyesterur
ethane 
scaffolds 
(DegraPol) 
Mid-
gestational 
fetoscopy 
rabbit model. 
AF volume was significantly higher in the 
DegraPol sealed sacs compared to unclosed 
sacs.  
Integration of plugs improved when using 
amniotic membrane scaffold comapred to 
DegraPol. Epithelialisation and proliferation 
indices improved with amniotic membrane 
scaffold as a sealant. 
  
Ochsenbein-
Kolble et al., 
(2007)170 
Human Precipitated 
egg white 
Syrnige FM 
explant 
model. 
Study suggests egg white can seal defects for 
up to 2 weeks in this model. However, whilst 
there is statistical significance between 
control and test group regarding amount of 
fluid leakage over 24 hours, the difference 
was approximately 5 mL, which is not 
necessarily clinically significant. 
Mendez-
Figueroa et 
al., (2010)252 
  127 
The new approaches include the use of bioinspired polymer hydrogel biomimetics 
involving mussel and sandcastle worm adhesives, with the primary function to act as a 
separation barrier and prevent amniotic fluid leakage (Table 5.5)172,220-223,253,254. Liquid 
sealants tested in vitro by Bilic et al., include cyanoacrylate glues and polyethylene glycol 
(PEG)-based hydrogel-type polymers. Based on previous reports demonstrating 
interfacial bonding to other tissues, and the ability to gel in situ, the synthetic PEG-based 
hydrogels investigated were a photopolymerisable gel used in the lung for closure of 
pulmonary air leaks, the commercially available SprayGel used previously as an anti-
adhesion barrier for myomectomy, and the mussel-mimetic adhesive sealant. The 
bioinspired mussel-mimetic is a catechol-functionalised PEG that forms hydrogels via 
crosslinking by oxidation after mixing with a cross-linking solution, sodium periodate. 
The strong adhesive properties of this mussel-mimetic derive from the 3,4-
dihydroxyphenylalanine (DOPA) amino acid found in high concentrations in the mussel 
foot, allowing strong underwater adhesion. The other liquid sealants tested included 
Dermabond and Histoacryl, which are alkyl-cyanoacrylate glues, known to strongly 
adhere to wet tissue via amniotic polymerisation of hydrogel groups. The alkyl-
cyanoacrylate glues appeared to severely damage the amniotic membrane epithelial layer, 
with one showing significant cytotoxicity. The photopolymerisable gel and SprayGel 
PEG-based hydrogel lacked adhesion to the fetal membrane. However, the DOPA-
functionalised PEG hydrogel showed improved adhesion to the fetal membrane with 
lower apoptosis levels and without disrupting the amniotic epithelial layer220. 
 
Since first investigating the adhesive properties of the mussel-mimetic glue, it has been 
further tested on elastomeric membranes and in vitro inflation devices that subject the 
fetal membranes to physiological levels of compression and tension. However, after 
examination in the mid-gestational rabbit model, fetal survival outcome was not 
significantly different to control sacs that did not receive the adhesive253. 
 
Similarly, the sandcastle worm is another marine creature that secretes a proteinaceous 
glue that helps bond sand grains underwater to form a protective shell. The strong 
adhesion is due to the polyacidic and polybasic properties of the proteins found in the 
secretions. By replicating the chemistry and molar ratios using synthetic 
poly(meth)acrylate copolymers, the group were able to achieve an adhesive complex 
coacervate that improved sealing in an in vitro syringe model. The glue has since been 
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tested in a Yucatan miniature swine model. However, unexpectedly the swine fetal 
membrane showed self-healing properties likely due to its vasculature, and therefore the 
swine model was unable to show a difference in fetal survival. 
 
Table 5.5: Bioinspired tissue adhesive strategies for sealing fetal membrane defects 
 
Species Sealant Model Key findings Study 
Human Photopolymerised 
PEG (pPEG) and 
catechol-
functionalised 
PEG (cPEG)  
mussel-mimetic 
hydrogel sealant. 
Sealing tested in 
vitro  using a 
cellerator device 
to stretch out 
fetal membrane. 
Only poly(ethylene glycol)-
based hydrogel mussel 
mimetic hydrogel sealant 
showed non-disruptive and 
non-toxic bonding to fetal 
membranes. 
Bilic et al., 
(2010)220 
Elastomeric 
membranes 
Mussel-mimetic 
tissue adhesive. 
Inflation device. Poly(ethylene glycol)-
based hydrogel used to seal 
elastomeric membrane 
defects. A critical burst 
pressure of 48 mbar reached 
after sealing. 
Haller et al., 
(2011)221 
Human Mussel-mimetic 
tissue adhesive. 
Inflation device. Poly(ethylene glycol)-
based hydrogel reached 
burst pressure of 60 mbar, 
comparable with fibrin glue 
alone. 
Haller et al., 
(2012)222 
Human Sandcastle worm 
mimetic tissue 
adhesive. 
Syringe FM 
explant model. 
The study develops a 
method to test fluid leakage. 
Addition of amniotic 
membrane patch and 
adhesive was used to seal 
artificially punctured fetal 
membranes. The sealant 
and membrane patch 
withstood an additional 12g 
compared to membrane 
patch alone. 
Mann et al., 
(2012)223 
Rabbit Mussel mimetic 
tissue adhesive. 
Mid-gestational 
rabbit fetoscopy 
model. 
Fetal survival no different 
in treated groups. 
Comparable to fibrin glue 
control. 
Kivelio et al., 
(2013)253 
Swine Sandcastle worm 
mimetic tissue 
adhesive. 
Yucatan 
miniature pig 
fetoscopy 
model. 
No difference in fetal 
survival in treated groups. 
Spontaneous healing of 
control defects reported in 
the swine model, therefore 
proving to be an inadequate 
model. 
Papanna et al., 
(2015)172 
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In summary, there are advantages to the new liquid sealants under development compared 
to the previous use of 3D biomaterial plugs, which include the injectable capabilities and 
the ability to adhere in a wet/moist environment.  However, there are many limitations 
associated with the previous attempts to seal fetal membrane defects. In particular, the 
use of miniature swine models is not helpful due to their spontaneous FM healing rate. 
The use of the mid-gestational rabbit model is not ideal, as the rabbit amniotic sac does 
not adhere to the decidua and myometrium as it does in human systems. The gestational 
age of the rabbit is also very short in comparison to humans with term being at 30 days. 
Therefore any sealing method can only be tested for up to 7 days before delivery and 
harvesting of the sample. Furthermore, the use of synthetic bioinspired liquid sealants 
require crosslinking agents such as sodium periodate, which acts as a strong oxidizing 
reagents that enable polymerization and formation of hydrogels. This chemical is a strong 
irritant and the effects on fetal membranes after 24 hours has not been reported. It is 
therefore necessary to investigate more long-term cytotoxicity and efficacy in vitro and 
in animal models other than the Yucatan miniature swine model before clinical testing 
can be proposed. 
 
The development of future sealants would benefit from being injectable and functional in 
a wet and dynamically mechanical environment. However, a tissue engineering approach 
that could facilitate the introduction of wound healing factors and inhibitors that enhance 
healing could improve liquid sealants that not only provide a barrier for prevention of 
amniotic fluid leakage but also induce healing mechanisms and promote repair in the fetal 
membranes. 
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5.1.2 Potential peptide amphiphiles for sealing defects in the fetal membranes 	
Peptide amphiphiles (PAs) have a widespread interest in tissue engineering, regenerative 
medicine, and drug delivery, due to their ability to inter- and intra-molecularly self-
assemble into highly ordered nanostructures with bioactive functionality. The use of PAs 
has not before been explored in the context of FM regeneration and the ability to use these 
systems to signal native cells presents an interesting opportunity. 
 
PAs are small synthetic molecules that contain both hydrophobic and hydrophilic 
domains, typically comprised of three regions: (1) Hydrophobic, (2) Peptide, and (3) 
Charged group domain (Figure 5.1). 
  
Figure 5.1: Peptide amphiphiles are composed of three key regions including the hydrophobic 
alkyl tail, the ß-sheet forming peptide domain, and the charged amino acid group domain. The 
amphilicity is provided by the combined hydrophilic nature of the alkyl tail and peptide 
domain with the hydrophilic charged group of amino acids. This interesting property enables 
the formation of 1D nanofibres, micelles, closed sacs, aligned fibres, and ribbons. Adapted 
from Hendricks et al., (2017)11  
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The hydrophobic domain consists of a long alkyl tail that varies in length and consists of 
various groups facilitating integration of bioactive epitopes onto the surface of the self-
assembled nanostructure.  
 
The peptide domain forms a ß-sheet that is adjacent to the hydrophobic alkyl tail with 
intermolecular hydrogen bonding due to the short peptide sequence that contains 
hydrophobic amino acids. The ability to form intermolecular hydrogen bonds as ß-sheets 
assists the formation of self-assembled 1D nanofibres, which are then responsible for the 
formation of 3D nanofibre networks. 
 
The charged group domain is adjacent to the hydrophobic ß-sheet forming region and 
contains charged amino acids which promotes solubility and facilitates PA design in 
response to changes in pH and electrolyte levels due to the charged amino acids acting as 
weak acids and bases. This triggers formation of 1D nanofibres and therefore the design 
of this domain is important in regulating the formation of 3D nanofibre networks once in 
contact with a physiological solution. The pH and salt-responsive property has inspired 
the addition of a fourth region, termed the bioactive epitope, which is adjacent to the 
charged group domain and has previously incorporated bioactive regions including cells, 
DNA, and growth factors that can form self-assembled PA nanofibre networks with 
biofunctionality once injected into a physiological environment. 
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5.1.3 Molecular self-assembly 
 
According to IUPAC Recommendations (2013), molecular self-assembly is the 
“spontaneous and reversible organisation of molecular entities by non-covalent 
interactions” further defined as “a process in which a system of pre-existing components, 
under specific conditions, adopts a more organized structure through interactions 
between the components themselves255.” 
 
Self-assembled hydrogels differ from conventional covalently cross-linked polymer 
hydrogels, as they do not require cross-linking or polymerisation to undergo gelation. 
Instead self-assembled hydrogels typically form following charge screening due to 
multivalent ions in solution, and therefore are not determined by covalent interactions. 
As previously described, PAs can self-assemble to form 1D high-aspect-ratio nanofibres, 
closed sacs, micelles, ribbons, and aligned fibres, with emergent potential in tissue 
engineering applications for soft and hard tissue regeneration256. 
 
5.1.4 Liquid-liquid interfacial systems for a tissue engineering approach 
 
The study of molecular organisation at the interface has previously been investigated 
between an air and water interface classically known as the Langmuir-Blodgett film; and 
between solid and liquids, for example the self-assembling monolayer formed by 
dissolving liquids on a solid surface257-259. Another example is the layer-by-layer 
deposition of polymers at a liquid interface260. Interestingly, the aqueous liquid-liquid 
interface has also been investigated using unassembled solutions of PAs and other 
solutions including polysaccharide hyaluronic acid, growth factors, and elastin-like 
polypeptides (Figure 5.2a, b)4,14,15. Hyaluronic acid is a non-sulfated glycosaminoglycan 
(GAG) that is highly negative and found in connective tissues, whilst elastin-like 
polypeptides are also negatively charged and engineered to share structural characteristics 
with proteins such as tropoelastin. Hyaluronic acid and elastin-like polypeptides are both 
high molecular weight molecules that have been shown to co-assemble with positive PAs 
(PA-K3) via strong electrostatic interactions to form solid membranes at the liquid-liquid 
interface (Figure 5.2a)4,8,261. 
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PAs have previously been tested with solutions of synovial fluid demonstrating gel 
formation at physiological pH for biomedical applications (Figure 5.2a)13. PA-K 
molecules, used at 1% (w/v), with branched RGDS sequences to promote cell adhesion, 
enabled the formation of gels when mixed in a 1:1 ratio with synovial fluid. However, no 
studies exist involving liquid-liquid interface systems of other physiological solutions 
such as blood and amniotic fluid when combined with solutions of PAs. Recently, PA-
based gels have been used to investigate wound regeneration for diabetic skin wounds 
and full thickness skin burns (Figure 5.2c)17,18. For example, a heparin-mimetic PA gel 
formed using negatively charged GAG-PA and positively charged PA-K, which was 
topically applied to a diabetic mouse wound model, reported to accelerate diabetic wound 
healing by promoting angiogenesis17. The same group also used the heparin-mimetic PA 
gel to treat full thickness burn injuries in a mouse model and demonstrated an increased 
rate of repair following topical application18. 
 
A major benefit of PAs regarding in situ fetal membrane sealing and regeneration is that 
they can exist in an unassembled state in solution with very low viscosity, and then be 
easily injected to interact with a physiological solution such as amniotic fluid and 
maternal blood. The presence of key physiological factors in the amniotic fluid (AF) 
could induce PA self-assembly to form cylindrical nanofibres leading to complex 3D 
nano-architectures for mimicking the fetal membrane extracellular matrix, which is 
highly dense and contains a complex anisotropic collagenous matrix. 
 
In summary, the use of PAs to form highly complex 3D nanostructures is of growing 
interest for developing new therapies for biomedical applications. Regarding fetal 
membrane sealing for the prevention and treatment of iatrogenic and spontaneous 
PPROM, PA-based gels offer advantages over previously attempted sealing techniques 
as they can be injected and when combined with physiological solutions self-assemble to 
form stable gels that microscopically mimic the extracellular matrix. The ability to design 
and alter the sequence of PA provides a never before ability to optimise the desired gel 
properties in applications such as fetal membrane wound sealing. Furthermore, previous 
complications include the ability of gels to remain stable and functional in a wet 
environment. As PAs form stable gels at the liquid-liquid interface this could help to 
address this complication. In addition, the ability to present bioactive epitopes in high 
density at the surface of self-assembled PA nanofibres alludes to the possibility of 
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designing therapies that not only act as a barrier to prevent amniotic fluid leakage but also 
if targeted correctly, can promote wound repair in a tissue that has absent wound healing. 
For the first time we propose the use of synthetic peptide amphiphiles that self-assemble 
to form 3D nanofibrous networks with potential to mimic amniotic membrane 
extracellular matrix microstructure. 
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Figure 5.2: Peptide amphiphile gels and biomedical applications. Self-assembling peptide 
amphiphile gels formed when combined with a variety of solutions including polysaccharides, 
growth factors, and physiological solutions (A). Self-assembly peptide amphiphile systems 
have also been used for engineering of blood vessels using protein-peptide elastin-like 
polypeptide (ELP) – PA systems (B) and for the topical application of PA gels for diabetic 
wound and burn injury regeneration (C). Adapted from: Capito et al., (2008)4; Ferreira et al., 
(2013)8; Guler et al., (2006)13; Hosseinkhani et al., (2006)14; Inostroza-Brito et al., (2015)15; 
Senturk et al., (2017)17 and Yergoz et al., (2017)18. 
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5.2 Methods 
5.2.1 Amniotic fluid collection 
 
Human amniotic fluid (AF) was used to study formation of macroscopic structures, if any, 
with solutions of positively charged peptide amphiphiles (PAs) at the liquid-liquid PA-
AF interface. AF was collected from women undergoing fetoscopic laser ablation of 
placental vascular anastomoses for twin-to-twin transfusion syndrome in mid-trimester 
pregnancies, and following amniodrainage for polyhydramnios, and amniocentesis for 
diagnostic genetic testing. Mid-trimester human AF was used to form macroscopic 
structures at the PA-AF interface.  
5.2.2 Fetal membrane collection 
 
Fetal membranes (n=9) were collected from term deliveries following elective Caesarean 
section to test the potential of PA-AF membranes for sealing FM defects using the in vitro 
FM wound model. Mean gestational age at delivery was 39+1 weeks with a range of 38+3 
– 41+2 weeks (median: 39+3 weeks). Mean maternal age at delivery was 32 with a range 
of 25 – 39 years of age (median: 34 years). The indication for caesarean section (Figure 
Figure 5.3: Indication for caesarean section shown as a percentage. These samples 
were used for testing peptide amphiphile sealing potential and toxicity within our 
in vitro wound model. 
  137 
5.3) includes placenta praevia, history of at least one previous caesarean section, and 
maternal medical reasons. 
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5.2.3 PDMS fluidic device fabrication 
 
Polydimethylsiloxane (PDMS) fluidic channels were used for the formation of self-
assembled macroscopic structures at the liquid-liquid PA-AF interface. PDMS was used 
as it is a hydrophobic and inert material, providing a large contact angle between liquid 
droplets. PDMS channels were formed using a novel method established within our 
laboratory (Figure 5.4). First, a 10:1 ratio of silicone elastomer and crosslinking agent 
was thoroughly mixed. Air bubbles were removed using a vacuum desiccator. The 
resulting mixture was cured for 45 minutes at 60oC. For PDMS channels, a bottom layer 
was partially cured and a second layer was deposited. After the first layer is fully cured 
and the second layer partially cured, 2 mm capillary tubes were inserted into the PDMS. 
After complete curing for a total of 45 minutes at 60oC, the capillary tubes were carefully 
removed to reveal 2 mm channels. 
Figure 5.4: Fabrication of PDMS channels for investigating formation of self-assembling 
membranes between amniotic fluid and peptide amphiphile solutions. The channels are 2 mm 
in diameter and provide a hydrophobic and inert surface for the study of liquid-liquid 
interfacial systems. 	
PDMS channel fabrication steps 
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5.2.4 Self-assembly of PA-AF macrostructures 
 
AF was either used immediately after collection or stored at 4oC in a sterile sealed 
container for up to 7 days before being transferred to -20oC. Self-assembly of 
macroscopic structures were studied using 0.5-2% (w/v) PA solutions with unaltered 
human AF. PDMS channels were used (Figure 5.5a) as a fluidic device to study the 
liquid-liquid interface self-assembling systems and prepare membranes in a reproducible, 
hydrophobic and inert environment. Within the PDMS channel, PA and AF solutions 
were combined in equal volumes using a range of 5-15 µL throughout experimentation. 
Using PDMS channels also allowed for small quantities of PA solution to be tested. AF 
(~5-15 µL) was first pipetted into the left side of a channel and then an equal volume of 
PA solution (~5-15 µL) into the opposite side and left to form an interface. Self-assembly 
was also tested by injecting either PA or AF into a larger volume of the other solution. 
Furthermore, the PA solution sealing ability was also tested with human fetal membrane 
defects in the in vitro FM wound model (Figure 5.5b-e). 
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Figure 5.5: Methods used to test the self-assembly of macrostructures at the amniotic fluid 
and peptied amphiphile interface. Self assembly was tested in PDMS channels (A) and within 
the artificial fetal membrane trauma model to test sealing capabilities (B-E). Fetal 
membranes (FM) were collected from term placentas from women undergoing elective 
caesarean section between 37 and 42 weeks of gestation. The FM was excised into square 
tissue explants (approx. 30 x 30 mm) and assembled with the crown insert (B). A 21 Gauge 
needle was used to create a 0.8 mm diameter FM defect (C). The FM crown model was 
transferred into the tissue culture plate and amniotic fluid (AF) injected into the well (D) to 
cover the area below the FM explant (* indicates AF injection site, schematic). Peptide 
amphiphile (PA) was applied to the FM defect from above (E, schematic, F). Self-assembly 
was also tested by injection of AF or PA into larger volumes of the other solution (not shown 
here). 
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5.2.5 PA synthesis and purification 
 
Solid phase peptide synthesis (SPPS) using an automated peptide synthesizer (CS Bio, 
USA) was used for peptide amphiphile (PA) synthesis. The standard 9-
fluorenylmethoxycarbonyl (Fmoc) protection chemistry on a 4-methylbenzhydrylamine 
(MBHA) Rink Amide resin (Novabiochem Corporation, UK) was used. Amino acid 
couplings were performed using four equivalents (4 mmol) of Fmoc-protected amino 
acids (Novabiochem Corporation, UK), four (4 mmol) equivalents of 1-
hydroxybenzotriazol (HOBT, Carbosynth Limited, UK) and six (6 mmol) equivalents of 
N,N’-diisopropylcarbodiimide (DIC, Sigma–Aldrich, UK) for 1h. Fmoc deprotections 
were performed with 20% piperidine (Sigma-Aldrich, UK) in N, N-dimethylformamide 
(DMF). Following Fmoc removal from the final amino acid residue, the alkyl tail moiety 
(palmitic acid, C16H32O2, Calbiochem, UK) was conjugated to the free N-terminus. The 
alkylation reaction was accomplished by using four equivalents of the fatty acid, four 
equivalents of HOBT, and six equivalents of DIC in DMF/dichloromethane. The reaction 
was allowed to proceed overnight and pursue until obtaining a negative Kaiser test. PA 
cleavage from the resin and deprotection were carried out with a mixture of trifluoracetic 
acid (TFA, Sigma-Aldrich, UK)/triisopropylsilane (TIS, Alfa Aesar, UK)/water 
(95:2.5:2.5) for 3h at room temperature. After filtration of the cleaved mixture, TFA was 
removed by rota-evaporation and the resulting viscous peptide solution was precipitated 
with cold diethylether at -20ºC. The precipitate was collected by centrifugation, washed 
twice with cold diethylether, allowed to dry overnight, suspended in water, and lastly 
freeze-dried. 
 
Peptide purification was carried out using 2545 binary gradient preparative High-
Performance Liquid Chromatography (Waters, USA) with a 2489 UV/Visible detector 
(Waters, USA) using a C18 column (Atlantis Prep OBD T3 Column, Waters, USA) and 
a water/acetonitrile (0.1% TFA) gradient. In the case of positive peptides the TFA 
counter-ions were exchanged by sublimation from 0.01 M hydrochloric acid. Finally, the 
peptides were dialyzed against deionized water using 500 MWCO dialysis tubing 
(Spectrum Europe B.V., The Netherlands) to remove salts, lyophilized to obtain a fluffy 
powder, and stored in closed containers at -20°C until use. The mass of the peptides was 
confirmed by electrospray ionisation (ESI, Thermo LXQ, Thermo Scientific, USA) and 
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matrix-assisted laser desorption ionisation-time of flight mass spectrometry (MALDI-
TOF MS, Applied Biosystems 4800 Proteomics Analyzer (TOF/TOF) mass 
spectrometer).  
 
5.2.6 PA subtypes and properties 
 
The PAs used in the present study and their corresponding sequence, molecular weight, 
isoelectric point, and zeta-potential are shown in Table 5.6. 
 
Table 5.6: The molecular details of the peptide amphiphiles used in the present study. 
 
Peptide sub-type Peptide sequence MW pI ζ (mV) 
PA-K2 
 
 
C15H31CONH-
VVVAAAKK-
CONH2 
1.0224 10 67.8±5.2 
PA-K3 
 
 
C15H31CONH-
VVVAAAKKK-
CONH2 
1.1506 10.3 67.5±3.3 
PA-K4 
 
 
 
C15H31CONH-
VVVAAAKKKK-
CONH2 
1.2788 10.5 66.6±4.0 
PA-E3 
 
 
 
 
C15H31CONH-
VVVAAAEEE-
CONH2 
1.1531 3.7 −33.1±3.0 
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PA-K4(TAMRA) 
 
 
C16-
VVVAAAKKK-
K(TAMRA)-
CONH2 
1.537 n/a n/a 
 
PA: peptide amphiphile; K: lysine; E: glutamic acid; Mw: molecular weight; pI: isoelectric point; ζ: zeta-
potential (mV). 
 
5.2.7 Fluorescently labelled peptide amphiphile self-assembly 
 
Fluorescently labelled peptide amphiphile was used to study direction of self-assembling 
membrane growth and discern the direction that PA was flowing. The peptide used was 
PAK3 (2%) with addition of the Fluorescent PA-K4(TAMRA) diluted to 0.01% in PAK3 
solution. The epifluorescence Leica DMI 4000B Fluorescence microscope was used to 
produce a time-lapse of fluorescently labelled PA by placing PDMS channel under the 
microscope and imaging the interaction between the 2 solutions. 
 
5.2.8 ζ-potential measurement (ζ) for amniotic fluid charge 
 
All ζ-potential measurements were performed after resuspension of the PAs at a 
concentration of 1mM in cell diluent (HEPES 10 mM supplemented with 0.9% NaCl, pH 
7.4). After loading the samples in folded capillary cells, measurements were performed 
at 25°C using a ζ-sizer instrument (Nano-ZS Zen 3600, Malvern Instruments, UK). For 
each PA, three separate samples were measured with at least five runs per sample.  
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5.3 Results 
 
Amniotic fluid (AF) suspensions from 2nd trimester patients were used for these 
experiments and mixed with dilute aqueous PA solution at varying concentrations (0.5 – 
2%). Positively charged PAs were used as 2nd trimester AF is known to contain proteins 
(0.16 – 10 g/L) and growth factors that have negative charge262. Overall net negative 
charge was confirmed by measuring Zeta-potential (mV, Figure 5.6a). Furthermore, 
GAGs that are highly negatively charged molecules were detected in 2nd and 3rd trimester 
AF samples (n=10, Figure 5.6b). A higher amount of GAG was detected in the 3rd 
trimester towards term (mean GA: 31+2; median GA: 30+3; range 29+1-33+4; n=12), 
compared to 2nd trimester AF (mean GA: 17+1; median GA: 18+4; range: 15+3-23+6; n=10). 
A 
Zeta Potential (mV) 
Zeta Potential distribution using 2nd trimester amniotic fluid 
0 
2 
4 
6 
8 
10 
12 
14 
2nd trimester 3rd trimester 
sG
A
G
 c
on
te
nt
 (µ
g/
µl
 a
m
ni
ot
ic
 fl
ui
d)
 **	
B 
Figure 5.6: Confirmation of negatively charged amniotic fluid suspensions and presence of 
highly negatively charged long unbranched polysaccharide glycosaminoglycans. 3rd trimester 
amniotic fluid (n=12) contained higher GAG content compared to 2nd trimester (n=10). Error 
bars represent mean ± SEM, where **p<0.01.  
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For self-assembly experiments, 2nd trimester amniotic fluid (mean GA: 17+1; median GA: 
18+4; range: 15+3-23+6) was used throughout, as this is the period of pregnancy where 
intrauterine fetal surgery and PPROM complications commonly occur. 
5.3.1 Peptide amphiphile – amniotic fluid (PA-AF) systems 
 
Peptide amphiphiles containing three lysine residues in the charged group domain 
(PAK3) have been commonly used to investigate self-assembly of 1-D cylindrical 
nanofibres4,15. We decided to investigate PAK3, a positive PA, when combined with 
human amniotic fluid, which is comprised of a multitude of negatively charged proteins. 
We further investigated changes in the number of lysine residues contained in the PA 
sequence, which changes the overall positive charge of the PA and therefore predicted to 
influence electrostatic screening when combined with human amniotic fluid. 
 
PDMS fluidic channels were used to study the initial interface between PAs with varying 
numbers of lysine residues (PA-K2, -K3, -K4) and mid-trimester amniotic fluid (Figure 
5.7). Membrane formation can be seen instantly in PA-K2, -K3, -K4, and amniotic fluid 
systems, at 5 seconds (Figure 5.7a, b, c), which possibly acts as a diffusion barrier formed 
via strong electrostatic interactions. Self-assembly of macrostructures occurred in PAK2-
AF and PAK3-AF systems, however PAK4-AF system resulted in a paste-like substance. 
The PAK2-AF system resulted in a very weak gel following a 6-hour incubation period, 
which easily disintegrated. 
 
The resulting gel from the PAK3-AF system was stable, and appeared to be solid, 
containing no fluid in the centre. Following a 6-hour incubation period the gel from the 
PAK3-AF system (Figure 5.7d, e, f) formed within the PDMS fluidic device or when 
PAK3 solutions were injected into larger AF volumes, formed a stable and solid gel that 
could be manipulated without disintegrating after contact. Injection of PAK3 (~50 µL) at 
2% (w/v) into a larger solution of human amniotic fluid (up to 50 mL) for longer time 
periods also resulted in formation of a solid gel at 24 hours when incubated at 37oC 
(Figure 5.7g). Interestingly, an overall negative PA, PAE3, also formed a very weak gel 
that could not be manipulated and which readily disintegrated upon contact. 
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Figure 5.7: Peptide amphiphile and amniotic fluid macrostructure self-assembly. PAs with varying 
lysine residues self-assembled with AF to form membranes that developed to form macrostructures 
with different structural stabilities. PAK2-AF system (A) resulted in a weak gel at 24 hours. PAK3-
AF system (B) resulted in a stable gel that could be handled without disintegrating. PAK4-AF system 
(C) resulted in a paste-like substance. PAK3-AF system also resulted in stable gels when the PAK3 
solution (2% w/v) was injected into larger AF volumes and incubated for 6 hours (D, E, F), and 
remained stable at 24 hours (G). PAE3-AF system formed a weak gel that easily disintegrated upon 
contact after 6 hours (H). 
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Following closer investigation of gel formation, it is clear that after self-assembly of an 
initial PAK3-AF interface (Figure 5.8a, b) the direction of gelation occurs towards the 
PA solution until the entire PA solution becomes engulfed (Figure 5.8c), opposite of that 
reported by Capito et al., where solutions of the hyaluronic acid are engulfed by the PAK3 
solution during gelation4. 
 
A 
B 
C 
The PDMS channel PAK3-AF system 
Figure 5.8: Formation of self-assembling membranes at the PAK3-AF interface using PDMS 
channels as a fluidic device. A schematic showing the typical procedure involving first 
pipetting ~5-15 µL of amniotic fluid to the left side of the channel and then introducing the 
same volume of the PAK3 (2% w/v) solution to the right side of the channel (A). A typical 
membrane as seen through a light microscope (B) and with no instrumentation (C). Following 
formation of an initial dense membrane at the PAK3-AF system interface, the formation of a 
gel occurs in the direction of the PA solution as shown by comparing self-assembly at 10 mins 
(C, left) and 2 hours (C, right). 	
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To confirm direction of membrane growth and gelation, the positively charged PAs 
including PAK2, PAK3, and PAK4 were injected into solutions of AF; and solutions of 
AF were injected into solutions of the PAs for comparison (Figure 5.9a,b).  
 
Following initial self-assembly of membranes at the interface, it is clear the direction of 
macrostructure growth and self-assembly is towards the PA solution. For all variation of 
PAs, membrane growth moved towards the PA solution. This self-assembly phenomenon 
occurred rapidly in all circumstances, where the volumes of PA solutions injected (~5 
µL) are completely engulfed within minutes. The initial membrane formation appears 
rapidly, and gel formation increases in density from 5 seconds to 10 minutes, originating 
from the PA-AF interface. In contrast, injection of AF (~5 µL) into a solution of the PA 
led to macrostructure formation towards the PA solution, but did not engulf the entire 
volume of AF over the same time period, indicating that the amount of self-assembly and 
macrostructure formation is dependent upon PA volume. 
 
Regarding the mechanism of gelation, it appears there are three distinct stages involved 
in the PA-AF system (Figure 5.9c). Initial membrane formation at the interface leads to 
rapid gelation via strong electrostatic interactions and rapid diffusion of ions across the 
diffusion gradient. This is then followed by a third stage, where the gel appears to increase 
in density beginning at the PA-AF interface and moving towards the centre of the PA 
solution, perhaps elicited by the slower diffusion of macromolecules within the amniotic 
fluid across the diffusion gradient. Furthermore, fluorescently labelled PAK4 conjugated 
with a TAMRA fluorophore did not mix with amniotic fluid when combined, and instead 
clear separation from the amniotic fluid solution is evident (Figure 5.9d). The initial 
interface between the PA solution and amniotic fluid appears to move in the direction of 
the amniotic fluid. This may be due to the formation of a gel and expansion against the 
sides of the channel as the membrane grows. However the initial PA-AF interfacial 
membrane that forms upon contact, prevents mixing of the two solutions. 
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Figure 5.9: Direction of PA-AF system membrane self-assembly and stages of gel formation. AF 
injection into PA solutions leads to self-assembly membrane growth away from the AF and towards 
the PA solution for PAK2, PAK3, and PAK4 shown at 5 seconds, 1 minute, and 10 minutes (A). PA 
injection into AF solutions leads to self-assembly membrane growth towards the PA solution until 
the entire PA solution is engulfed for PAK2, PAK3, and PAK4 solutions from 5 seconds to 10 
minutes (B). Schematic showing the stages of gel formation beginning with membrane formation at 
the interface, then the formation of a weak gel due to strong electrostatic interactions, finishing with 
the formation of a more stable gel due to the diffusion of larger molecules across the diffusion 
gradient (C). Fluorescently labelled PAK4 solution combined with AF demonstrates that PA 
molecules remain within the PA solution and do not mix with the amniotic fluid, rather the contents 
of the amniotic fluid diffuse towards the PA solution. 
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5.3.2 PAK3-AF self-assembling system: membrane microstructure 
 
Scanning electron micrographs of PAK3-AF macrostructures after 24 hours, formed by 
injection of PAK3 (2% w/v) into AF revealed a highly dense 3D nanofibrous network 
that mimics the dense native ECM of the fetal membrane (Figure 5.10a). After separating 
the PAK3-AF macrostructure using a scalpel and then dissecting open the structure, it is 
clear that the self-assembly of a nanofibre network occurs throughout the full thickness 
of the macrostructure, confirming that the macrostructure does not contain a fluid-filled 
centre. Throughout the PAK3-AF gel, the nanofibres are well-defined and arranged in 
random orientations. The surface of the PA-AF membrane in direct contact with the 
amniotic fluid side contains a dense network of well-defined nanofibres that appear to be 
coated in a rough layer of droplets. It is likely these are microscopic lipid droplet 
corpuscles found within the amniotic fluid, and are too large to diffuse through the initial 
membrane that self-assembles upon contact between the AF and PAK3 aqueous solution. 
 
Rapid fixation of the PAK3-AF system did not show a well-defined membrane, however, 
it was possible to produce electron micrographs of fixed nanofibres during the early 
fixation period of 5 seconds to 10 minutes. Nanofibres of less than 100 µm are shown at 
5 seconds, 30 seconds, and 10 minutes (Figure 5.10b). The density of nanofibres also 
appears to increase from 5 seconds to 10 minutes. 
 
Further analysis of membrane microstructure reveals a rough surface at the PAK3-AF 
interface, on the AF side, following 24 hours (Figure 5.11a). Further evidence of 
amniotic fluid organic components attached to the surface of the membrane is found at 
24 hours. Towards the PA side of the gel, the organic components are absent, revealing 
well-defined nanofibres arranged in random orientations (Figure 5.11b). Nanofibres are 
approximately 84 nm in diameter. Furthermore, cross-sectional analysis of PAK3-AF 
self-assembled gels reveal a highly dense PAK3-AF interfacial membrane (Figure 5.11c; 
region 2), with nanofibres mostly arranged perpendicular to the surface. This highly 
dense membrane is approximately 2 µm in thickness, consistent with the increased 
autofluorescence of PA membranes observed using confocal microscopy (Figure 5.11c, 
inset). The surface, originally in contact with the amniotic fluid (Figure 5.11c; region 1) 
also contains droplets that are likely to be organic components of the AF. Beyond the 
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highly dense membrane, the nanofibre network is less dense and contains well-defined 
nanofibres arranged in random orientations consistently through the full thickness of the 
gel (Figure 5.11c; region 3). 
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Figure 5.10: Electron micrographs of PAK3-AF system following injection of PAK3 aqueous solution 
into AF. Injection of PAK3 into AF results in formation of a gel composed of well-defined nanofibres 
that are randomly orientated throughout the full thickness of the gel (A). The surface of the PAK3-AF 
gel contains organic components. Early fixation of PAK3-AF system shows formation of nanofibres as 
early as 5 seconds (B). The self-assembling nanofibre network appears to increase in density from 5 
seconds to 10 minutes (B). 
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Figure 5.11: Electron micrographs of PAK3-AF system formed within the PDMS fluidic 
device. Following a 24-hour period, the PAK3-AF gels showed a rough amniotic fluid surface 
containing organic components (A). The PAK3 side contains well-defined nanofibres of 
approximately 84 nm in diameter and organised in random orientations (B). The PAK3-AF 
interface contains a highly dense region of nanofibres (region 2) arranged perpendicular to 
the surface (region 1), spanning a thickness of approximately 2 µm consistent with that shown 
from increased PA autofluorescence at the liquid-liquid interface using confocal microscopy. 
Adjacent to the perpendicular fibres is a less dense nanofibre network. 
A 
B 
C 
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5.3.3 Self-assembled PAK3-AF membranes for sealing artificial fetal membrane 
wounds 
 
Following formation of a stable gel using the PAK3-AF system, the ability to effectively 
seal FM defects was tested using the artificial FM trauma model developed previously 
for studying the expression of Cx43 (Chapter 4). Briefly, after assembling term FM 
within the crown insert, the tissue was wounded using a sterile 21G needle to create a 0.8 
mm defect. The PAK3 (2% w/v, ~10 µL) was then carefully applied to the top (chorionic 
membrane wound side) of the FM wound with amniotic fluid being injected until in 
contact with the inner AM surface (~2 mL). Therefore, the PA was exposed to the AF 
present within the FM wound margins on the AM side of the FM, as would occur in 
fetoscopic procedures if this technique was applied clinically. This would allow the PAK3 
to initiate self-assembly of cylindrical nanofibres and formation of a 3-D nanofibrous 
network. After 24 hours incubation (37oC), the PAK3-AF system resulted in gel 
formation across the fetal membrane wound. The wound margins were not visible on the 
chorionic membrane side (Figure 5.12a, c). However, the wound outline could be seen 
on the AM side (Figure 5.12b). Following fixation with paraformaldehyde (4%) the 
PAK3-AF gel appears dark red.  
 
Figure 5.12: Sealing of fetal membrane defects using the PAK3-AF system in the artificial fetal 
membrane trauma model. PAK3 aqueous solution (2% w/v) was applied over the wound from above. 
The wound margin cannot be seen on the chorionic membrane side (A, C), however is clearly visible 
on the amniotic membrane side. The PAK3 solution has self-assembled to form a macroscopic plug 
(yellow arrows) in the presence of amniotic fluid, sealing the fetal membrane defect over a 24 hour 
period.  
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Sealing of artificial fetal membrane defects can be seen using electron micrographs 
(Figure 5.13). Fetal membrane remains mostly viable (Figure 5.13a, green) following a 
24-hour culture period and creation of a 0.8 mm defect (Figure 5.13a, b). However, 
following initial trauma there is a small boundary of cells (~5 cell layer thick) that are 
non-viable (Figure 5.13a, red). Sealing of the artificial defect (Figure 5.13c) can be 
observed at high magnification, which shows some promising integration of native fetal 
membrane ECM nanofibres with the self-assembled nanofibres of the PA-based sealant, 
following 24 hours incubation with amniotic fluid (Figure 5.13c-i). 
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5.3.4 Histological analysis of sealed fetal membrane defects 
 
After wounding the fetal membrane using a 21G needle, the histological analysis of 
control samples reveals the non-healing nature of the fetal membrane (Figure 5.14a). The 
0.8 mm defect was located using India ink to mark the wound margin prior to tissue 
sectioning. Cross-sectional H&E staining shows viable cells within the loosely conjoined 
amniotic membrane and chorionic membrane layers. The amniotic epithelial layer 
Figure 5.13: Electron micrographs of fetal membrane defects sealed using the PAK3-AF system using 
the artificial fetal membrane trauma model. The fetal membrane used for these experiments contained 
viable cells over a 24 hour period (A) with a small 2 – 5 cell layer thick boundary of non-viable cells 
due to initial trauma following wound creation. A control fetal membrane defect of approximately 0.8 
mm shows absent healing following 24 hours (B). Following PAK3 application, sealing at the wound 
margin occurs (C, yellow line). Microstructure analysis reveals integration of human fetal membrane 
ECM nanofibres with self- assembled PAK3 nanofibres following 24 hour incubations (D, E, F). 
Higher magnification shows close association between the self-assembled PAK3-AF gel and the native 
fetal membrane ECM nanofibres.  
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remains intact, showing cuboidal amniotic epithelial cells covering the stromal layers that 
contain dispersed mesenchymal cells. The amniotic epithelial layer is clearly adhering to 
the chorion membrane, which contains a higher density of fibroblast and trophoblast cells 
dispersed within the stromal layers.  
 
 
  
Figure 5.14: Cross-sectional histological H&E staining of the human fetal membrane 
showing clearly the amniotic membrane (AM) and chorionic membrane (CM) layers, and the 
non-healing nature of the fetal membrane wound. The amniotic epithelial (ae) layer remains 
intact following sectioning, and no amniochorion separation can be seen. The wound was 
identified using india ink. 
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Application of PAK3 to the defect site results in self-assembly of a nanofibrous structure 
that completely seals the fetal membrane defect at both the amniotic membrane and 
chorionic membrane regions, showing no evidence of amniochorion separation (Figure 
5.15 b, c). The PAK3-AF gel also appears to be present on the surface of the chorionic 
membrane where residual amniotic fluid may have been present. A layer of PAK3-AF 
gel has also formed on the underside, adhering to the amniotic membrane surface, which 
may result following injection of PAK3 along the fetal membrane wound and during the 
early stages of membrane formation at the PAK3-AF interface (Figure 5.15b, c). 
Biocompatibility of the PA-based gel appears promising, as the PA on the surface of the 
amniotic membrane does not damage the layer, leaving the amniotic epithelial layer 
structurally intact with no ruptures present. The PAK3-AF gel also did not appear to 
damage the integrity of the cell-dense chorionic membrane layer. The structural integrity 
of the amniotic epithelial layer can be seen at higher magnification, indicating successful 
biocompatibility (Figure 5.15a). 
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Figure 5.15: Histological analysis of fetal membrane explants and PAK3-AF plug. 
Following PAK3 application, the PAK3-AF self-assembling nanofibrous structure can be 
seen plugging the fetal membrane defect (A, C), which also appears to be biocompatible 
following a 24 hour incubation period, with no sign of fetal membrane structural damage 
or loss of integrity to the amniotic epithelial layer (arrows, B). Histological analysis is 
representative for n=6. 
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5.3.5 Peptide amphiphile toxicity testing with fetal membrane specimens 
 
Cell viability of PA application was tested after fresh fetal membrane was allowed to 
stabilise after 24 hours in DMEM (Figure 5.16). Fetal membrane explants were then 
treated with 2% (w/v) solutions of PAK2, PAK3, PAK4, and PAE3, for 2 hours and then 
replaced with DMEM for the remainder of the 24-hour incubation period. Control tissue 
was incubated in DMEM and AF for 24 hours with no PA exposure. Following 24 hours, 
cell viability remained high in DMEM (92%) and AF (78.4%) incubations. Increasing the 
number of lysine residues within the PA molecules appears to increase toxicity. PAK2 
(72.4%) and PAK3 (69.8%) incubations showed high cell viability compared to PAK4 
(43.1%) exposure. Incubations with negative PAE3 containing the glutamic acid residue 
showed high cell viability after 24 hours (81%). Percentage cell viability is shown as the 
mean of the placental and cervical fetal membrane samples. For each PA incubation 
condition (n=3), the mean percentage viability was calculated from 3 replicate cell counts 
from different field views of approximately 0.5 mm2.  
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Figure 5.16: Fetal membrane cytotoxicity testing of peptide amphiphile subtypes. Cervical 
(CAM) and placental (PAM) amniotic membrane explants were separated and analysed 
separately following live/dead staining (A). Percentage cell viability is shown as the mean 
between PAM and CAM (B). Percentage cell viability remained high in DMEM (92%) and 
amniotic fluid (AF, 78.4%). When treated with PA, percentage cell viability remained high in 
PAK2 (72.4%), PAK3 (69.8%), and PAE3 (81%). Percentage cell viability was lowest after 
PAK4 incubations (43.1%). For each PA condition, 3 AM explants were incubated and 
live/dead staining measured in triplicate per AM explant. Error bars represent standard error 
of the mean. 
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5.4 Results summary 
 
• The amniotic fluid is known to contain a multitude of proteins and growth factors 
that have overall negative net charge. Here, we confirm the overall negative 
charge and report the presence of long unbranched negatively charged 
polysaccharides sulfated glycosaminoglycans (sGAG). Interestingly, the levels of 
sGAG increases in third trimester gestational age amniotic fluid compared to mid-
trimester amniotic fluid. 
 
• Positively charged peptide amphiphiles self-assemble when combined with 
human amniotic fluid to form 1D cylindrical nanofibres (~84 nm in diameter). 
These 1D cylindrical nanofibres form a complex 3D nanofibrous network that 
mimics the native ECM of the amniotic membrane. 
 
• Varying the number of lysine residues within the peptide amphiphile molecule 
changes the overall charge and effects the physical properties of the resulting 
macrostructure when combined with amniotic fluid. PAK2-AF system resulted in 
a weak gel, whilst PAK4-AF systems resulted in a paste-like substance. However, 
PAK3-AF systems resulted in a novel strong gel that could be manipulated 
without disintegration. 
 
• Formation of the PAK3-AF gel started with a thin membrane at the liquid-liquid 
interface, acting as a physical barrier, separating the two solutions. Membrane 
growth then occurred in the direction of the PA solution until the PA solution has 
undergone complete gelation or the amniotic fluid solution has been depleted. 
 
• It is likely that electrostatic complexation and differences in the osmotic pressures 
contributed to the direction of gelation towards the PA solution. Further diffusion 
of macromolecules across the diffusion barrier in the PAK3-AF system could 
have occurred over time, which appears to have increased self-assembly nanofibre 
formation towards the PA solution and therefore increase nanofibre density over 
time. 
  163 
• The PAK3-AF system was tested in the artificial fetal membrane trauma model, 
and successfully sealed defects of approximately 0.8 mm, adhering to the fetal 
membrane surface. High magnification electron micrographs reveal close 
integration of PA nanofibres with the native fetal membrane ECM. 
 
• Histological and cell viability analysis reveals promising PAK3-AF 
biocompatibility with no disruption to the amniotic epithelial layer and percentage 
cell viability similar to that of DMEM and AF incubated control fetal membrane. 
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5.5 Discussion 
 
This study set out to investigate the potential of a novel sealing strategy based on the 
molecular self-assembly of peptide amphiphiles and complexation with physiological 
molecules present within the amniotic fluid. We examined the interaction between 
positive PA molecules, which contained a varying number of lysine residues (i.e. PA-K2, 
PA-K3, and PA-K4) and fresh human mid-trimester amniotic fluid for the potential 
formation of self-assembled 1-D cylindrical nanofibres that could mimic the native fetal 
membrane ECM within the PA-AF system. Using an optimal PAK-AF system, we 
examined the approach within the artificial fetal membrane trauma model. 
Biocompatibility and cytotoxicity of the PA-AF system was examined using histological 
analysis and cell viability assays. 
 
The present study demonstrated the formation of a self-assembling nanofibrous 3-D 
structure after combining PA (PAK3) and human amniotic fluid. The formation of well-
defined 1-D cylindrical nanofibres was reported as early as 5 seconds in the PAK3-AF 
system.  Using PDMS designed fluidic channels of approximately 2 mm diameters, it was 
possible to observe the spontaneous formation of a self-assembled membrane at the PA-
AF interface. The PA-AF membranes propagate towards the PA solution indicated by 
decreased transparency towards the PA solution and away from the original membrane 
interface. In contrast, no changes in transparency were observed in the AF regions over 
time following co-assembly of PA and AF. 
 
Varying the number of lysine residues present within the charged group region of the PA 
resulted in changes in the outcome of the physical properties following incubations of the 
PA-AF combinations with AF. The PAK2-AF system resulted in the formation of a weak 
gel that disintegrated upon contact. However, the PAK3-AF system resulted in a more 
stable gel that could be manipulated without disintegrating. The PAK4-AF system did 
not form a gel, and instead resulted in a paste-like substance. Interestingly, during the 
initial membrane formation reported (5 seconds – 10 minutes) instantaneous distinct 
membranes can be seen, which propagate towards the PA solution and increases in 
density originating from the PA-AF interface. This membrane growth continues until the 
entire PA solution within the channel is engulfed. Following this primary finding the 
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PAK3-AF system was tested in larger amniotic fluid volumes, which also resulted in the 
formation of stable gel following the 6 – 24 hour incubations reported. Using PDMS 
fluidic channels, it was possible to highlight the direction of self-assembling membrane 
growth over time. This was confirmed by injecting solutions of PA or AF into larger 
volumes of the other solution. As suspected from the PDMS fluidic channel experiments, 
following initial membrane formation, the self-assembly of a larger macrostructure 
continued in the direction of the PA solution. Injecting smaller volumes of PA into AF 
led to complete gelation of the PA solution confirmed using scanning electron 
microscopy; however, injection of a smaller volume of AF into PA solutions did not lead 
to complete gelation of the PA solution, suggesting that complete gelation only occurs if 
sufficient AF volume is present within the system. 
 
Membrane growth in all PAK-AF systems is likely to occur following diffusion of 
macromolecules across the initial membrane barrier formed following rapid electrostatic 
screening between the positively charged PAK molecules and the negatively charged 
macromolecules present in the amniotic fluid. In addition, the two solutions do not 
combine, confirmed from fluorescently labelled PA, and therefore provides supporting 
evidence for the formation of a diffusion barrier at the AF-PA interface leading to 
macromolecule diffusion towards the PA solution. Interestingly, the PAE3-AF system 
also formed a weak gel that disintegrated on contact. This indicates that whilst the 
amniotic fluid is mainly composed of negatively charged molecules, electrostatic 
screening may still occur with positive components of amniotic fluid, and the positive 
moieties of AF proteins. Following charge complexation and the formation of a diffusion 
barrier, changes in charge density within the PA-AF system affects the final physical 
properties of the PA-AF gel. For example, similarities can be drawn between a previously 
published system using elastin-like polypeptides (ELPs) and PAs15. A lower charge 
density using ELP5-PAK2 resulted in thinner and more transparent membranes similar 
to that seen within the PAK2-AF system described here; which shows thinner membranes 
that show increased transparency compared to the PAK3-AF and PAK4-AF systems. 
Furthermore, increasing the charge density using an ELP5-PAK4 system led to a weaker 
membrane compared to the ELP5-PAK3 system, similar to that seen in the PAK4-AF 
system described here, which leads to the formation of a very weak membrane that 
disintegrates upon contact and resembles a paste-like substance compared to a more stable 
PAK3-AF system. Other than the electrostatic screening between amniotic fluid 
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components and the PA solutions, the difference in osmotic pressures likely plays an 
important role in gelation. Following initial membrane formation at the PA-AF interface 
the osmotic pressure gradient may influence the movement of fluid to the PA solution 
across the diffusion barrier and enhance self-assembly. It is likely that the changes in 
osmotic pressures may have assisted in gel formation and initial electrostatic 
complexation between negatively charged PA molecules and positively charged amniotic 
fluid protein moieties within the PAE3-AF system. 
 
Contrary to Capito et al., the PA-AF membrane formation does not appear as defined as 
the PAK3-Hyaluronic acid (HA) system liquid-liquid interface, although some 
similarities can be drawn4. It is likely that similar mechanisms of membrane formation 
occur between the AF components and the PAK3 solution. This group first described 
electrostatic complexation upon contact between the two solutions that simultaneously 
results in self-assembly of PA nanofibres, and consequently creates an immediate 
physical barrier separating the two solutions. The diffusion of the high molecular weight 
polysaccharide HA macromolecules through the physical barrier into the PA solution 
leads to the nanofibre orientating perpendicular to the interface, similar to the findings 
reported in the present study. Interestingly, the findings from PAK3-HA systems also 
report a rough amorphous layer on the surface with resemblance to the PA-AF system, 
although another region containing nanofibres parallel to the surface is not reported in the 
present study4,8,15,261. Furthermore, it is clear that at the PA-AF interface, there is a highly 
dense arrangement of nanostructures likely due to the increased concentration of amniotic 
fluid components such as polysaccharides at the interface. This then clearly becomes less 
dense with increasing distance from the interface as the diffusion of macromolecules is 
slowed. 
 
The significance of these findings are highlighted after the successfully sealing of a fetal 
membrane wound defect, tested within the artificial fetal membrane trauma model. 
Electron micrographs and histologic analysis show successful sealing at the defect site, 
revealing a close association between self-assembled PA nanofibres and the dense native 
ECM nanofibre network. This is a novel sealing method that we believe has not 
previously been reported. Furthermore, the self-assembly of PAs has also not previously 
been investigated using this physiological solution (i.e. amniotic fluid). Compared to 
other sealing strategies and synthetic hydrogel sealants tested, the PA-based plugging 
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strategy shows good biocompatibility and low toxicity using the PAK3-AF system220. 
Currently, there is no clinically available method to seal fetal membrane defects following 
fetal surgery and previous attempts including bioactive membrane scaffolds, collagen 
plugs, gelatin sponges, and synthetic hydrogels have provided disappointing 
results210,211,220,223,239. Importantly, the PAK3-AF system could be used to develop a 
therapy for sealing human fetal membrane defects that is easily injectable and shows 
promising biocompatibility. Furthermore, optimisation and scaling up of this technology 
could provide an option to seal larger defects that are of more irregular sizes and occur 
following spontaneous PPROM. In addition, the PA-AF plugging strategy could provide 
a safer alternative to the amniopatch, which involves the injection of high concentrations 
of platelet rich plasma and cryoprecipitate263. This method is associated with low efficacy 
and fetal complications including sudden fetal death, acute bradycardia, and amniotic 
band syndrome, linked to its direct effect on the fetus. However, as the PA does not 
combine with the AF and instead forms an instantaneous physical barrier at the PA-AF 
interface, these risks could be preventable. 
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Chapter 6 
 
Mechanotransduction mechanisms that induce fetal 
membrane weakening and tissue damage 	
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Chapter 6: Mechanotransduction mechanisms that induce fetal membrane 
weakening and tissue damage 
 
6.1 Introduction  
 
This chapter investigates the mechanotransduction that leads to tissue weakening in AM 
subjected to repetitive cyclic tensile strain. The mechanisms by which the fetal membrane 
weakens are not well understood. Potential upstream therapeutic targets are elucidated 
and the effect of inhibiting these targets on fetal membrane weakening factors and ECM 
components are investigated. Importantly, by further defining fetal membrane weakening 
mechanisms in response to repetitive cyclic tensile strain it is possible to identify potential 
targets for developing preventatives and treatments for PPROM. 
 
There is likely to be similarities between the biological fetal membrane weakening 
pathways leading to PPROM and the area of the fetal membrane known to undergo focal 
weakening due to biochemical alterations in healthy term delivery known as the zone of 
altered morphology (ZAM, see section 1.4). Normal physiological changes occur in the 
area of the fetal membrane overlying the cervix in synergy with cervical ripening in order 
to prepare for parturition. Whilst the fetal membrane weakening processes observed 
towards term in the ZAM are likely to be similar with that observed in PPROM, the 
upstream cellular signalling pathways and etiology remain poorly understood. 
 
6.1.1 Factors associated with fetal membrane weakening 
 
The main morphological changes occurring in fetal membranes prior to parturition in the 
ZAM are: (1) swelling of the stromal layers, specifically the spongy (intermediate) layer 
connecting the amnion to the chorion; (2) reduction in thickness of the decidua cellular 
layers, specifically the cytotrophoblast layer of the chorion; and (3) disruption between 
the amnion and chorion. There are several fetal membrane weakening factors reportedly 
associated with these alterations (Figure 6.1). Matrixmetalloproteases (MMP-1, MMP-3 
and MMP-9), cyclooxygenase-2 (COX-2), interleukins (IL-1, IL-6, IL-8), prostaglandin 
E2 (PGE2), oxidative stress (p38 MAPK), and pro-apoptosis factors have been associated 
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with an important role in PPROM12,264. Our group have previously shown that repetitive 
cyclic strain increases the expression of Cx43, also known to increase in the myometrium 
following uterine stretch86,89.  Increase in Cx43 expression in the amniotic membrane was 
associated with an increase in COX-2 gene expression, PGE2 release, and 
glycosaminoglycan (GAG) content, concomitant with a decrease in collagen and elastin 
content. 
 
 
 
The primary signals which initiate the inflammatory process and lead to AM weakening 
are unclear (Figure 6.1). The principal factors are MMPs, which degrade collagen and 
reduce mechanical strength32. Indeed, an increase in MMP-9 with a decrease in TIMP-1 
has been linked with a reduction in tensile strength of fetal membranes33. It is suggested 
that these changes occur due to a “host inflammatory response” in the fetal membrane, 
but are also found at higher levels in the amniotic fluid of PPROM patients33. 
Figure 6.1: List of reported fetal membrane weakening factors  
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Interestingly, MMP-9 amniotic fluid concentration is higher in PPROM patients 
compared to preterm birth patients who did not rupture their membranes33. Furthermore, 
MMP-9 specifically degrades collagen type IV, which is found at high levels in basement 
membranes, suggesting that this layer of the amniotic membrane could play a key role in 
overall membrane integrity. PGE2 is one known factor that contributes towards an 
increased production of MMP-1 and MMP-3 in fibroblast cells. MMPs have also been 
increased in amniocytes following IL-1 and TNFα exposure265. 
 
Furthermore, MMP activity induced by reactive oxygen species (ROS) has been linked 
to PPROM266. Recently, mechanistic differences have been made between spontaneous 
preterm birth and PPROM267. When comparing preterm birth patients, those that had 
PPROM showed higher oxidative stress with reduced antioxidant enzymes compared to 
patients who had not ruptured their membranes. DNA damage and cellular senescence 
was higher in PPROM, indicated by an increase in stress-dependent p38 MAPK activity. 
Further differentiation between PPROM patients and preterm birth patients who have not 
ruptured their membranes involve increased activity of apoptosis pathways mediated by 
TNFα in PPROM patients33. The IL-6 cytokine and respective receptor have also been 
shown to increase in PPROM patients due to a reduction in soluble gp130, a protein that 
inhibits IL-6 signalling268. Overall, the pathological signalling mechanisms that lead to 
PPROM are not well understood. It is important that research expands on the upstream 
biological pathways that lead to increased apoptosis in the ZAM region and collagen 
degradation, which can ultimately cause FM rupture. 
 
6.1.2 Mechanotransduction mechanisms in fetal membranes 
 
It has previously been proposed that overdistension of the uterus can predispose pregnant 
women to preterm birth. Indeed, uterine overdistension has been linked with preterm 
labour, mediated by inflammation as found in human and non-human primates111. 
Women are more likely to deliver preterm if they are carrying twin or higher order 
multiple pregnancies (54%)269. Polyhydramnios (over production of amniotic fluid) also 
increases the likelihood of preterm delivery270. Other uterine structural abnormalities such 
as unicornuate also increase the risk of preterm delivery271. Furthermore, studies have 
indicated that the FM does not have a high structural reserve, meaning that during 
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physiological loading, the FM is close to its failure stress and therefore failure is likely to 
be easily mediated during labour contractions due to the low structural reserve272. 
Interestingly, this could indicate that even small increases in stretch to the fetal membrane 
or overdistension of the uterus leading to fetal membrane stretch could initiate fetal 
membrane weakening pathways in preterm gestations prior to labour contractions. 
 
A variety of in vitro mechanical stretching devices have been used to study FM 
biomechanics and the mechanotransduction of FM weakening pathways. The types of 
experimental setup include devices that enable uniaxial, biaxial, inflation, and puncture 
testing (Figure 6.2)1,30,273,274. For example, uniaxial stretching of amniocytes increased 
IL-1β, IL-6 and IL-8 cytokines at 11% static stretch for up to 6 hours111. Interestingly, 
these cytokines also increased in the amnion of women who had polyhydramnios in 
addition to increased TNF-α transcription factor expression. Furthermore, uniaxial static 
stretch of cultures amniocytes led to increased expression of COX-2 and the transcription 
factors AP-1 and NF-kB, which is also observed in myometrial cells114,275 Burst testing 
is achieved by pressure acting perpendicular to the fetal membrane surface and has proved 
useful for the study of deformation behaviour on FM microstructure3. Furthermore, 
puncture testing has proved useful in measuring changes in FM strength after 
development of inflammation/infection and abruption in vitro models5.  
 
Taken together, these systems enable in vitro analysis of FM biomechanics and 
weakening mechanisms, and so far have highlighted the importance of understanding the 
inflammation/infection pathways, and understanding the effect of possible exposure to 
thrombin, which could lead to FM weakening. However, these systems have mainly 
focused on the use of static strain to the FM. Due to the dynamic nature of amniotic fluid 
volumes and uterine overdistension, we propose that the use of our cyclic tensile strain 
system that mimics labour contractions (cycles of 1 min CTS; 9 min rest, for 24 hours, 
1Hz) would provide an important contribution to the study of FM weakening 
mechanotransduction. This system would help to decipher mechanisms that lead to FM 
rupture preterm, whilst also providing an in vitro opportunity to examine therapeutic 
options to prevent PPROM. 
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Figure 6.2: Types of in vitro mechanical testing devices used for studying 
mechanotransduction and mechanical properties of fetal membranes. Testing devices include 
uniaxial (A) biaxial (B) inflation (C) and puncture testing (D). Adapted from Buerzle et al., 
(2003)1; Maradny et al., (1996)9; Mauri et al., (2016)3; and Oyen et al., (2004)16.  
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6.2 Methods 
6.2.1 Patient recruitment  
 
Human placentas were collected from University College Hospital London after written 
informed consent. The fetal membranes were separated from the placenta obtained from 
term patients who underwent elective caesarean section (between 37 and 42 weeks 
gestation). Women with placenta praevia, multiple pregnancy, antepartum haemorrhage, 
PPROM, fetal growth restriction, clinical chorioamnionitis, meconium, and maternal 
diabetes were excluded from the study. Ethical approval was granted by the Joint 
UCL/UCLH Committees on the Ethics of Human Research (Ref: 14/LO/0863). 
 
6.2.2 Uniaxial cyclic tensile strain loading using the ex-vivo bioreactor system 
 
AM was separated from the chorionic membrane by gentle traction and dissected into 5 
mm x 20 mm PAM and CAM strips in a cell culture hood. Following cyclic tensile strain, 
preliminary experiments confirmed high AM cell viability for all conditions used in the 
present study (Figure 6.3). All amniotic membrane (AM) explants were dissected and 
inserted into the mechanical stretching apparatus in the same orientation for all patients 
(Figure 6.4). In order to remain consistent, fibre orientation was always cut in the parallel 
orientation so that strain would occur consistently in the direction of the fibres as shown 
during preliminary SHG analysis of collagen fibre orientation (Figure 6.5).  
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Figure 6.3: Cell viability analysis performed for mechanotransduction studies in both 
CAM and PAM tissue regions. Cell viability was measured using Live/dead assay in 
amniotic membrane for tissue at t=0 hours, t=24 hours, and t=168 hours incubation in 
DMEM. Cell viability was also assessed in tissue following 24 hours cyclic tensile strain 
in the ex-vivo bioreactor system when incubated with DMEM, Cx43asODNs, AKTi, 
WTM, and NS-398. Error bars represent mean and standard deviation of 3 tissue regions 
from 3 separate donors. 
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Figure 6.4: Method of fetal membrane dissection. AM was separated from the 
chorionic membrane by gentle traction and dissected into 5 mm x 20 mm PAM and 
CAM strips in a cell culture hood. All amniotic membrane (AM) explants were 
dissected and inserted into the mechanical stretching apparatus in the same 
orientation for all patients. Only tissue exposed to DMEM during cyclic tensile strain 
experiments was dissected and used for analysis. 
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Figure 6.5: Second harmonic generation imaging microscopy of CAM and PAM 
specimens. Collagen fibre orientation as defined by SHG imaging was shown to align 
in parallel to the placental disc and transition towards a perpendicular orientation 
towards the cervical region. AM explants were loaded into the ex-vivo bioreactor 
chambers and strained in the same direction for consistency (yellow arrows). 
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During dissection the tissue was prevented from drying out by placing in sterile DMEM 
solution. To perform uniaxial cyclic tensile strain experiments the AM was clamped into 
the tissue chamber using the equipment in Figure 6.6a. All equipment was sterilized 
using an autoclave and opened only in the cell culture hood. Assembled chambers were 
filled with DMEM+20%FCS supplemented with 5 µg/ml penicillin and 5 µg/ml 
streptomycin. Some experiments involved incubation of the tissue with pharmacological 
agents, and if so it was at this point that they were added using a syringe with final 
concentrations having been established in the literature including 25 µM AKTi 
(selectively targets AKT-1/2 isoforms), 50 nM wortmannin (WTM, non-specific PI3-
kinase inhibitor), 10 µM Cx43 antisense or sense oligodeoxynucleotides 
(Cx43asODNs/Cx43sODNs), and 10 µM NS-398 (selective COX-2 inhibitor).182,276-278 
Once samples were loaded into the custom-made stainless steel mechanical loading 
chamber (Figure 6.6b), with a grip-to-grip distance of 30 mm they were loaded into the 
mechanical testing rig and fixed into the Bose machine (BOSE Enduratec, UK, 
Mechanical Test Systems Incorporation, Figure 6.7). 
 
The ex-vivo BOSE bioreactor system set-up (Figure 6.7) has been routinely used in our 
laboratory and optimised for uniaxial cyclic strain of the AM as previously described.86,279 
Uniaxial cyclic tensile strain experiments involved cyclic strain at a frequency of 1 Hz 
with samples exposed to 2% strain. Strain was applied in blocks of 1 minute strain (60 
cycles) in a sinusoidal waveform, and rest (~0% strain) held for 9 minutes (540 cycles) 
repeated for 24 hours (144 blocks); which simulate contraction cycles induced during the 
onset of labour. A maximum of 16 loading chambers were connected to an actuator arm 
and secured within the BOSE loading frame (BOSE Corporation, Eden, Prairie, 
Minnesota, USA), which was housed within a humidified incubator (5%CO2, 37oC). The 
loading chambers were each loaded with 2 mL of DMEM. Unstrained control specimens 
were incubated within the BOSE system’s incubator within separate tubes but did not 
undergo CTS.  
 
Following CTS experiments, the BOSE chambers (maximum 16 per experiment) were 
dismounted and media samples were drawn up from the chamber using a syringe. The 
glass cover was removed from the mechanical testing chamber and the stationary bottom 
grip tissue holder released to allow the movable upper grip tissue holder to be removed 
from the main chamber. The 1 mm thick plate was then removed and only the tissue 
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exposed directly to strain and DMEM, approximately 5 mm x 10 mm, was dissected for 
storage. The tissue underneath the movable upper grip and stationary bottom grip that 
was not exposed to strain was discarded. Depending on the experiment the tissue was 
now fixed or snap frozen in liquid nitrogen and stored at -80oC.
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Figure 6.6: Equipment used to assemble individual BOSE chambers (A) and assembly of BOSE 
chamber containing amniotic membrane clamped between the movable upper grip and 
stationary bottom grip (B). In order to secure amniotic membrane tissue between upper and 
bottom grips, the tissue is placed on the lower end of the movable upper grip and then secured 
in place with the 1 mm thick plate. The upper grip containing the tissue is then placed inside the 
chamber and the tissue is placed between the 2 bottom grip screw holes which is then secured 
in place by inserting the bottom grip. Once the tissue is secure, the glass cover is put on and 
DMEM injected through the pin hole. The top and bottom O-ring grooves prevent leakage of 
the DMEM. The movable upper grip is then connected to the actuator arm. 
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Stage Waveform Time (minutes) Cycles 
1 Sine 1 60 
2 Dwell 9 540 
3 Repeat - 144 Blocks 
Figure 6.7: Bose chamber system with individual chambers containing dissected AM tissue 
undergoing cyclic tensile strain. Bose system experimental set-up involved a frequency of 1 Hz 
and 144 Blocks were used to allow cyclic tensile strain of tissue for 24 hours with cycles of 1 
minute strain and 9 minutes rest. Sine waveform represents strained and dwell represents 
unstrained conditions. Total sine cycles = 8,640. Total dwell cycles = 12,960. 
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6.3 Results 
6.3.1 Understanding fetal membrane weakening mechanisms  
 
To test the hypothesis that repetitive cyclic tensile strain can lead to changes in the 
amniotic membrane ECM proteins and levels of weakening factors, amniotic membrane 
was repetitively stretched using an ex-vivo bioreactor, and experiments performed to 
measure collagen, elastin, sulfated glycosaminoglycan (sGAG) content and release of 
Prostaglandin E2, and total MMP activity. The effect of inhibiting stretch activated 
pathways and pro-inflammatory pathways on cyclic tensile strain induced changes were 
also investigated to determine if these typical weakening mechanisms that occur during 
repetitive cyclic tensile strain could be perturbed. Experiments were performed to inhibit 
Cx43, AKT (protein kinase B), PI3-kinases, and cyclooxygenase-2 (COX-2). 
 
6.3.1.1 The effect of cyclic tensile strain on glycosaminoglycan content 
 
AM was exposed to 24 hours of 2% CTS in cycles of 1 minute CTS and 9minutes rest at 
a frequency of 1 Hz. These data show that sGAG synthesis increased following CTS 
(Figure 6.8) in both cervical AM (CAM, P < 0.001), and placental AM (PAM, P < 0.001). 
Levels of sGAG were also increased in non-strained CAM tissue compared to patient-
matched PAM tissue (P < 0.05). There was no difference in sGAG content between CAM 
and PAM tissue that had undergone CTS for 24 hours (P > 0.05).  
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6.3.1.2 The effect of cyclic tensile strain on collagen content 
 
Collagen content in AM was quantified by hydroxyproline assay, which is an important 
component of the collagen triple helix structure. Collagen content decreased in CAM (P 
< 0.001) and PAM (P < 0.001) following CTS for 24 hours (Figure 6.9a). Collagen 
content was higher in PAM tissue compared to CAM tissue in non-strained control AM 
(P < 0.001). Following CTS for 24 hours collagen content remained higher in PAM 
compared to CAM tissue (P < 0.05). Second harmonic generation (SHG) imaging of 
collagen fibres revealed decreased SHG intensity (arbitrary units) over time in both CAM 
and PAM tissue following CTS suggesting repetitive CTS increases degradation of 
collagen within the AM (Figure 6.9b). 
 
Figure 6.8: The effect cyclic tensile strain (CTS) on cervical (CAM) and placental (PAM) 
amniotic membrane sulfated glycosaminoglycan content. Amniotic membrane was exposed to 
cycles of 1 minute strain and 9 minutes rest for 24 hours at a frequency of 1 Hz and compared 
to non-strained patient matched controls. Error bars represent mean ± SEM, where 
***p<0.001, *p<0.05. N=16 amniotic membrane samples per condition from N=4 patients. 
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Figure 6.9: The effect cyclic tensile strain on collagen content in cervical (CAM) and 
placental (PAM) amniotic membrane. Amniotic membrane was exposed to cycles of 1 minute 
strain and 9 minutes rest for 24 hours at a frequency of 1 Hz 
 
and compared to non-strained 
patient matched controls (A). SHG intensity was higher in PAM tissue compared to CAM 
tissue and decreased in both CAM and PAM tissue over time in response to CTS. Error bars 
represent mean ± SEM, where ***p<0.001, *p<0.05. N=16 amniotic membrane samples per 
condition from N=4 patients. SHG analysis was performed on bisected amniotic membrane 
samples from N=2 patients with 5 separate fields of view used for analysis in each condition. 
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6.3.1.3 The effect of cyclic tensile strain on elastin content 
 
There was a decrease in CAM elastin content following CTS for 24 hours compared to 
non-strained CAM tissue (P < 0.05, Figure 6.10); whilst elastin content also decreased 
in PAM tissue following 24 hours of CTS compared to non-strained PAM tissue (P < 
0.05). Interestingly, in unstrained control tissue, elastin content did not change in PAM 
tissue compared to CAM tissue (P > 0.05). 
 
6.3.1.4 The effect of cyclic tensile strain on prostaglandin E2 release 
 
These data show increased PGE2 release following 24 hours CTS in both CAM and PAM 
strained tissue (both P < 0.001, Figure 6.11). There was no difference in levels of PGE2 
release when comparing CAM and PAM strained tissue (P > 0.05). However, in non-
Figure 6.10: The effect of cyclic tensile strain on cervical (CAM) and placental (PAM) 
amniotic membrane elastin content. Amniotic membrane was exposed to cycles of 1 minute 
strain and 9 minutes rest for 24 hours at a frequency of 1 Hz and compared to non-strained 
patient matched controls. Error bars represent mean ± SEM, where *p<0.05. N=16 
amniotic membrane samples per condition from N=4 patients. 
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strained control tissue, CAM tissue released higher amounts of PGE2 into tissue media 
compared to non-strained PAM tissue (P < 0.001). 
 
 
6.3.1.5 The effect of cyclic tensile strain on total MMP activity 
 
Similarly to PGE2 data, total MMP activity increased following 24 hours of CTS for both 
CAM and PAM tissue measured from incubated media samples (both P < 0.001, Figure 
6.12). There was no difference in total MMP activity between strained PAM and CAM 
tissue (P > 0.05). Interestingly, in non-strained control tissue, CAM tissue released higher 
amounts of MMP into tissue media compared to PAM tissue (P < 0.05). These data 
indicate that there are significant differences between CAM and PAM regions of the AM, 
likely due to the zone of altered morphology present at term and located in the AM region 
overlying the cervix. 
Figure 6.11: The effect of cyclic tensile strain on cervical (CAM) and placental (PAM) amniotic 
membrane prostaglandin E
2
 release. Amniotic membrane was exposed to cycles of 1 minute 
strain and 9 minutes rest for 24 hours at a frequency of 1 Hz 
 
and compared to non-strained 
patient matched controls. Error bars represent mean ± SEM, where ***p<0.001. N=24 
amniotic membrane samples per condition from N=6 patients. 
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6.3.1.6 Inhibition of AKT and Cx43 activation 
 
Following 2% CTS for 24 hours activiation of Cx43 and AKT-1/2/3 was investigated by 
comparison with non-strained control tissue in both CAM and PAM regions. These data 
show increased protein expression of Cx43 and AKT-1/2/3 in both CAM and PAM tissue 
regions following CTS (Figure 6.13 and Figure 6.14). When normalised to GAPDH 
these data show increased activation of AKT-1/2/3 in PAM and CAM tissue (both P < 
0.05); and increased activation of Cx43 in PAM and CAM tissue (both P < 0.01) when 
compared to non-strained tissue at 24 hours incubation. Inhibition of AKT-1/2/3 is 
Figure 6.12: The effect of cyclic tensile strain on cervical (CAM) and placental (PAM) 
amniotic membrane total MMP activity (RFU). Measurements were taken using fresh 
DMEM, taken immediately after cyclic tensile strain with patient matched controls. 
Amniotic membrane was exposed to cycles of 1 minute strain and 9 minutes rest for 24 
hours at a frequency of 1 Hz and compared to non-strained patient matched controls. Error 
bars represent mean ± SEM, where ***p<0.001, *p<0.05. N=24 amniotic membrane 
samples per condition from N=6 patients. 
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achieved using 25 µM isozyme specific AKT-1/2 inhibitor, which is a well-established 
concentration in the literature182. Inhibition of Cx43 was achieved using  
10 µM Cx43asODNs in serum-free media to reduce degradation rate, and is a well-
established concentration124. Whilst this was the first time Cx43 and AKT inhibition is 
reported in fetal membranes, these concentrations resulted in sufficient knockdown, and 
therefore used for further experiments investigating the inhibition of these pathways. 
Interestingly, inhibition of AKT was most efficacious in CAM and PAM samples that 
underwent repetitive CTS compared to strained CAM and PAM tissue that were not 
exposed to AKTi (both P < 0.001). Incubation with Cx43asODNs resulted in Cx43 
knockdown in both CAM and PAM regions during both strained (P < 0.001) and non-
strained (P < 0.05) conditions compared to CAM and PAM tissue not exposed to 
Cx43asODNs. 
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Figure 6.13: Activation and inhibition and AKT-1/2/3 protein expression. Normalisation of 
AKT to GAPDH using densitometry analysis reveals increased expression of AKT after 
mechanical stimulation following cyclic tensile strain for 24 hours. AKT is inhibited during 
CTS when incubated with AKTi. Error bars represent the mean ± SEM where *p<0.05; 
***p<0.001, N=3 patients with 3 AM samples per condition. 
  190 
		 	
Figure 6.14: Activation and inhibition and Cx43 protein expression. Normalisation of Cx43 
to GAPDH using densitometry analysis reveals increased expression of Cx43 after mechanical 
stimulation following cyclic tensile strain for 24 hours. Cx43 is inhibited during CTS and non-
strained conditions when incubated with Cx43asODNs, confirmed following incubations with 
Cx43sODN as a negative control. Error bars represent the mean ± SEM where *p<0.05; 
**p<0.01; ***p<0.001, N=3 patients with 3 AM samples per condition. 
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6.3.1.7 Targeting mechanotransduction pathways reduces fetal membrane weakening 
factors 
 
Isozyme-specific AKT-1/2 inhibition 
 
Following incubations with isozyme-specific AKT-1/2 inhibitor (Figure 6.15), sGAG 
content reduced when incubated with AKTi for 24 hours in non-strained CAM (P < 0.05) 
but did not show statistically significant reduction in sGAG content in PAM tissue for 
non-strained conditions (P > 0.05). However, incubations with AKTi during CTS resulted 
in reduction of sGAG content in PAM regions (P < 0.01) but not in CAM regions ( P > 
0.05) Conversely, collagen content was higher in both CAM (P < 0.05) and PAM 
(P<0.01) therefore reducing collagen degradation typically seen during 24 hours of CTS. 
However, elastin content did now show any statistically significant changes when 
incubated with AKTi in both strained and non-strained conditions. Furthermore PGE2 
release dramatically decreased in strained and non-strained CAM samples when 
incubated with AKTi (both P < 0.001). PGE2 release also decreased in PAM tissue media 
samples that had undergone CTS (P < 0.001), although no change occurred in non-
strained PAM tissue media samples when treated with AKTi, likely due to the relatively 
low PGE2 levels reported in non-strained PAM tissue media. Similarly, total MMP 
activity reduced in CAM tissue media for both non-strained and strained conditions when 
incubated with AKTi (both P < 0.001). Although total MMP activity was only reported 
to reduce in PAM tissue media samples incubated with AKTi during CTS compared to 
non-treated PAM controls during CTS (P < 0.01). Whereas no difference in total MMP 
activity was reported in non-strained PAM tissue media samples when treated with AKTi; 
likely due to relatively low total MMP activity occurring in non-treated and non-strained 
PAM tissue media samples. 
 
Cx43 inhibition using Cx43asODNs 
 
Following incubations with Cx43asODNs (Figure 6.16) these data show a decrease in 
sGAG content in response to 24 hours CTS when incubated with Cx43asODNs in both 
CAM and PAM tissue (both P < 0.001). In non-strained control tissue there was no 
difference in sGAG content when incubated with Cx43asODNs for 24 hours (P > 0.05). 
Collagen content increased returning close to normal levels when incubated with 
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Cx43asODNs during CTS in both CAM and PAM tissue (both P < 0.05). There was no 
difference in collagen content reported in non-strained CAM and PAM tissue incubated 
with Cx43asODNs when compared with non-treated control CAM and PAM tissue. 
Furthermore, no changes in elastin content were reported when incubated with 
Cx43asODNs in PAM and CAM for strained and non-strained conditions. Both PGE2 
and total MMP activity were reduced in CAM and PAM tissue media samples that were 
incubated with Cx43asODNs during CTS compared to non-treated tissue (all P < 0.001). 
PGE2 levels decreased in non-strained CAM tissue media treated with Cx43asODNs 
compared to non-treated (P < 0.01) but no difference was reported in PAM tissue media. 
Total MMP activity reduced in both CAM and PAM non-strained tissue media when 
incubated with Cx43asODNs compared to non-treated tissue media samples (CAM: P < 
0.001; PAM: P < 0.01). 
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Figure 6.15: The effect of cyclic tensile strain and inhibition of AKT on cervical (CAM) and 
placental (PAM) amniotic membrane GAG (A), collagen (B), and elastin (C) production; and 
release of PGE2 (D) and total MMP (E). Error bars represent mean ± SEM, where 
***p<0.001, **p<0.01, *p<0.05. N=8 amniotic membrane samples per condition from N=4 
patients (GAG, collagen, and elastin assays). N=12 amniotic membrane samples per condition 
from N=6 patients (PGE2 and MMP assays). 
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Figure 6.16: The effect of cyclic tensile strain and inhibition of Cx43 on cervical (CAM) and 
placental (PAM) amniotic membrane GAG (A), collagen (B), and elastin (C) production; and 
release of PGE2 (D) and total MMP (E). Error bars represent mean ± SEM, where 
***p<0.001, **p<0.01, *p<0.05. N=8 amniotic membrane samples per condition from N=4 
patients (GAG, collagen, and elastin assays). N=12 amniotic membrane samples per condition 
from N=6 patients (PGE2 and MMP assays). 
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Non-specific PI3-kinase inhibition 
 
Non-specific inhibition of PI3-kinases using wortmannin (WTM, Figure 6.17) decreased 
sGAG content in PAM tissue that had undergone CTS for 24 hours compared to non-
treated strained PAM tissue (P < 0.001). However, no difference in sGAG content was 
noted in CAM tissue treated with WTM. Furthermore, no difference in sGAG content 
was reported in non-strained tissue treated with WTM compared to non-treated tissue. 
Collagen content in strained CAM and PAM tissue increased when incubated with WTM 
compared to non-treated strained controls (both P < 0.01). However, no difference in 
collagen content occurred in non-strained CAM and PAM tissue when treated with WTM 
for 24 hour incubations. No difference in elastin content is reported for WTM incubations 
within all conditions, compared to non-treated controls. PGE2 release decreased in CAM 
and PAM tissue that had undergone CTS and were treated with WTM (both P < 0.001). 
PGE2 release also decreased in non-strained CAM tissue when treated with WTM for 24 
hour incubations compared to non-treated CAM tissue (P < 0.001); whilst no difference 
was reported in PAM treated tissue. Similarly, total MMP activity decreased in CAM and 
PAM tissue that had undergone CTS and were treated with WTM (both P < 0.001). 
Similar to PGE2 changes, total MMP activity reduced in non-strained CAM tissue media 
when treated with WTM for 24 hour incubations compared to non-treated CAM tissue (P 
< 0.001); whilst no difference was reported in PAM tissue treated with WTM. 
 
6.3.2 Targeting pro-inflammatory pathways reduces fetal membrane weakening factors 
 
Cyclooxygenase-2 (COX-2) inhibition using NS-398 
 
Blocking COX-2 using NS-398 (Figure 6.18) reduced sGAG content in CAM and PAM 
tissue that had undergone CTS compared to non-treated CAM and PAM strained tissue 
(CAM: P < 0.001; PAM: P < 0.01). In non-strained CAM tissue, sGAG content decreased 
when incubated with NS-398 compared to non-treated CAM tissue (P < 0.01); whilst no 
difference was reported in PAM tissue. Collagen content increased in CAM tissue that 
had undergone CTS when treated with NS-398 compared to non-treated strained CAM 
tissue (P < 0.05); however, no difference was reported under the same conditions with 
PAM tissue. No difference in collagen content was reported in non-strained CAM and 
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PAM tissue treated with NS-398, compared to non-treated controls. Interestingly, elastin 
content increased in CAM and PAM tissue that had undergone CTS when incubated with 
NS-398, compared to non-treated strained CAM and PAM tissue (both P < 0.01). No 
difference in elastin content was reported in non-strained conditions when CAM and 
PAM tissue was incubated with NS-398. PGE2 and total MMP activity dramatically 
decreased in CAM and PAM tissue media samples that had undergone CTS and were 
incubated with NS-398 compared to non-treated strained CAM and PAM tissue media 
samples (all P < 0.001). PGE2 release decreased in non-strained CAM tissue when treated 
with NS-398, compared to non-treated CAM tissue (P < 0.001); however, no difference 
in PGE2 was reported in PAM tissue media samples. Furthermore, these data show total 
MMP activity decreased in non-strained CAM and PAM tissue media samples when 
treated with NS-398 and compared to non-treated CAM and PAM tissue media samples 
(both P < 0.001). 
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Figure 6.17: The effect of cyclic tensile strain and inhibition of PI3-kinase on cervical (CAM) 
and placental (PAM) amniotic membrane GAG (A), collagen (B), and elastin (C) production; 
and release of PGE2 (D) and total MMP (E). Error bars represent mean ± SEM, where 
***p<0.001, **p<0.01, *p<0.05. N=8 amniotic membrane samples per condition from N=4 
patients (GAG, collagen, and elastin assays). N=12 amniotic membrane samples per condition 
from N=6 patients (PGE2 and MMP assays). 
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Figure 6.18: The effect of cyclic tensile strain and inhibition of cyclooxygenase-2 on cervical 
(CAM) and placental (PAM) amniotic membrane GAG (A), collagen (B), and elastin (C) 
production; and release of PGE2 (D) and total MMP (E). Error bars represent mean ± SEM, 
where ***p<0.001, **p<0.01, *p<0.05. N=8 amniotic membrane samples per condition from 
N=4 patients (GAG, collagen, and elastin assays). N=12 amniotic membrane samples per 
condition from N=6 patients (PGE2 and MMP assays). 
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6.4 Results summary 
 
A summary of percentage changes following cyclic tensile strain experiments can be seen 
in Tables 6.1 – 6.5. 
 
• Sulfated glycosaminoglycan (sGAG) content increases in both cervical (CAM) 
and placental (PAM) amniotic membrane samples following 2% cyclic tensile 
strain for 24 hours compared to non-strained controls. In non-strained samples 
sGAG content is higher in CAM regions compared to PAM samples. 
 
• Following 2% cyclic tensile strain for 24 hours, collagen content decreases in both 
CAM and PAM samples compared to non-strained control. In non-strained 
control samples, PAM contained higher collagen content compared to CAM 
samples. SHG intensity also decreased in both PAM and CAM samples following 
2% cyclic tensile strain for 24 hours. 
 
• Elastin content decreased in PAM samples but not CAM samples following cyclic 
tensile strain for 24 hours. In non-strained control samples, elastin content was 
higher in PAM samples compared to CAM.  
 
• PGE2 and total MMP release increased in CAM and PAM samples following 
cyclic tensile strain for 24 hours. In non-strained control samples, PGE2 and total 
MMP activity in media from CAM specimens contained higher PGE2 and total 
MMP activity compared to PAM after 24 hours. 
 
• Cyclic tensile strain induced activation of Cx43 and AKT-1/2/3 after 24 hours 
compared to non-strained samples in both PAM and CAM specimens. 
 
• Inhibition of isozyme specific AKT-1/2 kinase, non-specific PI3-kinase, and 
Cx43 3xoression suppressed the effect of cyclic tensile strain on synthesis of 
sGAG and release of PGE2 an total MMP activity. Degradation of elastin and 
collagen also diminishes following inhibition of these pathways. 
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• Inhibition of COX-2 also reduced the effects of cyclic tensile strain on synthesis 
of sGAG, and release of PGE2 and MMP. Degradation of elastin and collagen also 
diminished following inhibition of COX-2 activity. 
 
• Inhibiting pro-inflammatory and stretch-activated pathways may reduce cyclic 
tensile strain induced fetal membrane weakening by reducing MMP/PGE2 
induced degradation of collagen and elastin. Swelling and softening of amniotic 
membrane induced by sGAG content can also be reduced by inhibiting these 
pathways. 
 
 
Table 6.1: Overall response to repetitive cyclic tensile strain of the human amniotic 
membrane given as a percentage change for GAG, collagen, elastin, PGE2 and total 
MMP activity (values represent mean ± SEM). 
 
 
 
 
Measurement AM region -CTS +CTS % change 
GAG 
CAM 
PAM 
13.30 (±0.45) 
8.86 (±0.55) 
22.75 (±1.28) 
20.45 (±0.89) 
+71.05 
+130.81 
Collagen 
CAM 
PAM 
28.96 (±2.05) 
45.89 (±1.17) 
7.48 (±3.86) 
22.65 (±5.69) 
-74.17 
-50.64 
Elastin 
CAM 
PAM 
10.96 (±0.25) 
10.13 (±0.65) 
6.35 (±0.34) 
5.37 (±0.94) 
-42.06 
-46.99 
PGE2 
CAM 
PAM 
1318.27 (±119.96) 
458.85 (±55.44) 
2615.41 (±87.71) 
2163.67 (±139.16) 
+98.40 
+371.54 
MMP 
CAM 
PAM 
16784.13 (±632.29) 
9751.25 (±587.02) 
39442.50 (±1968.36) 
36109.50 (±1311.76) 
+135.0 
+270.31 
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Table 6.2: Overall summary for AKTi treated human amniotic membrane tissue with 
patient-matched controls following cyclic tensile strain. Given as a percentage change 
(values represent mean ± SEM).  
 
 +AKTi  +AKTi 
Measurement 
AM 
region 
-CTS -CTS % change +CTS +CTS % change 
GAG 
CAM 
 
PAM 
14.77 
(±0.55) 
6.75 
(±0.78) 
7.87 
(±0.35) 
6.14 
(±0.32) 
-46.72 
 
-9.04 
25.46 
(±2.19) 
24.0 
(±1.52) 
23.26 
(±0.86) 
14.12 
(±1.99) 
-8.64 
 
-41.17 
Collagen 
CAM 
 
PAM 
30.61 
(±1.91) 
47.63 
(±1.75) 
26.04 
(±0.98) 
44.74 
(±0.57) 
-14.93 
 
-6.07 
4.68 
(±0.40) 
16.20 
(±0.78) 
15.11 
(±1.17) 
34.01 
(±0.71) 
+222.86 
 
+109.94 
Elastin 
CAM 
 
PAM 
12.39 
(±0.38) 
9.31 
(±0.46) 
11.41 
(±0.91) 
9.15 
(±0.93) 
-7.91 
 
-1.72 
6.15 
(±0.48) 
5.20 
(±0.78) 
7.16 
(±0.53) 
6.11 
(±0.31) 
+16.42 
 
+17.50 
PGE2 
CAM 
 
PAM 
1399.67 
(±233.17) 
386.49 
(±68.15) 
344.90 
(±91.40) 
391.97 
(±69.12) 
-75.36 
 
+1.42 
2844.02 
(±114.48) 
2594.85 
(±234.70) 
629.67 
(±46.15) 
714.28 
(±83.73) 
-77.86 
 
-72.47 
MMP 
CAM 
 
PAM 
17765.28 
(±69.15) 
10623.68 
(±102.25) 
6939.96 
(±312.94) 
6790.40 
(±445.33) 
-60.94 
 
-36.08 
39823.36 
(±731.9) 
34755.46 
(±753.64) 
23007.55 
(±933.46) 
26743.92 
(±689.39) 
-42.23 
 
-23.05 
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Table 6.3: Overall summary for Cx43asODN treated human amniotic membrane tissue 
with patient-matched controls following cyclic tensile strain. Given as a percentage 
change (values represent mean ± SEM). 
 
 +Cx43asODNs  +Cx43asODNs 
Measurement 
AM 
region 
-CTS -CTS % change +CTS +CTS % change 
GAG 
CAM 
 
PAM 
14.46 
(±0.21) 
11.50 
(±0.47) 
12.10 
(±0.20) 
12.45 
(±0.29) 
-16.32 
 
+8.26 
30.21 
(±0.62) 
21.32 
(±1.34) 
19.41 
(±0.45) 
13.72 
(±0.30) 
-35.75 
 
-35.65 
Collagen 
CAM 
 
PAM 
29.36 
(±0.53) 
45.07 
(±0.48) 
23.59 
(±0.04) 
46.02 
(±0.18) 
-19.65 
 
+2.11 
9.04 
(±0.19) 
24.67 
(±1.45) 
15.99 
(±0.17) 
36.24 
(±1.12) 
+76.88 
 
+46.90 
Elastin 
CAM 
 
PAM 
11.49 
(±0.58) 
10.53 
(±0.63) 
10.50 
(±0.89) 
11.38 
(±1.12) 
-8.62 
 
+8.07 
6.83 
(±0.50) 
4.25 
(±0.18) 
8.46 
(±0.36) 
6.09 
(±0.89) 
+23.87 
 
+43.29 
PGE2 
CAM 
 
PAM 
1004.89 
(±95.68) 
686.41 
(±78.80) 
321.06 
(±95.70) 
308.50 
(±102.98) 
-68.05 
 
-55.06 
2286.71 
(±186.41) 
1827.61 
(±172.35) 
963.03 
(±172.10) 
667.13 
(±188.90) 
-57.89 
 
-63.50 
MMP 
CAM 
 
PAM 
15110.42 
(±211.40) 
7885.58 
(±208.29) 
6931.90 
(±381.82) 
2182.06 
(±106.77) 
-54.13 
 
-72.33 
41090.66 
(±2797.26) 
41927.96 
(±495.74) 
30029.81 
(±2716.5) 
16435.53 
(±2515.75) 
-26.92 
 
-60.80 
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Table 6.4: Overall summary for wortmannin treated human amniotic membrane tissue 
with patient-matched controls following cyclic tensile strain. Given as a percentage 
change(values represent mean ± SEM). 
 
 +WTM  +WTM 
Measurement 
AM 
region 
-CTS -CTS 
% 
change 
+CTS +CTS 
% 
change 
GAG 
CAM 
 
PAM 
15.52 
(±0.63) 
10.45 
(±0.25) 
11.77 
(±0.71) 
12.76 
(±0.43) 
-24.16 
 
+22.11 
27.67 
(±1.87) 
23.51 
(±1.88) 
24.33 
(±2.31) 
14.76 
(±0.86) 
-12.07 
 
-37.22 
Collagen 
CAM 
 
PAM 
29.88 
(±0.17) 
45.47 
(±0.94) 
26.89 
(±0.91) 
41.43 
(±4.28) 
-10.01 
 
-8.88 
9.50 
(±1.94) 
20.30 
(±0.58) 
19.12 
(±1.23) 
28.70 
(±1.19) 
+101.26 
 
+41.38 
Elastin 
CAM 
 
PAM 
10.40 
(±0.51) 
9.63 
(±0.28) 
10.27 
(±0.52) 
10.77 
(±0.43) 
-1.25 
 
+11.84 
5.99 
(±0.63) 
5.35 
(±0.72) 
7.66 
(±0.40) 
5.85 
(±0.37) 
+27.88 
 
+9.35 
PGE2 
CAM 
 
PAM 
1407.37 
(±106.03) 
330.16 
(±106.32) 
528.59 
(±28.32) 
366.33 
(±54.55) 
-62.44 
 
+10.96 
2428.03 
(±137.25) 
2043.17 
(±138.91) 
948.39 
(±54.99) 
935.07 
(±87.39) 
-60.94 
 
-54.23 
MMP 
CAM 
 
PAM 
17693.06 
(±2514.33) 
10542.63 
(±410.53) 
6842.50 
(±1063.69) 
7142.97 
(±299.56) 
-61.33 
 
-32.25 
38610.65 
(±3324.55) 
33032.10 
(±467.14) 
26366.81 
(±1666.79) 
22327.77 
(±2143.37) 
-31.71 
 
-32.41 
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Table 6.5: Overall summary for NS-398 treated human amniotic membrane tissue with 
patient-matched controls following cyclic tensile strain. Given as a percentage change 
(values represent mean ± SEM). 
 
 +NS-398  +NS-398 
Measurement 
AM 
region 
-CTS -CTS 
% 
change 
+CTS +CTS 
% 
change 
GAG 
CAM 
 
PAM 
13.86 
(±0.77) 
12.0 
(±0.48) 
7.73 
(±0.23) 
7.67 
(±0.19) 
-44.23 
 
-36.08 
24.95 
(±0.36) 
27.54 
(±0.43) 
15.97 
(±0.40) 
21.60 
(±0.67) 
-35.99 
 
-21.57 
Collagen 
CAM 
 
PAM 
25.97 
(±0.06) 
45.39 
(±1.03) 
27.03 
(±0.06) 
48.15 
(±0.14) 
+4.08 
 
+6.08 
6.70 
(±0.13) 
29.42 
(±0.28) 
12.37 
(±0.15) 
35.35 
(±1.44) 
+84.63 
 
+20.16 
Elastin 
CAM 
 
PAM 
9.56 
(±0.52) 
11.06 
(±1.02) 
9.43 
(±0.49) 
9.63 
(±0.18) 
-1.36 
 
-12.93 
6.45 
(±0.76) 
6.68 
(±0.18) 
9.74 
(±0.70) 
9.44 
(±0.65) 
+51.01 
 
+41.32 
PGE2 
CAM 
 
PAM 
1599.42 
(±159.50) 
276.96 
(±38.43) 
128.90 
(±35.39) 
31.81 
(±5.43) 
-91.94 
 
-88.51 
2474.06 
(±69.12) 
1751.53 
(±102.16) 
242.66 
(±40.65) 
365.48 
(±15.55) 
-90.19 
 
-79.13 
MMP 
CAM 
 
PAM 
16569.03 
(±434.77) 
9956.32 
(±443.2) 
1545.25 
(±199.87) 
1508.99 
(±322.38) 
-90.67 
 
-84.84 
38248.32 
(±1558.38) 
34725.55 
(±669.11) 
7540.90 
(±183.38) 
7013.39 
(±129.43) 
-80.28 
 
-79.80 
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6.5 Discussion 
 
The mechanotransduction mechanisms leading to fetal membrane weakening and rupture 
are unknown. Physiologically, it is known that a combination of stretch and pre-weakened 
tissue facilitated by biochemical alterations leads to the initiation and rupture of the fetal 
membranes. However, it is likely that similar pathways play a role in weakening and 
rupture of preterm tissue that occurs in PPROM, although upstream mediators and 
detailed pathways are yet to be detailed. Investigations have primarily focused on the 
influence of pro-inflammatory cytokines, ECM degradation by MMPs, oxidative stress, 
and apoptosis on PPROM, developing from inflammation/infection and thrombin-
induced weakening due to placental bleeding (abruption) pathways. 
 
The present study were to investigate the effect of repetitive CTS on AM weakening 
mechanisms using an ex-vivo bioreactor; and investigate the effects of inhibiting Cx43 
and Akt (also known as protein kinase B, known to stabilise Cx43 gap junctions) on the 
outcome of AM weakening mechanisms. Furthermore, we investigate the inhibition of 
PI3 kinase (known to be the major mode of Akt activation) and selectively inhibit COX-
2, an enzyme rapidly expressed in response to cytokines and pro-inflammatory mediators. 
 
The present study demonstrates definitive changes following repetitive cyclic tensile 
strain in major ECM components including sulfated GAG, collage, and elastin, as well as 
changes in the release of weakening factors associated with pro-inflammatory pathways 
(PGE2 and MMPs). It is well known that amniotic membrane in the region overlying the 
cervix undergoes biochemically mediated weakening in preparation for parturition, 
therefore analysis was performed on both this tissue (termed cervical amniotic membrane, 
CAM) and tissue close to the placenta (within 3 cm of the placental disc, PAM). 
 
In response to 24 hours CTS, sulfated GAG content increases in both CAM and PAM 
tissue regions, whilst collagen and elastin content decreases in both regions of the 
amniotic membrane. Whilst the reduction of collagen and elastin content in response to 
repetitive CTS can result in weakened structural and elastic properties of the fetal 
membrane, the relationship between elevated GAG content and FM weakening could be 
detrimental to FM mechanical integrity by promoting tissue softening due to enhanced 
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proteoglycans. Interestingly, total GAG content during cervical ripening has been 
reported to increase with increased gestational age and parturition, concomitant with a 
reduction in collagen, where fibres appear thinner and more dispersed280,281. It is likely 
that in the amniotic membrane, the changes in sGAG content will effect the organisation 
of collagen and lead to increased fetal membrane softening. Importantly, GAGs are long 
unbranched polysaccharides that contain negatively charged repeating disaccharide units. 
This property attracts Na+ ions, which is beneficial in tissues such as cartilage, as It creates 
a hydrostatic pressure leading to swelling of the tissue providing enhanced protection to 
compressive forces. However, whilst enhanced GAG content in the FM is probably a 
normal physiological response that occurs during cervical ripening in a healthy 
pregnancy, the pathways involved are also likely to occur in preterm tissue regarding 
cases of PPROM. Furthermore, the alterations in amniotic membrane ECM components 
are accompanied by an increase in both PGE2 and total MMP activity within tissue 
secretions for both CAM and PAM regions. PGE2 is known to increase in the cervix 
during cervical ripening and induces remodelling of cervical connective tissue by 
increased production of proteoglycans282. We report similar mechanisms in the fetal 
membrane following repetitive cyclic tensile strain where increased PGE2 levels enhance 
sGAG synthesis, and in turn this softening of the amniotic membrane leads to a reduction 
of collagen mediated by over production of MMP demonstrated in both PAM and CAM 
strained tissue. This repetitive mechanical stimulation could activate stretch-responsive 
proteins that initiate a pro-inflammatory response leafing to overstimulation of ECM 
degradation pathways. 
 
Interestingly, static stretch of cultured amniotic cells leads to enhanced expression of 
COX-2 and PGE2 synthesis induced the pro-inflammatory transcription factor activator 
protein-1 (AP-1) and nuclear factor-κB (NF-κB)114. Previous studies also show increased 
expression of COX-2, oxytocin receptor, and Cx43 in the myometrium89,90,283. Indeed, 
stretch of the uterus, and myometrium are likely to play a role in activation of pro-
inflammatory pathways that lead to normal ECM degradation and FM rupture in healthy 
pregnancies. However, it has been reported that overdistension of the myometrium can 
contribute to the occurrence of preterm delivery94. Importantly overdistension of the 
uterus will also contribute to stretching of the fetal membranes and increase the risk of 
activating stretch sensitive inflammatory pathways that induce ECM degradation in the 
amniotic membrane. 
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We report differences between the two regions of term amniotic membrane (CAM and 
PAM) that were not subjected to repetitive cyclic tensile strain and instead incubated for 
24 hours. It was found that in CAM regions, there was elevated sGAG associated with 
reduced collagen content compared to PAM regions. In addition, elevated PGE2 release 
and MMP activity is reported in CAM tissue secretions even without repetitive 
mechanical stimulation compared to PAM regions. These findings can be explained by 
the formation of a zone of altered morphology (ZAM) that overlies the cervix and 
weakens in preparation for parturition, whilst tissue distal from the ZAM is not affected. 
The ZAM is characterised by swelling of the collagenous layers in the amnion and 
thinning of the cell-dense chorionic trophoblast later with a reduced thickness of the 
overall FM. This specific area is also associated with increased MMP activity and cellular 
apoptosis. We also report a reduced SHG intensity in CAM regions compared to PAM, 
which reduces further with repetitive mechanical stimulation. The fibres are thinner and 
appear to reduce in length following increased periods of cyclic tensile strain. This area 
of tissue is specifically programmed to rupture at term and therefore similar mechanisms 
activated in the ZAM could be induced by overdistension and repetitive cyclic tensile 
strain leading to weakened fetal membrane and increasing the risk of PPROM. 
 
Summarising the findings for the amniotic membrane response to repetitive cyclic tensile 
strain (Figure 6.19) using an ex-vivo bioreactor system, we report an increase in amniotic 
membrane sGAG synthesis with a reduction in collagen and elastin content; concurrent 
with an increase in MMP activity and PGE2 release. Furthermore, we see a distinct 
difference in CAM and PAM amniotic membrane regions, indicating activation of pro-
inflammatory induced ECM degradation in the cervical region marked by elevated sGAG 
synthesis and reduced collagen content whilst total MMP activity and PGE2 release is 
also elevated, compared to placental amniotic membrane regions from the same donor. 
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Previously, we have demonstrated increased Cx43 and COX-2 expression in response to 
repetitive cyclic tensile strain284. Here, we confirm activation of Cx43 in response to 
stretch, but also show activation of Akt (also known as protein kinase B). Akt is well 
known to be involved in a pathway called PI3K-Akt pathway, involving interaction with 
phosphatidylinositol 3-kinase (PI3K), and Akt activation is known to play a role in 
forming larger stable Cx43 gap junctional plaques285. The functional relationship between 
Akt and Cx43 has recently been evidenced in other cell types, where Cx43 gap junction 
channel opening during mechanical stimulation results from phosphorylation of Cx43 by 
Akt182. However, the presence and activation of Akt in amniotic membrane has not been 
reported, and here we show increased expression of Akt for the first time in addition to 
increased expression of Cx43. 
 
After demonstrating an increase in Cx43 and Akt expression in response to repetitive 
cyclic tensile strain, associated with disruption of amniotic membrane matrix composition 
that could lead to FM rupture, studies were performed to investigate the inhibition of 
Cx43 and the PI3-Akt pathways as well as COX-2 mediated inflammatory pathways. For 
the first time we report on the inhibitory effects of Cx43asODNs and AKTi on AM matric 
composition and production of inflammatory factors PGE2 and MMP during free swelling 
and cyclic tensile strain conditions in an ex-vivo bioreactor model. Further experiments 
Figure 6.19: Putative flow of major events that could lead to fetal membrane rupture in 
response to stretch and activation of stretch-activated proteins (SAPs). 
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involving the inhibitory effects of wortmannin and NS-398 on PI3-kinase and COX-2 
pathways, respectively, are also reported for the first time. These data show that inhibition 
of PI3-Akt pathways dampens cyclic tensile strain induced softening involving increased 
GAG synthesis of the amniotic membrane in placental AM tissue, but is not statistically 
significance in cervical AM regions. Interestingly, it appears that inhibition of the PI3-
Akt pathway during cyclic tensile strain decreases the amount of collagen degradation, 
which is concomitant with a reduction in MMP activity and PGE2 release during tissue 
strain in both CAM and PAM tissue regions. However, there is no marked effect on 
elastin content when inhibiting the PI3-Akt pathways in both free-swelling and strained 
tissue. Furthermore, the inhibitory effects of Cx43asODNs on matrix composition and 
FM weakening factors reveal striking similarities to inhibition of PI3-kinase and Akt, 
leading to a reduction in collagen degradation reduced AM softening mediated by 
reduction in GAG content, and a reduction in MMP and PGE2 release in both CAM and 
PAM regions during cyclic tensile strain. Selective inhibition of COX-2 using NS-398 
led to the only changes observed in elastin content during cyclic tensile strain. COX-2 is 
rapidly expressed in response to pro-inflammatory molecules and is responsible for the 
first step in prostanoid synthesis, including PGE2. By selectively inhibiting COX-2 we 
report a decrease in both collagen and elastin degradation, which returns close to basal 
levels, as well as reduced tissue softening mediated by enhanced GAG synthesis 
concurrent with a reduction in MMP/PGE2 release to almost negligible levels in both 
tissue regions during free swelling and mechanically stimulated conditions. 
 
Limited studies have attempted to delineate pathways associated with fetal membrane 
weakening that could provide avenues for future PPROM therapeutics. However, recent 
studies by Kumar et al., have provided strong evidence towards the involvement of 
inflammation/infection and decidual bleeding/abruption pathways linking to 
PPROM5,286. This group described an overlap between these two FM weakening 
pathways and by modelling inflammation using TNF-a and abruption using thrombin, 
they show induction of Granulocyte-macrophage colony-stimulating factor (GM-CSF) 
on the choriodecidual side leading to FM weakening. Interestingly, they also demonstrate 
reduced fetal membrane weakening via inflammation and abruption pathways by 
blocking the action of GM-CSF. Furthermore, targeting this pathway using progestogen 
has been explored with promising results, however the optimal progestogen is still under 
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investigation287. Importantly, the increase in GM-CSF is observed only on the 
choriodecidua side of the FM exposed to TNF-a or thrombin as and not the amnion side5. 
 
Whilst the inflammation/infection and abruption pathways can lead to FM weakening 
involving increased production of GM-CSF in the choriodecidual side of the FM, we 
provide interesting FM weakening evidence specific the amnion only, in response to 
repetitive mechanical stimulation (summarised in Figure 6.20). Future studies involving 
GM-CSF and its activation in response to cyclic tensile strain could provide fruitful in 
understanding the relationship between the choriodecidual side and amnion side of the 
FM leading to overall weakening of the fetal membrane. The findings presented here 
provide the premise to explore stretch-activated pathways that could lead to FM 
weakening and rupture.  Further optimisation of agents using dose-responsive studies are 
required and for longer time periods (up to 1 week). Combining these findings with 
rupture strength testing in the future will be beneficial in characterising how the inhibitory 
effects of such agents translates to changes in the physical properties of the FM. Overall, 
we provide a novel avenue of research in the development of therapeutics for preventing 
PPROM. 
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Figure 6.20: Synergy of events that lead to fetal membrane rupture following activation of stretch-
activated inflammatory pathways. Previously identified fetal membrane weakening pathways 
described by Kumar et al., and development of stretch-activated fetal membrane weakening pathways 
could synergistically work towards ECM degradation, choriodecidual separation, and fetal 
membrane rupture. An improved understanding of these mechanisms could lead to the further 
development of therapeutics for preventing PPROM. GM-CSF pathway figure adapted from Kumar 
et al., (2014)5.  
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Chapter 7: Final Discussion and Future Prospects 
 
The development of approaches to repair AM would benefit PPROM patients who have 
ruptured their membranes at early gestational age. Prolonging the latency period from 
rupture of membranes to delivery is imperative for improving clinical outcome. Future 
research is needed to reduce preterm birth rates and alleviate the large socio-economoic 
impact. Difficulty resides with the multifactorial etiology of PPROM, which complicates 
research efforts. The present study utilised a multidisciplinary approach to investigate the 
mechanotransduction mechanisms of FM weakening and potential strategies to repair the 
AM after fetoscopic surgery and artificial in vitro trauma.  
 
7.1 Cx43 is overexpressed in AM after fetoscopic surgery and artificial in vitro trauma 
and delays cell migration and repair 
 
Examination of fetoscopic defects revealed no spontaneous healing in all cases, leaving 
a wound with a diameter of ~3 mm, that exhibited thickened wound margins indicating 
tissue remodelling at the wound edge. These thickened wound edges have previously 
been reported in human FM162. 
We demonstrate significantly enhanced Cx43 protein plaque formation that range 
in size from 0.1 to 1 µm, similar to that observed in skin tissue. Examination of Cx43 
protein and gene expression shows significantly increased expression in the wound edge 
of the AM and limits the ability of mesenchymal cells to adopt a migratory phenotype. 
The overexpression of Cx43 may slow down cell migration as observed during normal 
cutaneous wound healing.   
We observed polarisation of mesenchymal cells in the wound edge of the AM that 
was tangential to the highly aligned collagen fibres. These traits are only found at the 
wound margin, with control AM revealing rounded mesenchymal cells and randomly 
orientated collagen bundles. Interestingly, collagen SHG intensity increased towards the 
wound edge of the AM, and contributes to the thickened wound edge observed 
macroscopically in the AM. The polarised mesenchymal cells at the wound margin are 
indicative of the “purse-string” wound healing contraction mechanisms seen in 
embryonic wound healing and leads to the hypothesis that wound healing mechanisms 
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are present in human AM. However, the resulting trauma after fetoscopy surgery could 
leave a wound that is too large and beyond the limits of FM repair capabilities.  
Development of an artificial in vitro trauma model enabled further investigation 
of AM trauma in FM collected form women at term pregnancies. When term AM are 
wounded in vitro (~0.8 mm diameter defects), we demonstrate striking similarities in 
Cx43 protein and gene expression when compared to preterm AM after fetoscopy 
surgery. We observed temporal changes in mesenchymal cell morphology and collagen 
fibre orientation such that these traits were tangential to the wound edge in the AM after 
168 hours of trauma. The levels of Cx43 gene and protein expression were significantly 
enhanced in the wounded AM after 168 hours of trauma when compared to control AM. 
It is possible that the “purse-string” wound healing contraction mechanisms could 
potentially be undergoing an attempt to repair the damaged AM. However, even with 
smaller wounds (0.8 mm), term tissue in the present model was unable to mount a 
successful wound healing response after 7 days of culture. The levels of Cx43 expression 
in wounded AM compared to control AM may likely complicate wound healing dynamics 
and limit the migration of mesenchymal cells that is required for effective wound 
contraction and secretion of new granulation tissue. In summary, the identification of a 
putative target Cx43 is an important key finding that if knocked down, could enhance 
human AM repair and prevent iatrogenic PPROM. 
 
7.2 Development of a new PA-based sealing strategy for human AM repair 	
We developed a novel PA-based strategy for sealing FM defects after artificial trauma. 
Combining solutions of human amniotic fluid with the FM induced self-assembly and 
formation of a 3D nanofibrous architecture that closely mimics the ECM of native FM. 
Indeed, self-assembling PA gels have previously provided promising results for healing 
diabetic wound and burn injuries17,18. To our knowledge, this is the first study reported to 
induce spontaneous temporal self-assembly of FM in the presence of amniotic fluid. 
The present study shows that the PAK3-AF system is optimal in sealing FM 
defects compared to PA systems that have too few (<3) or too many lysine residues (>3). 
For example, the PAK2-AF system formed a comparably weak gel that disintegrated 
upon manipulation, whereas the PAK4-AF system did not form a stable gel. The PAK3-
AF system provides a promising starting point for PA-based rapidly self-assembling 
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biomaterial that is biocompatible and potentially could lead to the development of an 
injectable model utilised in a clinical setting. This would allow injection through a 10-Fr 
cannula, and optimal functionality within a wet environment.  
7.3 Mechanotransduction mechanisms that induce AM weakening and production of 
inflammatory mediators leading to ECM damage 	
The potential therapeutic targets that could influence mechanotransduction and induce 
weakening in the AM leading to ECM damage were explored. AM explants were 
subjected to CTS in the presence and absence of chemical inhibitors that influence the 
Cx43 (Akti, Cx43 asODNs, PI3K), inflammatory (COX-2, PGE2) and repair pathways 
(Collagen, GAGs, elastin). Mounting evidence links overdistension of the uterus to 
PPROM and preterm labour, mediated by inflammation, choriodecidual separation and 
FM rupture111. Twin or higher order multiple pregnancies, polyhydramnios (over 
production of amniotic fluid), and uterine structural abnormalities have been associated 
with increased PPROM and preterm delivery incidence269,270,288. With this in mind, a 
repetitive CTS regimen was used to investigate potential weakening of the AM over a 24 
hour period in tissue collected from term pregnancies.  
CTS significantly increased GAG synthesis, MMP activity and PGE2 release in 
CAM and PAM compared to unstrained control membranes. This response was paralleled 
with an associated reduction in collagen (SHG and protein levels) and elastin content in 
CAM and PAM subjected to CTS when compared to unstrained control membranes. 
Previously, we have shown that CTS leads to increased COX-2 and Cx43 in AM284. 
Similar mechanotransduction mechanisms induced within the present ex-vivo FM explant 
bioreactor model could be activated following in utero stretch forces. In utero stretch 
forces stem from polyhydramnios, overdistension of the uterus, twin or higher order 
multiple pregnancies, or uterine structural abnormalities, and could cause AM strain and 
induce biochemical AM changes associated with increased expression of the stretch 
sensitive proteins Cx43/AKT, and pro-inflammatory enzyme COX-2. Inhibition of 
molecules using Cx43asODNs (specific targeting of Cx43), AKTi (specific targeting of 
AKT-1/2), NS398 (selective COX-2 inhibition), and WTM (non-specific targeting of 
PI3-kinases) perturb the effect of CTS-induced AM damage, and provide potential 
therapeutic targets for further research. Whilst it has been shown that PGE2 and MMPs 
are key factors involved in parturition and FM rupture, the upstream mechanisms are 
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unknown. We have established a model that enhanced PGE2 and MMPs in response to 
CTS. This system has provided a reproducible environment in which to study the effects 
of inhibiting potential targets and develop therapeutics for prevention of FM weakening 
mechanisms. Potential therapeutic options to prevent FM weakening have previously 
been investigated. By modelling TNF  -induced inflammation and bleeding through 
thrombin exposure, Kumar et al., has identified Granulocyte-Macrophage Colony-
Stimulating Factor (GM-CSF) as a potential target to prevent MMP induced damage 
originating from the choriodecidua side5. Recent investigations revealed that GM-CSF 
levels increase on the choriodecidua side but not in the outer amnion layer in response to 
TNF-alpha and thrombin5. This group was able to show that 3 progestogens 
(progesterone, 17-alpha hydroxyprogesterone caproate, and medroxyprogesterone 
acetate) can block production of GM-CSF, which is involved in the FM weakening 
pathway. 17-alpha hydroxyprogesterone caproate is available for clinical use during 
PPROM treatment. However, it has recently been reported that this progestogens is not 
optimal in the inhibition of FM weakening involving GM-CSF activation287. Whilst these 
reports show promise in targeting choriodecidual factors that lead to FM weakening, this 
chapter provides additional therapeutic targets for further investigation regarding FM 
weakening specific to the AM. 		 	
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7.4 Implications and future research 
 
7.4.1 Identification of targets for mechanotransduction and FM weakening 	
Future research will be performed to explore FM weakening mechanisms in more detail. 
Following on from the mechanotransduction mechanisms defined in this thesis, key areas 
of future research include the investigation of our CTS loading conditions on preterm 
tissue. Whilst we have focused investigations on term AM, naturally the next step would 
be to complement these studies with tissue obtained from preterm deliveries, including 
samples obtained from women with and without preterm contractions. This would inform 
on whether the mechanotransduction mechanisms observed in term tissue are replicated 
in preterm tissue that has not been exposed to labour contractions. Further investigations 
of preterm tissue that has been exposed to preterm labour contractions would complement 
these studies and help to define whether the mechanisms elucidated within our ex-vivo 
FM explant bioreactor correspond to PPROM patients. 
In obtaining these preterm samples, the next steps would be to investigate 
expression of Cx43. We have shown that Cx43 is a stretch-sensitive protein and its 
activation is linked with AM weakening mechanisms. It is likely that there are gestational 
age dependent differences in expression of Cx43 and therefore future research would 
develop a Cx43 profile throughout gestation. Furthermore, differences in Cx43 
expression will be investigated in samples obtained from PPROM patients with preterm 
tissue from patients who have not ruptured their membranes. This would make an 
important comparison and help to identify whether Cx43 expression is abnormally 
expressed in PPROM tissue at sites of rupture. Due to the many risk factors associated 
with PPROM, it will be critical to develop an extensive database where comparisons of 
Cx43 levels can be compared depending on race/ethnicity, maternal age, parity, previous 
preterm birth history, and medical condition, all of which could influence FM weakening 
and lead to PPROM. In the future, this could give a strong indication on whether Cx43 
levels vary in patients with greater risk of PPROM. 
Furthermore, the relationship between Cx43 and AKT will be explored further. 
Whilst we cannot claim in this thesis that Cx43 and AKT act synergistically or through 
separate CTS-induced AM weakening mechanisms, the evidence provided in this thesis 
leads to further research questions. The next steps would be to further define their 
connection, if any. Indeed, research in other cell types suggests a strong link between 
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AKT and Cx43. For example, mechanical stress in osteocytes leads to Cx43 hemichannel 
opening, required for remodelling processes182. Recent evidence suggests Cx43 is 
phosphorylated by AKT, which enhances their interaction causing increased hemichannel 
opening182. To our knowledge, AKT phosphorylation of Cx43 has not been investigated 
in the AM. This provides an exciting opportunity to explore the hypothesis that 
mechanisms leading to hemichannel opening could lead to the initiation of FM 
weakening. Further research is required to identify whether Cx43 is phosphorylated by 
AKT in AM following CTS. This could help to improve our understanding on AM 
weakening mechanotransduction mechanisms following CTS, and postulate a potential 
mechanism (Figure 7.2). This will provide a new area for development of therapeutics 
that prevent AM weakening mechanotransduction mechanisms. 
 
 
To investigate this we will conduct further functional pharmacological studies in the AM 
following CTS. Important questions will include whether AKT directly phosphorylates 
Cx43 at a known phosphorylation site (S373). Previous research has shown that Cx43 
can be phosphorylated by AKT at the S373 site289. This then leads to reduced interaction 
with the tight junction protein, Zonula occludens-1 (ZO-1) suggesting activation of a 
“molecular switch” which leads to increased Cx43 plaque size and communication289. 
To complement these studies, mechanical strength testing will also be an 
important addition to confirm whether the biochemical changes induced by inhibiting 
potential therapeutic targets correlates to changes in mechanical strength in both preterm 
and term AM. Rupture strength (N) will be tested following culture of AM with 
therapeutic agents within the ex-vivo FM explant bioreactor model. To do this AM will 
be removed from the ex-vivo bioreactor after CTS cultured with or without therapeutic 
agents. Both the AM from close to the cervix and placenta will be mechanically tested 
PI3K   AKT   Cx43
     
AM weakening 
ECM degradation 
FM rupture 
Figure 7.2: Potential mechanotransduction mechanism leading to FM rupture. Future work 
will investigate the relationship between AKT and Cx43. 
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after cultures as these two regions have been shown to have different rupture strengths in 
term FM30. The cervical fetal membrane is shown to have a rupture strength of around 5 
N whilst FM distal from the cervical region has a rupture strength of 8 N. Importantly, 
AM samples from PPROM patients will be cultured using therapeutic agents and then 
mechanically tested to identify changes in rupture strength that may occur as a result of 
inhibiting AM weakening mechanisms. To perform mechanical testing the MTS 
Bionix100 (MN, USA) mechanical testing system with a 50N cell load will be used. This 
will allow strain to failure (rupture strength), tangent modulus, and ultimate tensile stress 
to be identified. Ultimately this work is required to establish whether culturing with 
therapeutic agents can impact AM strength to help develop therapies to prevent and treat 
PPROM. 
 
7.4.2 Pharmacological strategies for the induction of healing mechanisms and repair of 
FM defects 
 
Future research will aim to explore ways to restore the normal functionality of AM. The 
induction of healing will be investigated by selective targeting of Cx43. PPROM 
incidence increases following fetal surgery, therefore as we have identified high 
expression of Cx43 in AM after trauma (both preterm and term), the next steps would be 
to develop strategies to heal and repair AM by targeting this protein. By using 
Cx43asODNs we have identified that Cx43 knockdown perturbs the effect of CTS-
induced ECM damage, however, this thesis does not investigate the effect of Cx43asODN 
application to AM after trauma. Therefore, future work will investigate the modulation 
of Cx43 on AM healing. To investigate the effect of Cx43asODNs on AM healing, we 
will use Pluronic-F127 gel as a delivery vehicle. Whilst this is not ideal in a clinical 
environment, Pluronic gel will allow the slow release of Cx43asODNs to the AM wound 
(over a period of 24 hours) in order to examine whether AM healing is enhanced. Pluronic 
gel has been used as a delivery vehicle for slow release of Cx43asODNs before, and has 
successfully enhanced wound healing in rat diabetic skin wound models by promoting 
cell migration126. These promising results in other chronic wounds provide rationale to 
investigate Cx43 targeting in AM defects. 
To examine Cx43 modulation on AM healing, future studies will initially use a variety of 
models to reflect the physiological environment (Figure 7.3). Initially, our artificial in 
vitro FM explant trauma model. Leading on from this, the development of a FM inflation 
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model would further test repair extent by comparing burst pressures with healed and non-
healed AM. Finally, AM healing could be examined within the ex-vivo CTS bioreactor 
model, where delivery of Cx43asODNs can be introduced through 21G needle using 
pluronic gel or another adhesive sealant as a delivery vehicle. 
 
  
 
 
 
 
Another option which may be more appropriate in a clinical environment is the use of 
Cx43asODN coated collagen scaffolds290. Recently, these have been developed to 
promote healing of chronic wounds and show an 85% downregulation of Cx43 at the 
wound edge in rat wounds290. Furthermore, they show superior release over Pluronic 
F127 gel, by providing continuous release of Cx43asODNs over a period of 7 days. 
Cx43asODN coated collagen scaffolds is an area of research that will be explored for 
healing of the AM. Regarding iatrogenic defects following fetal surgery, scaffolds could 
be implanted through a laparoscope and surgically inserted into a fetoscopic defect. 
Successful targeting of Cx43 at the wound edge in AM could promote AM repair 
by accelerating cell migration by reducing cell adhesion and proliferation128. Knockdown 
of Cx43 enhances Rac-1 and RhoA GTPase activation, which is associated with changes 
in cytoskeletal proteins, specifically leading to increased lamelipodial protrusions. By 
decreasing levels of Cx43 at the wound edge of the AM epithelial and mesenchymal cells, 
future research will examine whether AM wounds can overcome their limited healing 
capacity. 
 
Figure 7.3: Models that will be used in future research to investigate repair of the AM. 
Initially, experiments will be conducted using the artificial in vitro trauma model (1), then 
progress to an inflation device (2) and ex-vivo bioreactor model (3). 
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7.4.3 Strategies for sealing the AM using tissue engineering models 
  
Fetal membrane repair is a new research area for tissue engineering approaches. The 
repair of numerous other tissues have benefited from tissue engineering approaches, 
which usually adopt a variety of scaffold materials with or without the presence of cells. 
As discussed previously, sealing of FM defects could be combined with a 
pharmacological approach by coating collagen scaffolds with Cx43asODNs290. In a 
clinical environment these could be introduced through a laparoscope following 
fetoscopic surgery and surgical placed in the FM defect. Whilst future research will 
examine the potential of this approach, previous research regarding collagen plugs for 
FM sealing has had limited success, and do not reduce the rate of PPROM210. Future 
investigations will aim to develop a biomaterial that can be combined with bioactive 
functionality to enhance FM repair. 
In this thesis we explored the use of self-assembling PAs that are injectable in 
solution and form a scaffold upon contact with a physiological solution (i.e. amniotic 
fluid). Whilst the PA solution ultimately forms the scaffold material, future research will 
explore the potential of a PA-based gel and cell mixture to stimulate tissue repair 
mechanisms. Furthermore, future work will aim to develop a PA that shows increased 
adhesiveness and functions in a wet environment. In addition, conjugation of Cx43 
mimetic peptides or silencing technologies to PA molecules could be explored to further 
enhance repair capacity by promoting migration of native mesenchymal cells found at the 
AM wound edge. Display of bioactive epitopes on PA molecules is an exciting avenue of 
research that can be exploited to further enhance FM wound healing capacity.  
 
In the future, predictive PPROM models could help to develop personalised treatment 
following fetal surgery. For example, a recent study identified that the likelihood of 
PPROM increases with elevated lactic acid and MMP-8 in the amniotic fluid measured 
during fetal surgery291. The present study provides an improved understanding on the 
absence of AM healing, and the mechanotransduction mechanisms behind AM 
weakening. Furthermore, a novel FM sealing strategy is explored for the prevention of 
PPROM after fetal surgery.  
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